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In 1906, Alois Alzheimer described for the ﬁrst time a form of dementia that later became 
known as Alzheimer’s disease.1 At necropsy, he had observed that the brain of a 51-year-old 
woman with progressive cognitive decline was ﬁlled with –at that time still anonymous– amy-
loid plaques and neuroﬁbrillary tangles. Since then, numerous investigators saw in patients 
with dementia the same pathological ﬁndings that Alzheimer had seen. Clinically, Alzheimer’s 
disease is recognized by a long period of progressive cognitive decline. Braak and Braak 
showed in the late eighties that the accumulation of plaques and tangles in the brain follows 
a predictable pattern over time that parallels this cognitive decline.2 In their now widely ac-
cepted staging system, they identify a long phase where the medial temporal lobe is the ﬁrst 
area to be afﬂicted whereas only in the later disease stages the pathology involves the iso-
cortices. However, recent pathological studies show that brains of elderly patients, unlike the 
middle–aged patient that Alzheimer had observed, who in life receive a diagnosis of Alzhei-
mer’s disease have a rather mixed bag of brain pathology. Not only the traditionally recognized 
amyloid plaques and neuroﬁbrillary tangles are observed but also cerebrovascular disease is 
found which could have contributed to the cognitive decline.3
The search for causes of Alzheimer’s disease is hampered by its long preclinical period and 
the pathological diversity that contribute to clinical symptoms of Alzheimer’s disease. Environ-
mental or physiological factors that are present at time of a clinical diagnosis of Alzheimer’s 
disease may not have effectuated the brain damage in the preclinical period. Furthermore, dif-
ferent key mechanisms could be involved in either the development of the speciﬁc Alzheimer 
pathology i.e. neuroﬁbrillary tangles and amyloid plaques, or cerebrovascular disease such as 
lacunar infarcts and white matter disease. We took the approach of focusing on the preclini-
cal stages of the disease by making magnetic resonance imaging (MRI) of the brain in non-
demented elderly and assessing the extent of brain atrophy. The advantage of this approach 
is that brain atrophy on MRI, particularly atrophy of structures in the medial temporal lobe, 
is evident years before a clinical diagnosis of Alzheimer’s disease and speciﬁcally reﬂects 
neuronal loss and neuroﬁbrillary tangles.4 By identifying causes of atrophy on MRI, which we 
consider a preclinical sign of Alzheimer’s disease, we hope to shed light on mechanisms by 
which Alzheimer’s disease develops. The studies described in this thesis formed part of the 
Rotterdam Scan Study, a large population-based cohort study among elderly who were at time 
of MRI free of clinical dementia. Vascular risk factors are increasingly recognized to contribute 
to the clinical syndrome of Alzheimer’s disease in late life,5 yet it is unclear whether this is only 
through induction of cerebrovascular disease that in itself causes cognitive decline or whether 
vascular factors also have more direct effects on brain atrophy. In chapter 2 of this thesis, the 
focus is on vascular risk factors in relation to brain atrophy on MRI. Chapter 3 is devoted to 
the endocrine factors plasma estradiol levels and genetic variation in the estrogen receptor 
α polymorphism. The potential of estrogen replacement therapy in preventing Alzheimer’s 
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disease has recently received a lot of attention and there is considerable controversy on the 
role of estrogens in the etiology of Alzheimer’s disease. Also in chapter 3, type 2 diabetes 
mellitus and insulin resistance are investigated as potential risk factors for brain atrophy on 
MRI. The functional signiﬁcance and clinical correlates of atrophy on MRI are addressed in 
chapter 4. We examined whether atrophy on MRI was associated to memory performance, 
risk of dementia and depression. Finally, in chapter 5, the main ﬁndings in the context of cur-
rent knowledge on the etiology of Alzheimer’s disease, methodological aspects and sugges-
tions for future research are discussed.
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Blood pressure and medial temporal lobe atrophy
Blood pressure may be associated to clinical Alzheimer’s disease (AD) in several ways. High 
blood pressure levels can lead to cerebrovascular damage, which contributes to cognitive 
decline in AD. However, high blood pressure may also trigger the development of AD pathol-
ogy, i.e. neuroﬁbrillary tangles and amyloid plaques. In vivo, atrophy of the hippocampus and 
amygdala on MRI is a good and early indicator of AD pathology. We investigated the associa-
tion of blood pressure levels with hippocampal and amygdalar atrophy on MRI. Additionally, 
we examined the association of markers of large vessel (carotid atherosclerosis) and small 
vessel disease (white matter lesions on MRI) with atrophy of the hippocampus and amygdala. 
In 1995-1996, 511 non-demented elderly (60-90 year) underwent brain MRI. Blood pressure 
levels were assessed concurrently with MRI and 5 years before the MRI. A high diastolic 
blood pressure 5 years before MRI predicted more hippocampal atrophy in persons untreated 
for hypertension. Conversely, in persons treated for hypertension a low diastolic blood pres-
sure was related to atrophy. Small vessel disease, but not large vessel disease, coexisted 
with hippocampal and amygdalar atrophy. These results indicate that high blood pressure and 
markers of small vessel disease in the brain are associated with atrophy of structures affected 
by AD. A low blood pressure level may be either a cause or consequence of atrophy.
Chapter 2.1
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Introduction
Although Alzheimer’s disease (AD) is originally considered to be a non-vascular disease, this 
view is challenged by observations that vascular factors contribute to the development of 
late-onset AD.1-3 In this respect, the most frequently investigated vascular factor is blood pres-
sure.4, 5 Long-term longitudinal studies have shown that a high blood pressure increases the 
risk of clinical AD.6-8 Yet cross-sectional studies9, 10 and studies with a shorter follow-up11, 12 
reported a low blood pressure in patients with AD. 
It is unclear whether and which structural brain changes could underlie the associations be-
tween blood pressure and clinical AD. High blood pressure levels can lead to cerebrovascular 
damage such as white matter lesions (WML) and small brain infarcts that contribute to cog-
nitive decline in a patient with clinical AD.13-15 Alternatively, more direct links between blood 
pressure and AD are suggested by the observation that persons with hypertension have in-
creased neuroﬁbrillary tangles and brain atrophy at autopsy.16, 17 To explore the latter in vivo, 
we decided to study the relation between blood pressure and hippocampal and amygdalar 
atrophy on MRI in non-demented elderly. The hippocampus and amygdala are highly affected 
by amyloid plaques and neuroﬁbrillary tangles even in the earliest stage of the development 
of Alzheimer’s disease.18 Histopathological studies conﬁrm that neuronal loss, neuroﬁbrillary 
tangles and amyloid plaques at autopsy are highly correlated to atrophy visible on MRI.19-21 If 
the association between blood pressure and clinical AD is (partly) mediated through effects 
on the development of Alzheimer neuropathology in the medial temporal lobe, one would 
expect to ﬁnd an association between blood pressure levels and atrophy of the hippocampus 
and amygdala on MRI. We additionally examined whether markers of small vessel disease in 
the brain (WML) or large vessel disease (carotid atherosclerosis) are associated to atrophy of 
the hippocampus and amygdala on MRI and modiﬁes the association between blood pressure 
and atrophy on MRI.
Methods
Participants
The Rotterdam Study is a large population-based cohort study in the Netherlands designed 
to investigate prevalence, incidence and determinants of diseases in the elderly.22 Baseline 
examinations were done in 1990 to 1993. In 1995 to 1996, we randomly selected 965 living 
members (60-90 years of age) of the cohort in strata of sex and age (5 years) for participation 
in the Rotterdam Scan Study designed to study age-related brain changes on MRI.1 As part of 
the eligibility criteria, we excluded from this selection people with dementia (n=17)23 or MRI 
contraindications (n=116). Thus, 832 persons were eligible and invited. Among these, 563 
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participants gave their written informed consent to participate in the study, which included 
undergoing an MRI scan of the brain (response rate: 68%). Complete MRI data was available 
for 511 participants.24 Participants were in general healthier than non-participants.25 The study 
protocol was approved by the medical ethics committee of the Erasmus Medical Center.
MRI procedures
Standard T1, T2 and proton-density weighted axial MR images and a custom-made three-
dimensional (3D) MRI sequence covering the whole brain were made using a 1.5 Tesla MR 
unit (VISION MR, Siemens, Erlangen, Germany). The MRI acquisition parameters have been 
described.24, 26 
MRI assessment of hippocampal and amygdalar volumes
We constructed a series of coronal brain slices (contiguous 1.5-mm slice thickness) from the 
3D MRI, aligned to be perpendicular to the long axis of the hippocampus. We manually traced 
the boundaries of the hippocampus and amygdala on both sides on each slice with a mouse-
driven cursor.24 The summed surface was multiplied by slice thickness to yield estimates of 
the hippocampal and amygdalar volume (ml). The left and right-sided volumes were summed 
to yield the total hippocampal and amygdalar volume. As a proxy for head size, we measured 
on the middle sagittal MRI slice the intracranial cross-sectional area.24 We corrected for head 
size differences across individuals by dividing the uncorrected volumes by the participant’s 
calculated head size area and subsequently multiplying this ratio by the average head size 
area (men and women separately).27 
Assessment of blood pressure and vasculopathy
At baseline and time of MRI we assessed blood pressure with a random zero sphygmoma-
nometer.28 Participants were asked to bring all prescribed medications to the research center 
where a physician recorded the use. At baseline and time of MRI, participants underwent 
ultrasonography of the carotid arteries.29 The presence of atherosclerotic plaques was deter-
mined at six locations: common carotid artery, carotid bifurcation, and internal carotid artery 
at the left and right side and summed (range 0-6). The intima-media thickness was measured 
by longitudinal two-dimensional ultrasound of the anterior and posterior wall of both com-
mon carotid arteries. We calculated the mean of these four locations. Cerebral WML on MRI 
were assessed on proton-density and T2 weighted axial MR images and were scored in the 
periventricular regions (range 0-9) and the subcortical regions (approximated volume).26 We 
deﬁned a group with severe WML on MRI similar to previous analyses30 as having either a 
subcortical WML score or periventricular WML score in the upper quintile of the distribution. 
Brain infarcts were deﬁned as focal hyperintensities on T2 weighted images, and, if present in 
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the white matter, with corresponding prominent hypointensity on T1 weighted images.31
Other measurements
Body mass index (BMI) was calculated as weight divided by the square of height. A physician 
assessed participants’ smoking habits with a structured questionnaire and we categorized 
this into never, former or current smoking. Serum total cholesterol and high-density lipopro-
tein (HDL) were determined with an automated enzymatic procedure.
Data analysis
We assessed the relation between blood pressure continuously and in categories at baseline 
or at time of MRI and atrophy with multiple linear regression. As preliminary analysis and pre-
vious studies on AD and cognitive impairment.7, 32-34 suggest differences in relations between 
persons with or without antihypertensive medication, we stratiﬁed for antihypertensive medi-
cation use. With multiple linear regression, we investigated the association between WML, 
carotid atherosclerosis and atrophy. Analyses were adjusted for age and sex and additionally 
for other cardiovascular factors. Finally, we repeated the analyses on blood pressure and atro-
phy in strata of severity of WML on MRI. Assumptions of the model were veriﬁed by residual 
diagnostics. 
Blood pressure and medial temporal lobe atrophy
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Results
Table 1 gives several characteristics of the study sample both at baseline and at time of 
MRI. 
Table 1. Characteristics of the study sample at baseline (1990-1993) and time of MRI (1995-1996)
Baseline 
(n=511)
Time of MRI
(n=511)
Age, year 68.8  ±  8.0 73.4 ± 8.0
Sex, % women 49.1 49.1
Cholesterol / HDL ratio 5.4 ± 1.8 4.9 ± 1.5
Current smoking, % 19.6 16.3
BMI, kg/m2 26.2 ± 3.4 26.3 ± 3.6
Diastolic blood pressure, mmHg 73.0 ± 10.8 76.5 ± 11.6
Systolic blood pressure, mmHg 136.5 ± 20.3 145.8 ± 20.3
Antihypertensive medication, % 30.3 38.9
Carotid plaques, score range 0-6 1.3 ± 1.5 1.6 ± 1.6
Intima-media thickness, mm 0.76 ± 0.14 0.87 ± 0.14
Periventricular WML on MRI, grade - 2.7 ± 2.2
Subcortical WML on MRI, ml - 1.80 ± 3.40
Infarcts on MRI, % - 28.0
Values are unadjusted means ± SD or percentages
People using antihypertensive medication at both baseline and follow-up had on average 
smaller hippocampal (age and sex adjusted difference –0.15, 95% CI –0.32 to 0.02, P=0.09) 
and amygdalar volumes (–0.20, 95% CI –0.34 to –0.06, P=0.005) compared to people without 
antihypertensive medication. A higher diastolic blood pressure at baseline in persons untreat-
ed for hypertension was related to smaller hippocampal volumes (Figure 1). Per SD increase 
in diastolic blood pressure at baseline, we found in persons untreated a 0.10 ml smaller hip-
pocampal volume (95% CI –0.19 to –0.02, P=0.02). Diastolic blood pressure at time of MRI 
was not associated with hippocampal or amygdalar volume in persons without antihyperten-
sive treatment (Figure 1). Conversely, in persons using antihypertensive medication, a lower 
diastolic blood pressure at time of MRI was related to smaller volumes on MRI, statistically 
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signiﬁcant for the amygdala (Figure 1). Per SD increase in diastolic blood pressure at time of 
MRI, 0.10 ml (95% CI 0.00 to 0.20, P=0.05) larger amygdalar volumes were found. These as-
sociations did not change after adjusting for the cholesterol/HDL ratio, BMI or smoking. 
Figure 1. Association between diastolic blood pressure levels at baseline (upper panel) or at time of MRI 
(lower panel) and volumes of the hippocampus (left panel) and amygdala (right panel). Adjusted for age 
and sex and normalized to head size. *P<0.05 compared to diastolic blood pressure <70 mmHg
No associations were found with systolic blood pressure levels (Figure 2). 
People with more carotid atherosclerosis at either baseline (data not shown) or time of MRI 
did not have smaller volumes on MRI (Table 2). People with more WML had smaller hippo-
campal or amygdalar volumes (Table 2). This relation did not disappear after adjusting for blood 
pressure levels, antihypertensive medication use, cholesterol/HDL ratio, BMI and smoking. 
People with infarcts on MRI did not have signiﬁcantly smaller hippocampal or amygdalar vol-
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umes (age and sex adjusted difference in hippocampal volume –0.10 ml (95% CI –0.27 to 0.07, 
P=0.24) and in amygdalar volume –0.01 ml (95% CI –0.15 to 0.13, P=0.89)). 
Figure 2. Association between systolic blood pressure levels at baseline (upper panel) or at time of MRI 
(lower panel) and volumes of the hippocampus (left panel) and amygdala (right panel). Adjusted for age 
and sex and normalized to head size
The association that we found in persons without antihypertensive treatment between a high 
diastolic blood pressure at baseline and hippocampal atrophy on MRI remained when exclu-
ding persons with severe WML on MRI (per SD increase in 0.13 ml smaller hippocampal vol-
ume (95% CI 0.03 to 0.23, P=0.02). The association between concurrent low diastolic blood 
pressure level and more atrophy in persons using antihypertensive medications was however 
restricted to people with coexistent severe WML on MRI (Table 3). 
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Table 2. Cross-sectional associations between markers of vasculopathy and hippocampal and amygdalar 
volumes on MRI (n=511)
Hippocampal volume (ml) Amygdalar volume (ml)
Estimate (95% CI) P Estimate (95% CI) P
Carotid atherosclerosis
IMT –0.01 (–0.09 ; 0.07) 0.84 –0.01 (–0.07 ; 0.06) 0.83
Carotid plaques –0.00 (–0.09 ; 0.08) 0.92 –0.01 (–0.07 ; 0.06) 0.83
WML on MRI
Periventricular -0.11 (-0.19 ; -0.03) 0.01 -0.05 (-0.12 ; 0.02) 0.14
Subcortical -0.09 (-0.17 ; -0.01) 0.02 -0.08 (-0.14;-0.02) 0.01
Values are adjusted regression coefﬁcients (with 95% conﬁdence interval (CI) and P-value) per SD in-
crease in atherosclerosis or white matter lesions (WML) on MRI. Adjustments were made for age and 
sex
Table 3. Cross-sectional association between diastolic blood pressure level and volumes of hippocampus 
and amygdala on MRI according to WML severity on MRI
Hippocampal volume (ml) Amygdalar volume (ml)
No antihypertensive medication (n=313) Estimate (95% CI) P Estimate (95% CI) P
Diastolic BP
No or moderate WML* (n=245) -0.01 (-0.12; 0.10) 0.83 0.06 (-0.02;0.15) 0.14
Severe WML* (n=68) 0.17 (-0.05;0.38) 0.12 0.06 (-0.11;0.22) 0.50
Antihypertensive medication (n=198) Estimate (95% CI) P Estimate (95% CI) P
Diastolic BP
No or moderate WML* (n=129) -0.05 (-0.20;0.10)† 0.47 0.04 (-0.08;0.16)† 0.52
Severe WML* (n=69) 0.20 (0.01;0.39) 0.04 0.19 (0.02;0.36) 0.03
Values are adjusted regression coefﬁcients (with 95% conﬁdence interval (CI) and P-value) per SD in-
crease in diastolic blood pressure level. * White matter lesions (WML) on MRI categorized according to 
upper quintile cut-off of distribution in either subcortical or periventricular WML.
†P-value of interaction term of diastolic blood pressure level and WML for hippocampus=0.03 amygda-
la=0.07
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Discussion
We found in this community cohort of non-demented elderly that a high diastolic blood pres-
sure in persons not treated for hypertension was associated with more hippocampal atrophy 
on MRI. Higher severity of WML coexisted with atrophy of the hippocampus and amygdala. 
Finally, in persons using antihypertensive medications a low diastolic blood pressure was 
related to more hippocampal and amygdalar atrophy. 
The clinical distinction between vascular dementia and AD is sometimes difﬁcult hampering 
studies investigating vascular risk factors in relation to clinically diagnosed AD.35 In elderly 
people, dementia symptoms are mostly due to mixed disease i.e. both cerebrovascular dam-
age and AD pathology contribute to the cognitive symptoms.36 We had the opportunity to 
assess hippocampal and amygdalar atrophy on MRI that can be regarded as preclinical MRI 
markers of AD.19-21, 37 These assessments in vivo may help us clarifying whether vascular fac-
tors inﬂuence the AD pathology in the medial temporal lobe. However, we need to bear in 
mind that a small volume of the hippocampus or amygdala on MRI does not always reﬂect 
atrophy caused by incipient AD. For some persons a small regional brain volume will be innate 
or due to diseases other than AD. Future serial MRI studies can provide information to distin-
guish people with a high rate of brain volume loss due to AD pathology.38
The results of studies on the association between blood pressure and AD are determined by 
the time period between blood pressure level assessment and AD diagnosis.5, 39 Longitudinal 
population studies with a long follow-up have shown high blood pressure levels in people 
who develop clinically overt AD several years later.6-8 Especially in persons not using antihy-
pertensive medications, a higher blood pressure is a risk factor for clinical AD7 and cognitive 
impairment.32, 34 High blood pressure levels may lead to a spectrum of brain changes, which 
all could separately or in combination cause cognitive decline. Generalized brain atrophy,40-42 
WML,25, 41, 42 and infarcts on MRI31 are observed in persons with hypertension and are associ-
ated with cognitive decline and dementia.13 Another potential structural intermediate in the 
association between high blood pressure and clinical AD is damage to hippocampal neurones, 
as suggested by an autopsy study showing more neuroﬁbrillary tangles and amyloid plaques 
in the hippocampus of persons with a high blood pressure.17 How exactly these pathological 
changes in the hippocampus develop due to high blood pressure is unclear. Long-standing 
hypertension and chronic brain hypoperfusion in rats may upregulate levels of nitric oxide in 
the hippocampus, lead to amyloid accumulation and memory loss.43 The coexistence of WML, 
which reﬂects microangiopathy,44 and atrophy of the hippocampus and amygdala on MRI has 
been reported before.45 Its coexistence may be explained by both having a similar aetiology 
such as high blood pressure that in our sample was strongly related to WML.25 Alternatively, 
as adjusting for blood pressure levels did not change the relation between WML and atrophy, 
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generalized microangiopathy may reduce cerebral blood ﬂow to the hippocampus46 and in-
duce loss of hippocampal neurones.47 Of interest, infarcts on MRI were not associated with 
the degree of atrophy of the hippocampus and amygdala on MRI. The majority of infarcts on 
MRI are lacunar infarcts31 due to microangiopathy. Unlike WML however, they are caused by 
acute occlusions of single small vessels possibly not affecting blood ﬂow to the medial tem-
poral lobe. Carotid atherosclerosis was not associated with atrophy of the hippocampus or 
amygdala suggesting that the association found between atherosclerosis and clinical AD48 is 
not through effects on the hippocampus or amygdala but purely through WML or infarcts.
Studies in which blood pressure is assessed shortly before or at time of diagnosis of AD 
showed patients to have lower blood pressure levels compared to controls.9-12, 49, 50 Two hy-
potheses have been put forward to explain these associations with low blood pressure: (1) a 
low blood pressure is a secondary phenomenon of the dementia process or (2) a low blood 
pressure primarily contributes to development of dementia. Regarding the ﬁrst hypothesis, 
the hippocampus and amygdala have a role in blood pressure regulation51, 52 and atrophy of 
these structures due to AD pathology could result in a decrease of blood pressure level. How-
ever, this being true, we would expect similar associations between atrophy and low blood 
pressure levels in all persons whereas in our study the association was strongest in those 
using antihypertensive medication. This is in line with the stronger association found between 
a low blood pressure and AD in persons on antihypertensive treatment.11, 12, 50 According to 
the second hypothesis, a too low blood pressure level can be detrimental to the brain.53 Un-
der normal conditions, cerebral autoregulatory mechanisms will keep up adequate cerebral 
blood ﬂow despite a low systemic blood pressure level.54 This is achieved by vasodilatation 
of the arterioles of the brain.55 In persons with chronic hypertension and microangiopathy56, 
57 the ability to vasodilate is reduced and a low systemic blood pressure might lead to hypo-
perfusion and ischemia of the brain particularly to the sensitive hippocampus and amygdala. 
Our ﬁnding that a low diastolic blood pressure level was particularly associated to atrophy in 
persons with antihypertensive medication (most likely with a history of chronic hypertension) 
and severe WML may ﬁt this hypothesis.
To conclude, our ﬁndings support the idea that blood pressure has effects on atrophy of struc-
tures in the medial temporal lobe that have a central role in AD. However, as our study was 
cross-sectional we cannot infer causality of the associations. Prospective studies are needed 
to conﬁrm or reject the associations we found.
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Chapter 2.2
Blood pressure and global brain atrophy
The relation between blood pressure level and degree of global brain atrophy is equivocal. We 
evaluated past and present blood pressure levels and change in blood pressure over 20 years 
in relation to the degree of cortical atrophy on magnetic resonance imaging (MRI). In 1995-
1996, we measured blood pressure and performed MRI in 1,077 non-demented elderly (age 
60-90 years). For 513 of these, we had information on a blood pressure level 20 years before. 
The degree of cortical atrophy was semi-quantitatively scored (range 0-15). In late life, a high 
(≥90 mmHg) and low (<65 mmHg) diastolic blood pressure were associated with more corti-
cal atrophy than a diastolic blood pressure level between 65-74 mmHg (adjusted difference 
0.60 units (95% conﬁdence interval (CI), 0.18-1.02) and 0.77 units (0.28-1.25), respectively). 
Persons whose diastolic blood pressure had declined more than 10 mmHg over 20 years had 
more cortical atrophy than those with stable blood pressure levels (adjusted difference 0.53 
units, 0.05-1.02). Both high and declining diastolic blood pressure levels are associated with 
more global brain atrophy on MRI.
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Introduction
Global brain atrophy is a common ﬁnding on magnetic resonance imaging (MRI) scans of 
elderly persons. Elderly with more pronounced brain atrophy perform worse on neuropsycho-
logical testing,1 and may even be at increased risk to develop Alzheimer’s disease.2 Besides 
age, no deﬁnite risk factor for the development of severe brain atrophy has yet been identiﬁed. 
High blood pressure levels in mid or late life have been suggested to increase the degree of 
brain atrophy in later life,3, 4 but other observational studies reported that a low blood pressure 
level or a decline in blood pressure are associated with severe brain atrophy.5, 6 In a popula-
tion-based sample of older people we investigated the relation between blood pressure levels 
and degree of brain atrophy on MRI. We investigated blood pressure levels 20 years before 
MRI, change in blood pressure over time, and concurrent blood pressure level in relation to 
the degree of brain atrophy on MRI. 
Methods
Study sample
This study is based on data from the Rotterdam Scan Study, which was designed to investi-
gate determinants and consequences of brain abnormalities on MRI in the elderly.7 In 1995-
1996, 1,904 subjects aged 60-90 years were randomly selected in strata of age (5 years) and 
sex from two population cohort studies.8, 9 We excluded 187 subjects who were demented, 
blind or had MRI contraindications at time of selection. Of the 1,717 eligible non-demented 
subjects, complete information including a cerebral MRI scan was obtained in 1,077 who 
gave written informed consent (participation rate 63%, mean age 72.2 years, 52% women). 
Subjects who consented to the MRI examination were on average younger and healthier than 
subjects who refused the MRI examination.10 In 513 subjects, originating from one of the co-
horts (participation rate 59 %),8 we had information on a blood pressure level 20 years before 
MRI (measured from 1975-1978; age at that time between 40 and 70 years). The Medical 
Ethics Committee of Erasmus Medical Center, the Netherlands, approved the study. 
Measurements
Measurements were done similarly at both examinations. Blood pressure was measured 
twice in a seated position with a random-zero sphygmomanometer. We used the average of 
these two measurements. In six subjects with MRI, we had no information on concurrent 
blood pressure level. Subjects showed prescribed medications to a physician who coded 
these according to the Anatomic-Therapeutic-Chemical index. Antihypertensive medications 
were medications falling into classiﬁcation codes C02, C03 and C07. Diabetes mellitus was 
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considered present when subjects reported use of oral antidiabetic medication or insulin 
(classiﬁcation code A10). A physician asked about smoking habits (current, never or former) 
and quantiﬁed this as pack-years of cigarettes smoked (=number of cigarettes per day X year 
of smoking/20) (pack-years could only be quantiﬁed at time of MRI). Body mass index (BMI) 
was calculated as weight divided by height square.
 
MRI procedures
An axial T1, T2 and proton density weighted brain MRI scan was made with 1.5-Tesla scanners 
(Gyroscan, Philips NT, Best, The Netherlands or VISION MR, Siemens, Erlangen, Germany).10 
Slice thickness was 5 or 6 mm with an interslice gap of 20 %. Images were optimized on the 
scanner screen and printed on laser hard copies. The extent of cortical atrophy was scored 
blinded to all clinical characteristics on a four point rating scale based on the size of the gyri 
and sulci from 0 (no cortical atrophy) to 3 (severe cortical atrophy) at ﬁve regions (frontal, pa-
rietal, temporal and occipital lobes and the insular region) with use of reference scans (Figure 
1). 
Figure 1. Axial brain slices at the level of the basal ganglia showing brains with sum score of cortical 
atrophy of A=0, B=5, C=10, D=15. Cortical atrophy was scored from 0-3 at the frontal, parietal, temporal 
and occipital lobes and the insular region
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The sum of these ﬁve regions (0-15) was calculated. Two experienced raters scored all scans 
for cortical atrophy independent of each other. When the raters differed more than one point 
in any of the ﬁve regions a consensus reading was held, otherwise the mean score was calcu-
lated. Intra and interrater studies based on the ﬁrst 200 scans showed good reproducibility for 
scoring cortical atrophy (intrarater weighted kappa 0.82 and interrater weighted kappa 0.81). 
White matter lesions were scored in periventricular (grade 0-9) and subcortical white matter 
regions (approximated volume) on the proton density scans.10 White matter lesions had to be 
hyperintense on the proton density and T2 weighted images, without prominent hypointen-
sity on the T1 weighted images. We deﬁned infarcts as focal hyperintensities on T2 weighted 
images.11 Infarcts in the white matter also had to have corresponding hypointensities on T1 
weighted images, in order to distinguish them from white matter lesions.
Data analysis
Age and sex adjusted linear regression was used to quantify the relation between several 
characteristics and atrophy. We used analysis of covariance (ANCOVA) to calculate adjusted 
means of cortical atrophy in blood pressure level categories. This was done for blood pressure 
levels 20 years before MRI, change in blood pressure level, and concurrent blood pressure 
level. When the ANCOVA suggested a linear association between the blood pressure variable 
and atrophy, we performed a multivariate linear model to calculate the increase in cortical 
atrophy units per 10 mmHg increase in blood pressure level. A possible U-shaped association 
between blood pressure measures and atrophy was evaluated by adding the quadratic term 
of the blood pressure variable to the linear model. We then report the P-value of the regres-
sion coefﬁcient of the quadratic term. All analyses were adjusted for age, sex, and cigarette 
smoking (at examination in 1975-1978: smoking status; current, former, never; concurrent 
with MRI: pack-years of cigarette smoking). Additional adjustments were made for presence 
of diabetes, BMI, and white matter lesions. We evaluated whether relations differed accor-
ding to antihypertensive medication use through stratiﬁed analyses. In addition, all analyses 
were repeated with the different regions of atrophy as dependent variables separately. Finally, 
we repeated all analyses excluding subjects with an infarct on MRI.
For missing data on categorical covariates, we used a missing indicator, whereas for missing 
data on continuous covariates we used the median value of the respective value as calculated 
from the total sample. Data were missing on cigarette smoking (n=24), diabetes (n=3), body 
mass index (n=3), and subcortical white matter lesions (n=4). All analyses were followed by 
residual analyses to conﬁrm assumptions of the model.
Blood pressure and global brain atrophy
25
Results
Table 1 shows characteristics of the total study sample at time of MRI and characteristics of 
the part with additional examinations 20 years before MRI.
Table 1. Characteristics of the total study sample in 1995-1996 (at time of MRI scan) and of subjects with 
additional examinations in 1975-1978
Total study sample Examinations in
1995-1996 (n=1077) 1975-1978 (n=513)
Age, years 72 ± 7 51 ± 7 
Sex, % women 52 53
Systolic blood pressure (mmHg) 147.3 ± 21.6 131.4 ± 17.0 
Diastolic blood pressure (mmHg) 78.7 ± 11.7 81.3 ± 10.9 
Antihypertensive medication, % 35 15
Smoking cigarettes, % current 16 37
Prevalent diabetes mellitus, % 6 1
Body mass index (kg/m2) 26.7 ± 3.6 25.0 ± 3.0 
Subcortical white matter lesions (ml) 1.4 ± 2.9 -
Periventricular white matter lesions, grade 2.4 ± 2.2 -
Infarcts on MRI, % 24 -
Cortical atrophy, range 0-15 5.56 ± 2.86 -
Values are unadjusted means ±standard deviation or percentages unless otherwise speciﬁed
 
The degree of cortical atrophy was signiﬁcantly higher with increasing age (0.22 units per year 
(95% conﬁdence interval (CI), 0.20 to 0.24) and more pronounced in men than in women (sex 
difference 0.90 units (95% CI, 0.56 to 1.24)). Users of antihypertensive medications in late life, 
but not in mid life, had more pronounced cortical atrophy (age- and sex-adjusted difference 
0.52 units (95% CI, 0.23 to 0.82), and –0.26 units (95% CI, –0.75 to 0.22), respectively). 
Figure 2 shows cortical atrophy according to concurrent blood pressure level. Subjects with 
a high diastolic blood pressure level (85-90 mmHg and above 90 mmHg) had adjusted 0.48 
units (95% CI, 0.01 to 0.94) and 0.60 units (0.18 to 1.02) more cortical atrophy than subjects 
with a diastolic blood pressure level between 65 and 74 mmHg. In addition, subjects with a 
diastolic blood pressure level less than 65 mmHg had adjusted 0.77 units (95% CI, 0.28 to 
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1.25) more cortical atrophy than subjects with a diastolic blood pressure level between 65 and 
74 mmHg. This U-shaped association between diastolic blood pressure level and degree of 
cortical atrophy was statistically signiﬁcant (P of quadratic term = 0.02), and remained after 
additional adjustments for diabetes, BMI, and white matter lesions (P of quadratic term = 
0.05). The association was similar for users and non-users of antihypertensive medications. 
Concurrent systolic blood pressure level was not related to the degree of cortical atrophy 
(Figure 2) (per 10 mmHg a decrease of –0.02 units (95% CI, –0.09 to 0.04)).
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Figure 2. Cortical atrophy according to concurrent blood pressure levels. Values are adjusted means 
(+standard error) of cortical atrophy. Adjusted for age, sex, and pack-years of cigarette smoking. Numbers 
in the respective categories were for diastolic blood pressure 122, 271, 350, 140, 188 and for systolic 
blood pressure 99, 215, 186, 268, 303.*Adjusted mean in blood pressure level category differs from ad-
justed mean in diastolic blood pressure level category 65-74 mmHg P<0.05
Higher diastolic blood pressure levels 20 years before MRI predicted more cortical atrophy 
in later life in subjects without antihypertensive medication (n=434) (per 10 mmHg increase 
in diastolic blood pressure 0.17 units (95% CI, 0.00 to 0.34), but not in subjects with antihy-
pertensive medication (n=79) –0.03 units (95% CI, –0.44 to 0.38). The association in subjects 
without antihypertensive medication weakened after adjusting for diabetes, BMI, and white 
matter lesions (per 10 mmHg increase in diastolic blood pressure 0.15 units (95% CI, –0.03 to 
0.33). The number of subjects without antihypertensive medication allowed us to examine the 
association between previous diastolic blood pressure and atrophy in age categories of 40-50, 
50-60 and 60-70. The association was strongest in the youngest (per 10 mmHg increase in 
diastolic blood pressure respectively 0.26 units (95% CI, 0.05 to 0.48); 0.12 (95% CI, –0.17 to 
0.42); 0.13 (95% CI, –0.68 to 0.95). Systolic blood pressure levels 20 years before MRI were 
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not associated with the degree of cortical atrophy in later life (data not shown). 
On average, subjects declined very little in diastolic blood pressure over 20 years (change –0.2 
mmHg). A steeper decline in diastolic blood pressure was associated with signiﬁcantly more 
cortical atrophy compared to a stable blood pressure level over time (Figure 3). Persons who 
had experienced a decline of more than 10 mmHg in diastolic blood pressure level had 0.53 
units (95% CI, 0.05 to 1.02) more cortical atrophy than persons with a stable blood pressure 
level over time (change between –5 and +5 mmHg). 
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Figure 3. Cortical atrophy according to change in blood pressure level over 20 years time. Values are 
adjusted means (+standard error) of cortical atrophy. Adjusted for age, sex, and pack-years of cigarette 
smoking. Numbers in the respective categories were for diastolic blood pressure change 115, 81, 123, 
76, 112 and for systolic blood pressure change 65, 120, 188, 60, 74.*Adjusted mean in blood pressure 
change category differs from adjusted mean in diastolic blood pressure level change from –5 to 5 mmHg 
P<0.05 
The decliners with ensuing late life diastolic blood pressure level less than 65 mmHg (n=27) 
had 1.27 units (95% CI, 0.45 to 2.13) more cortical atrophy than decliners with ensuing late life 
diastolic blood pressure level above 65 mmHg (n=88). Likewise, persons with a low diastolic 
blood pressure in late life who had experienced a decline of more than 10 mmHg (n=27) had 
1.69 units (95% CI, -0.04 to 3.43) more cortical atrophy compared to persons with a low di-
astolic blood pressure without a preceding decline of more than 10 mmHg (n=7). The associa-
tion between a decline of more than 10 mmHg in diastolic blood pressure and more cortical 
atrophy was present in persons without antihypertensive medications at anytime (n=336), 
(0.80 units (95% CI, 0.18 to 1.42)), whereas the association in chronic antihypertensive users 
was unclear due to small numbers (n=56). In persons who used antihypertensive medica-
Chapter 2.2
28
tion only at late life (n=98), the decliners had 0.34 units (95% CI, -0.84 to 1.51) more cortical 
atrophy compared to subjects with a stable blood pressure level. There were only 23 subjects 
who used antihypertensive medication in earlier life without using antihypertensive medica-
tion in later life. An increase in diastolic blood pressure of more than 10 mmHg was also asso-
ciated with more cortical atrophy (Figure 3), but the apparent U-shaped association between 
diastolic blood pressure change and atrophy was not statistically signiﬁcant (P of quadratic 
term = 0.14). The associations did not change by additional adjustments for diabetes, BMI, 
and white matter lesions. Systolic blood pressure change over 20 years was not associated 
with the degree of cortical atrophy (Figure 3). 
When analyzing the relation between blood pressure and the separate regions in which we 
measured cortical atrophy, no differential pattern emerged for any of the relations between 
blood pressure and atrophy. Finally, excluding subjects with an infarct on MRI did not materi-
ally change any of the results.
Discussion
The main ﬁnding of this study is that in a population of non-demented elderly a high diastolic 
blood pressure level 20 years before MRI predicted more pronounced cortical atrophy. Sec-
ond, both concurrent high and low diastolic blood pressure levels were associated with more 
atrophy. Finally, subjects who had experienced a steep decline in diastolic blood over a 20-
year period, and had subsequently a low diastolic blood pressure at late life, had more cortical 
atrophy than subjects with a stable blood pressure level over time. These associations were 
independent of other vascular risk factors, cerebral white matter lesions or infarcts on MRI.
Some limitations of this study have to be considered. First, people had to be alive to be in-
cluded in our study. Subjects with either very low or high blood pressure levels earlier in life 
may have preferentially died and hence could have been underrepresented in our sample. 
Most likely, this led us to underestimate the association between previous blood pressure 
levels or change in blood pressure level and brain atrophy. Some evidence that this played a 
role comes from our observation that higher previous blood pressure levels were associated 
with more atrophy especially in the youngest for whom higher blood pressure levels will not 
have a large impact on mortality rate. A second limitation is that our rating of brain atrophy 
is rather crude compared to that of others who used quantitative, yet time-consuming, tech-
niques.2 However, this crude rating should decrease the possibility of ﬁnding any association. 
Finally, we only had single measurements of blood pressure. Due to regression dilution this 
also would lead us to underestimate the effect of blood pressure on atrophy.
Our ﬁnding that previous or later life high blood pressure levels are associated with more 
global brain atrophy in late life is in concordance with observations in clinical hypertensive pa-
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tients12-14 and population studies.3, 4 As previously reported in our sample, high blood pressure 
levels were associated with severe white matter lesions and infarcts.11, 15 Given the fact that 
white matter lesions, infarcts and severe global brain atrophy commonly occur in the same 
brain,16 we considered that the relation between high blood pressure and atrophy could be 
due to the relation between blood pressure and other cerebrovascular pathology. However, 
adjusting for the severity of white matter lesions or excluding those with infarcts did not 
change the association between blood pressure and atrophy, suggesting that blood pres-
sure is independently associated with atrophy. Biological support of an association between 
high blood pressure and atrophy comes from a pathological study that showed higher mid 
life blood pressure levels to be associated with more neuroﬁbrillary tangles in the cortex and 
brain atrophy at death.17 However, this study was done in Honolulu comprising a different 
ethnical population under other environmental factors. Replication needs to be done in a Cau-
casian population such as ours. Another pathological study showed that elderly who died with 
hypertension had more senile plaques in the cortex than those without hypertension.18
Besides a high blood pressure level, we also found dropping blood pressure and lower con-
current blood pressure levels to be associated with more global brain atrophy, as was also 
reported by others.5, 6 From our sample with examinations 20 years before MRI, we observed 
that most of the subjects with low blood pressure levels in late life came from higher blood 
pressure levels earlier in life. Hence it may be that these previous higher blood pressure levels 
were responsible for more global brain atrophy at late life. However, it seems unlikely that 
this explains the whole association between a low or dropping blood pressure level and more 
global brain atrophy, given our observation that higher previous blood pressure levels were 
not very strongly associated with more global brain atrophy at late life. We can speculate on 
two interpretations of the association between low or dropping diastolic blood pressure levels 
and atrophy. First, a decline in blood pressure level over time may lead to mild ischemia of the 
brain.19, 20 In healthy subjects, a low systemic blood pressure level will not have a large impact 
on cerebral blood ﬂow because the brain has the ability to keep cerebral blood ﬂow constant 
by cerebral autoregulation.21 However, in subjects with impaired cerebral autoregulation, the 
lower limit of blood pressure at which cerebral autoregulation still functions is shifted towards 
a higher blood pressure level,22 and subsequently a low systemic blood pressure level may 
be inadequate for healthy brain perfusion.19, 23 As a second interpretation for the association 
between a drop in blood pressure and atrophy, one might speculate that atrophy of the brain, 
once it is severe enough, causes a decline in blood pressure levels. The central nervous sys-
tem is involved in blood pressure regulation24, 25 and in the very elderly it was observed that 
those with more frontal or insular atrophy had on average lower blood pressure levels.5 Our 
results did however not indicate a differential association between a low blood pressure level 
and atrophy in speciﬁc regions. The association between low blood pressure and atrophy in 
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this non-demented population ﬁt ﬁndings in patients with early Alzheimer’s disease in which 
blood pressure levels drop, possibly due to an increase in atrophy.26, 27
In summary, we found that in a non-demented population both a high and a declining blood 
pressure predicted more global brain atrophy on MRI. Prospective studies using several 
measurements of atrophy and blood pressure are required to unravel the chronology of these 
associations. 
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Chapter 2.3
Homocysteine and brain atrophy
Patients with Alzheimer’s disease have higher plasma homocysteine levels than controls but 
it is uncertain whether higher plasma homocysteine levels are involved in the early patho-
genesis of the disease. Hippocampal, amygdalar and global brain atrophy on brain magnetic 
resonance imaging (MRI) have been proposed as early markers of Alzheimer’s disease. In 
the Rotterdam Scan Study, a population-based study of age-related brain changes in 1,077 
non-demented people aged 60 to 90 years, we investigated the association between plasma 
homocysteine levels and severity of hippocampal, amygdalar and global brain atrophy on MRI. 
We used axial T1 weighted MR images to visualise global cortical brain atrophy (measured 
semi-quantitatively; range 0-15) and a 3D HASTE (half-Fourier acquisition single-shot turbo 
spin echo) sequence in 511 participants to measure hippocampal and amygdalar volumes. 
We had non-fasting plasma homocysteine levels in 1,031 of the participants and in 505 of 
the participants with hippocampal and amygdalar volumes. Individuals with higher plasma 
homocysteine levels had on average more cortical atrophy [0.23 units (95% CI 0.07 to 0.38 
units) per standard deviation increase in plasma homocysteine levels] and more hippocam-
pal atrophy [difference in left hippocampal volume –0.05 ml (95% CI –0.09 to –0.01) and in 
right hippocampal volume –0.03 ml (95% CI –0.07 to 0.01) per standard deviation increase in 
plasma homocysteine levels]. No association was observed between plasma homocysteine 
levels and amygdalar atrophy. These results support the hypothesis that higher plasma homo-
cysteine levels are associated with more atrophy of the hippocampus and cortical regions in 
elderly at risk of Alzheimer’s disease.
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Introduction
Patients with Alzheimer’s disease or cognitive impairment have higher plasma homocysteine 
levels than cognitively unimpaired older subjects.1-3 Recently, a high plasma homocysteine 
level was shown to be a strong, independent risk factor for the development of Alzheimer’s 
disease.4 Elevated plasma total homocysteine level has emerged as a vascular risk factor5 and 
vascular factors may play an important role in the pathogenesis of Alzheimer’s disease.6 Fur-
thermore, homocysteine has direct neurotoxic effects on hippocampal and cortical neurones.7, 
8 In Alzheimer patients, homocysteine was associated with atrophy of the medial temporal 
lobe and patients with higher homocysteine levels had a more rapid rate of atrophy over time.1 
Since Alzheimer’s disease is characterised by a long prodromal period, its etiology may be bet-
ter investigated in relation to early preclinical markers of the disease. Hippocampal, amygdalar 
and global brain atrophy on MRI may serve as such early markers.9-11 The aim of this study was 
to investigate the association between plasma homocysteine levels and these brain MRI out-
comes as putative early markers of Alzheimer’s disease in a non-demented older population. 
Methods
Study Sample
This study is based on data collected in the Rotterdam Scan Study, a population-based co-
hort study, designed to investigate the determinants and consequences of age-related brain 
changes in the elderly.6 In 1995-1996, we randomly selected 1,904 elderly participants (aged 
60 to 90 years) stratiﬁed by gender and age (5 years) from two ongoing population-based 
cohort studies: the Rotterdam Study12 and the Zoetermeer Study.13 The presence of dementia 
was assessed in a stepwise approach as used in the Rotterdam Study.14 First, participants 
were screened with the Mini-Mental State Examination (MMSE) and the Geriatric Mental 
State Schedule (GMS). Those scoring below 26 on the MMSE or more than 0 on the GMS 
were additionally assessed with the CAMDEX interview.15 Subjects thereafter suspected to 
be demented were examined by a neurologist. Finally, an expert panel reviewing all relevant 
information decided whether an individual was to be considered demented or not, based on 
criteria of the DSM-IIIR. Additionally, persons who were blind or had contraindications for MRI 
were excluded, leaving 1,717 persons eligible. A total of 1,077 individuals participated (partici-
pation rate of 63 %) and gave written informed consent to a protocol, which was approved by 
the medical ethics committee of Erasmus Medical Center, Rotterdam, the Netherlands.
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MRI acquisition
All 1,077 participants underwent an axial T1, T2 and proton-density weighted brain MRI scan 
in a 1.5-Tesla unit [Philips (n=514) and Siemens (n=563)].16 For the 563 subjects originating 
from the Rotterdam Study,12 we added a 3D Half-Fourier Acquisition Single-Shot Turbo Spin 
Echo (HASTE) sequence to the protocol (inversion time 440 ms, repetition time 2800 ms, 
128 contiguous sagittal slices of 1.2-mm, matrix 192x256, ﬁeld of view 256x256). Two HASTE 
modules were sequentially acquired after the inversion pulse (effective echo time of 29 ms 
and 440 ms), of which the ﬁrst was used for the volumetric assessments of the hippocampus 
and amygdala. Of the 563, ﬁfty-two participants developed claustrophobia, leaving 511 partici-
pants with a HASTE sequence. 
Hippocampal and amygdalar volumes
The HASTE sequence was used to reconstruct coronal slices (contiguous 1.5-mm slices) per-
pendicular to the long axis of the hippocampus (Figure 1). 
  Figure 1. Coronal slice on which the hippocampus (H) and amygdala (A) are depicted
The left and right hippocampus and amygdala were manually traced using a mouse-driven 
cursor based on a reference atlas.17 Tracing proceeded from posterior to anterior, starting 
at the slice where the crux of the fornices was in full proﬁle. The in-plane boundaries of the 
hippocampus were deﬁned to include the subiculum, the CA1 through CA4 sectors of the 
hippocampus proper and the gyrus dentatus. Tracing of the amygdala included all of its nuclei. 
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As the anterior boundary of the amygdala is poorly deﬁned in nature, we deﬁned this to be the 
slice at the rostral extreme of the temporal stem. Volumes (ml) were calculated [sum of areas 
(mm2) X 1.5 mm/1000]. We measured the midsagittal area (cm2) by tracing the margin of the 
inner table of the skull in order to have a proxy for total intracranial volume.9 Two readers, who 
were blinded to clinical information, measured the 511 scans. Intra- and interreader studies 
based on 14 random scans showed good reproducibility. Intrarater intraclass correlation coef-
ﬁcients for the left and right hippocampus were r=0.93 and r=0.90, and interrater intraclass 
correlation coefﬁcients were r=0.87 and r=0.83, respectively. For the left and right amygdala 
the intrarater intraclass correlation coefﬁcients were r=0.82 and r=0.78, the interrater intrac-
lass correlation coefﬁcients were r=0.80 and r=0.77, respectively. 
Global brain atrophy rating
The severity of global brain atrophy was scored on T1 weighted hard copies, blinded to clinical 
information, based on the widening of sulci and narrowing of gyri in comparison to reference 
scans. A score from 0 (no cortical atrophy) to 3 (severe cortical atrophy) at ﬁve different brain 
regions (frontal, parietal, temporal and occipital lobes and insular region) was given. The sum 
score of all ﬁve regions (range 0-15) was used for the analyses. The intrarater weighted kappa 
was 0.82, and the interrater weighted kappa was 0.81. 
Plasma homocysteine measurements
Non-fasting blood samples were collected and processed at time of MRI as described previ-
ously.18 Blood samples were unavailable in 39 participants due to errors in the blood collection 
process. Plasma levels of total homocysteine were determined by ﬂuorescence polarisation 
immunoassay on an IMx analyser (Abbott). Seven individuals with extreme values were ex-
cluded from the analyses since their plasma homocysteine levels fell outside the range 5-45 
µmol/l in order to minimize the effects of regression dilution bias. Finally, 1,031 participants 
were available for the analyses on global brain atrophy, and 505 participants for the analyses 
on hippocampal and amygdalar atrophy.
Covariates
We obtained information on the following covariates by interview and physical examination in 
1995-1996: diabetes mellitus, hypertension (systolic blood pressure level ≥160 mmHg, or di-
astolic blood pressure level ≥95 mmHg, or use of blood pressure lowering medication), pack-
years of cigarette smoking, vitamin supplements19 and serum creatinine levels (enzymatic 
assay). Presence of carotid artery plaques, and the intima-media thickness of the common 
carotid artery, were assessed as markers of atherosclerotic disease.20 White matter lesions 
on MRI were scored in periventricular (grade 0-9) and subcortical regions (approximated vol-
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ume).16 Infarcts on MRI were deﬁned as focal hyperintensities on T2 weighted images, with-
out prominent hypointensities on T1 weighted images.19
Data analysis
The relation between plasma homocysteine level and atrophy was evaluated using both 
homocysteine in quintiles and as continuous variable. Since homocysteine levels increase 
markedly with age, quintiles were deﬁned in an age-speciﬁc manner for each of ﬁve-year 
age categories. We compared adjusted means of hippocampal and amygdalar volumes and 
global brain atrophy across the age-speciﬁc quintiles of plasma homocysteine by analysis 
of covariance (ANCOVA). The analyses were adjusted for age, sex, diabetes, hypertension, 
pack-years of cigarette smoking, serum creatinine, and, for the hippocampal and amygdalar 
analyses, midsagittal area. Because these analyses did not suggest a non-linear association 
between homocysteine and atrophy, we performed multivariate linear regression to calculate 
the change in atrophy per standard deviation (SD) increase in plasma homocysteine level. We 
investigated whether carotid atherosclerosis, white matter lesions or presence of infarcts on 
MRI mediated the association between homocysteine and atrophy by adding these covariates 
to the model. Assumptions of the models were conﬁrmed by residual analyses.
Results
Selected characteristics of the total study sample and the subset with hippocampal and 
amygdalar volumes are shown in Table 1. 
Table 1. Characteristics of the study sample in total and of the subset with hippocampal and amygdalar 
volumes
Characteristic Total (n=1031) Subset (n=505)
Age, years 72 ± 7 73 ± 8
Sex, % women 52 50
Total homocysteine (µmol/l) 11.5 ± 4.1 11.9 ± 4.3
Presence of diabetes, % 7 6
Presence of hypertension, % 52 53
Pack-years of cigarette smoking 19 ± 24 20 ± 25
Serum creatinine level (µmol/l) 88.9 ± 18.6 89.7 ± 19.9
Values are unadjusted means ± SD or percentages unless otherwise speciﬁed
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Plasma homocysteine levels increased with increasing age (1.5 µmol/l increase per 10 years) 
and were higher in men (sex difference 1.2 µmol/l). Sixty-one participants (5.9%) reported use 
of multivitamin supplements, and these individuals had lower plasma homocysteine levels 
than non-users (age and sex adjusted difference –1.3 µmol/l; 95% CI –2.3 to –0.3). 
Figure 2 shows the association between plasma homocysteine levels and hippocampal vol-
umes. People with higher plasma homocysteine levels had smaller hippocampal volumes 
[difference in left hippocampal volume –0.05 (95% CI –0.09 to –0.01) and right hippocampal 
volume –0.03 (95% CI –0.07 to 0.01) per SD increase in plasma homocysteine level adjusted 
for age, sex, diabetes, hypertension, pack-years of cigarette smoking, creatinine levels and 
midsagittal area]. 
Figure 2. Hippocampal volumes according to age-speciﬁc quintiles of plasma homocysteine levels. The 
mean volumes (standard error) are plotted at the median of each quintile and are adjusted for age, sex, 
diabetes, hypertension, pack-years of cigarette smoking, creatinine levels and midsagittal area. Note that 
the left hippocampus is on average smaller than the right hippocampus 
Further adjustment for carotid atherosclerosis, white matter lesions and infarcts did not 
change this association (data not shown). In contrast, there was a non-signiﬁcant decrease 
in amygdalar volume with increasing plasma homocysteine levels (Figure 3). Per SD increase 
in plasma homocysteine level, the left amygdalar volume decreased –0.01 (95% CI –0.04 to 
0.03) and the right amygdalar volume decreased –0.02 ml (95% CI –0.05 to 0.02).
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Figure 3. Amygdalar volumes according to age-speciﬁc quintiles of plasma homocysteine levels. The 
mean volumes (standard error) are plotted at the median of each quintile and are adjusted for age, sex, 
diabetes, hypertension, pack-years of cigarette smoking, creatinine levels and midsagittal area. Note that 
the left amygdala is on average smaller than the right amygdala 
Figure 4. Global brain atrophy according to age-speciﬁc quintiles of plasma homocysteine levels. The 
mean atrophy score (standard error) is plotted at the median of each quintile and is adjusted for age, sex, 
diabetes, hypertension, pack-years of cigarette smoking and creatinine levels
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Figure 4 shows the association between plasma homocysteine levels and severity of cortical 
atrophy. The degree of cortical atrophy increased with increasing plasma homocysteine levels 
[per SD 0.23 units more (95% CI 0.07 to 0.38)]. This association was unaltered after adjusting 
for carotid atherosclerosis [per SD 0.22 (0.06 to 0.37)] and slightly weakened after adjusting 
for white matter lesions and infarcts [per SD 0.19 (0.03 to 0.34)]. 
The results were not materially altered after exclusion of regular users of multivitamin sup-
plements.
Discussion
This study found that increasing plasma homocysteine levels are associated with more hip-
pocampal and cortical atrophy in an older non-demented population. 
The chief strength of the present study is the population-based study design and the large 
number of volumetric assessments of the hippocampus and amygdala. However, a limitation 
was that the instruments used to assess global brain atrophy were somewhat imprecise. 
Plasma homocysteine levels reﬂect vitamin status, renal function and genetic variations in 
the enzymes controlling homocysteine metabolism genes.5 Recently, it was shown that a 
low plasma folate level may predict more neocortical atrophy at death21 though homocysteine 
may have mediated this association. There is no available data on effects of genetic varia-
tions in homocysteine metabolism on brain atrophy. Two putative effects of homocysteine 
support a causal association between higher plasma homocysteine levels and brain atrophy. 
First, homocysteine damages the vascular walls22 from arteries.23, 24 People with more global 
brain atrophy have more frequently atherosclerosis in the carotid arteries and white matter 
lesions on MRI, which are assumed to be small vessel disease.25, 26 However, the associa-
tion between plasma homocysteine levels and atrophy was unaltered by adjusting for carotid 
atherosclerosis and only partly reduced by adjusting for white matter lesions, suggesting 
that other pathways may be involved. Second, neurotoxic effects of homocysteine in cul-
tures of cortical and hippocampal neurones could partly explain the associations.7, 8 These 
studies in rats showed that hippocampal neurones were even more sensitive to the effects 
of homocysteine7 than cortical neurones.8 Some individuals with hippocampal, and possibly 
global, brain atrophy are more likely to develop clinical Alzheimer’s disease.10, 11 The ﬁndings 
of the present study suggest that higher homocysteine levels may be associated with early 
Alzheimer pathology. However, due to the cross-sectional design of the current study, it re-
mains uncertain whether high homocysteine levels actually precede changes in pathology 
and cause the brain to shrink. Prospective studies using several atrophy and homocysteine 
measurements are necessary to unravel cause and consequence. The ﬁnding that high base-
line homocysteine levels in patients with Alzheimer’s disease predicted more rapid atrophy 
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of the medial temporal lobe over the following three years supports a causal association.1 
Our results conﬁrm cross-sectional studies which show a high plasma homocysteine level to 
be associated with Alzheimer’s disease and cognitive impairment.1-3 Furthermore, they are in 
keeping with a prospective study which showed that a high plasma homocysteine level is an 
independent risk factor of Alzheimer’s disease.4
Several large-scale randomised trials with folic acid-based vitamin supplements to lower ho-
mocysteine levels are currently being conducted and almost all of these trials include an 
assessment of cognitive function, some have sub-studies that also include MRI measure-
ments. Further large-scale trials are required to assess whether lowering plasma homo-
cysteine levels may prevent Alzheimer-related structural abnormalities or delay progression of 
clinical symptoms of Alzheimer’s disease. 
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Alcohol intake and brain MRI ﬁndings
Background:  Light-to-moderate alcohol consumers have a lower risk of dementia and possi-
bly Alzheimer’s disease compared to abstainers. As vascular disease may contribute to symp-
toms of Alzheimer’s disease, reduction of cerebrovascular disease in light alcohol consumers 
could account for these observations. However, a low concentration of alcohol may also have 
direct effects on the hippocampus, a brain structure highly affected by Alzheimer’s disease. 
Objective: We investigated alcohol intake in relation to brain magnetic resonance imaging 
(MRI) ﬁndings of presumed vascular origin (white matter lesions and infarcts) and ﬁndings 
more speciﬁcally found in early Alzheimer’s disease (hippocampal and amygdalar atrophy).
Design: In a population-based sample of 1,074 non-demented elderly (age 60-90) we made 
brain MRI on which we rated white matter lesions and brain infarcts. In a subset of 509 
people, hippocampal and amygdalar volumes on MRI were measured. Alcohol intake was as-
sessed with a structured questionnaire. We categorized alcohol intake into lifetime abstaining, 
very light (<1 drink weekly), light (≥1 drink/week to <1 drink/day), moderate (≥1 drink/day to <4 
drinks/day) and heavy (≥4 drinks/day).
Results: Light-to-moderate alcohol drinkers had less severe white matter lesions and brain 
infarcts on MRI compared to abstainers or heavy drinkers. Abstainers and very light drinkers 
had smaller hippocampal and amygdalar volumes on MRI than light-to-moderate drinkers, but 
only if carrying an apolipoprotein (APOE) ε4 allele. 
Conclusions: Our data suggest that light-to-moderate alcohol intake is associated with a low-
er prevalence of vascular brain ﬁndings and -in APOE ε4 carriers- hippocampal and amygdalar 
atrophy on MRI. 
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Introduction
Several prospective population-based studies have shown that light-to-moderate alcohol con-
sumers have a lower risk of dementia compared to abstaining or heavy alcohol use.1-4 Most 
studies ﬁnd a relation with vascular dementia,2, 4, 5 consistent with the known beneﬁcial ef-
fects of light-to-moderate alcohol consumption on vascular risk proﬁle6 and risk of stroke.7 
Vascular pathology likely contributes to the clinical syndrome in a large proportion of elderly 
Alzheimer patients.8, 9 A plausible explanation for the associations that are seen between 
alcohol consumption and overall dementia or Alzheimer’s disease3, 4, 10 is therefore that this 
is through an effect on vascular pathology. Alternatively, alcohol in low amounts could have 
stimulatory effects on the release of acetylcholine in the hippocampus11 and other non-vas-
cular mechanisms might play a role.12 A non-vascular relation between alcohol intake and 
Alzheimer’s disease was indeed suggested by our observation in the Rotterdam Study that 
alcohol intake seemed only associated with Alzheimer’s disease in carriers of the apolipopro-
tein (APOE) ε4 allele,2 the risk allele for Alzheimer’s disease.13 
To further investigate what could underlie the relation between alcohol intake and risk of 
dementia, we decided to focus on the relation between alcohol intake and structural brain 
ﬁndings on MRI of non-demented elderly. We hypothesized that if the effect of alcohol on 
dementia risk were purely through an effect on vascular pathology, one would see a relation 
between alcohol intake and markers of cerebrovascular disease (brain infarcts, white mat-
ter lesions9, 14-16 but not between alcohol intake and putative presymptomatic MRI markers 
of Alzheimer’s disease (hippocampal and amygdalar atrophy17-22 We investigated this in the 
population-based Rotterdam Scan Study.
 
Methods
Study sample
This study was based on data collected in the Rotterdam Scan Study, a population-based 
cohort study designed to investigate determinants and consequences of age-related brain 
changes on MRI.23 The study had its baseline examinations from 1995 to 1996. At that time, 
we made a random selection of 1,904 elderly aged 60 to 90 years originating from two popu-
lation cohort studies in strata of age (5 years) and sex. After exclusion of persons with demen-
tia,24 or contraindications to undergo MRI (such as metal clips, pacemaker, or claustrophobia), 
1,717 persons were eligible of whom 1,077 participated and gave written informed consent 
(participation rate 63%, mean age 72.2 years, 52% women). The medical ethics committee 
of Erasmus Medical Center approved the study protocol.
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Alcohol intake
A physician questioned each participant at baseline examinations about alcohol intake with a 
structured questionnaire. Alcohol intake was coded into lifetime abstaining, former drinking 
and current drinking (deﬁned as having consumed alcohol during the past 12 months). Current 
and former drinkers were asked about the amount of their alcohol consumption. The amount 
assessed with this questionnaire correlated well with the information obtained by a food fre-
quency questionnaire administered ﬁve years before in part of the sample (Pearson r=0.72, 
P<0.01).25 We categorized current alcohol drinkers into very light (<1 drink weekly), light (≥1 
drink/week to <1 drink/day), moderate (≥1 drink/day to <4 drinks/day) and heavy (≥4 drinks/
day) drinkers similar to our previous report on dementia.2 For three participants information 
on alcohol intake was missing. 
MRI acquisition
All participants underwent axial T1, T2 and proton-density weighted brain MRI scanning with 
a 1.5-Tesla unit (Philips or Siemens) at baseline.26 Only the Siemens MRI unit, in which 563 
participants had their MRI brain scan, allowed us to additionally include a custom-made three 
dimensional (3D) MRI sequence (Half-Fourier Acquisition Single-Shot Turbo Spin Echo27 for 
volumetric assessment of the hippocampus and amygdala. Fifty-two of the 563 participants 
developed claustrophobia during the MRI acquisition and another two had no information on 
alcohol intake, leaving 509 participants with information on alcohol intake and hippocampal 
and amygdalar volumes. 
Cerebrovascular disease on MRI 
MRI measurements were performed blinded to clinical information of the participants.26, 28 
White matter lesions were considered present if visible as hyperintense on proton-density 
and T2 weighted images, without prominent hypointensity on T1 weighted scans. Periven-
tricular white matter lesions were scored semi-quantitatively from 0-9 and subcortical white 
matter lesions were counted in different size categories to approximate a total lesion volume 
(ml).26 We deﬁned infarcts as focal hyperintensities on T2 weighted images. Infarcts in the 
white matter also had to have corresponding hypointensities on T1 weighted images in order 
to distinguish them from white matter lesions. Infarcts on MRI were classiﬁed as silent or 
symptomatic.28
Hippocampal and amygdalar volumes on MRI
We constructed a series of coronal brain slices (contiguous 1.5-mm slice thickness) from 
the 3D MRI, aligned to be perpendicular to the long axis of the hippocampus. We manually 
traced the boundaries of the hippocampus and amygdala on both sides on each slice with a 
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mouse-driven cursor.27 The summed surface areas were multiplied by slice thickness to yield 
estimates of the hippocampal and amygdalar volume (ml). The left and right-sided volumes 
were summed to yield the total hippocampal and amygdalar volume. As a proxy for head 
size, we measured on the middle sagittal MRI slice the intracranial cross-sectional area.27 We 
corrected for head size differences across individuals by dividing the uncorrected volumes by 
the subject’s calculated head size area and subsequently multiplying this ratio by the average 
head size area (men and women separately).29, 30 
Covariates
The following covariates were assessed at baseline by interview and physical examination: 
pack-years of cigarette smoking, educational level, body mass index, diabetes mellitus and 
hypertension.28 APOE genotype testing was performed31 and available for 969 participants in 
the total sample and 436 participants in the subset with hippocampal and amygdalar volume 
assessment; the remainder was mainly missing owing to no blood available. Participants 
were classiﬁed into carrier or non-carrier of an APOE ε4 allele; those with genotype APOE 
ε2ε4 (n=22 in the total sample and 9 in the subsample) were excluded in analyses considering 
APOE genotype.
Data analysis
We used multivariable linear regression to quantify the association between alcohol intake 
categories and white matter lesions and hippocampal and amygdalar volumes. With logis-
tic regression, we calculated the adjusted odds ratio (95% conﬁdence interval (CI)) of brain 
infarcts across alcohol intake categories using abstainers as the reference category. For tests 
of linear trend, we treated the categories of alcohol intake as continuous variable. For tests of 
quadratic trend, we squared the linear trend variable. As covariates we included age, sex and 
pack-years of cigarette smoking. Additionally, we adjusted for educational level, body mass 
index, diabetes and hypertension. We evaluated whether the effects of alcohol differed across 
sex and APOE genotype (carrier or non-carrier of the APOE ε4 allele) by performing stratiﬁed 
analyses and including interaction terms in the model. 
Results
There were no differences in baseline characteristics between the total sample and the sub-
sample with assessment of hippocampal and amygdalar volumes on MRI (Table 1). In Table 2 
characteristics according to alcohol intake categories are given for the total sample. Former 
drinkers (n=86 in the total sample and n=42 in the subsample) more frequently had hyper-
tension and diabetes mellitus compared to current drinkers supporting our presumption that 
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former drinkers could have stopped drinking due to illness. Therefore, former drinkers were 
excluded from analyses on alcohol intake and brain MRI ﬁndings.
Table 1. Characteristics of the total study sample and of the subsample with assessment of hippocampal 
and amygdalar volumes on 3D MRI
Total sample
(n=1074)
Subsample with 3D MRI
(n=509)
Age, years 72 ± 7 73 ± 8
Women, % 52 49
Current alcohol intake, drinks/day 1.2 ± 1.3 1.2 ± 1.4
Former alcohol users, % 8 8
Pack-years of cigarette smoking 19 ± 24 20 ± 25
Primary education, % 35 31
Body mass index, kg/m2 27 ± 4 26 ± 4
Presence of diabetes, % 7 6
Presence of hypertension, % 52 53
Presence of APOE ε4 allele, %* 28 27
Presence of symptomatic infarct on MRI, % 4 6
Values are means ± standard deviation or percentages.
*Available in 969 out of the 1074 and in 436 out of the 509.
Table 3 shows that light alcohol drinkers had the lowest degree of periventricular white mat-
ter lesions on MRI (adjusted difference compared to abstainers 0.69 (95% CI 0.25 to 1.13, 
P = 0.002); compared to heavy drinkers 0.79 (95% CI 0.17 to 1.41, P = 0.01)). They also had 
less subcortical white matter lesions but differences did not reach statistical signiﬁcance (ad-
justed difference compared to abstainers 0.57 (95% CI –0.05 to 1.20, P = 0.07); compared 
to heavy drinkers 0.35 (95% CI –0.54 to 1.24, P = 0.44)). Brain infarcts on MRI were less 
frequently found in very light and light drinkers but none of the odds ratios reached statistical 
signiﬁcance (Table 3). When we excluded persons with symptomatic infarcts on MRI (n=42), 
because they could have changed alcohol intake after the stroke, results remained similar. The 
associations did not change after additional adjustments for educational level, body mass in-
dex, diabetes and hypertension and were similar in men and women and in APOE ε4 carriers 
and non-ε4 carriers.
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Table 4 shows that overall there was no association between alcohol intake and hippocampal 
or amygdalar volumes on MRI. However, the effect of alcohol intake on volumes differed ac-
cording to APOE genotype (P-value of interaction term = 0.02 for hippocampal volume and 
P = 0.07 for amygdalar volume). In carriers of the ε4 allele, alcohol intake was positively as-
sociated with hippocampal and amygdalar volumes, whereas in non-ε4 carriers there was no 
association (Figure 1). The associations between alcohol intake and hippocampal or amygdalar 
volumes did not change after additional adjustment for educational level, body mass index, 
diabetes and hypertension and were similar in men and women. 
Figure 1. Hippocampal and amygdalar volume on MRI according to alcohol intake in strata of APOE geno-
type (non-ε4 carrier (n=288) and ε4 carrier (n=101)). Volumes were adjusted for age, sex and pack-years of 
cigarette smoking and normalized to average head size. Error bars indicate standard error of the mean
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Discussion
In this population-based study in the elderly, we found that light-to-moderate alcohol drinkers 
had less cerebral white matter lesions and brain infarcts on MRI compared to abstainers and 
heavy drinkers. In APOE ε4 carriers, but not in non-ε4 carriers, we found a positive association 
between alcohol intake and hippocampal and amygdalar volumes on MRI. 
The strength of our study is the large sample with brain MRI and volumetric assessments of 
the hippocampus and amygdala. Some methodological issues need to be discussed. First, we 
relied on self-reported alcohol intake, which may have led to underreporting or overreporting. 
Although we may misclassify absolute amounts of alcohol intake, the ranking of people ac-
cording to their alcohol intake will be adequate.32 Second, we assessed average alcohol intake 
over a 1-year period before MRI examinations while it might be better to have information on 
the average alcohol intake over the lifetime. Finally, we had no detailed information on the 
type of alcoholic drink used. Previous studies showed that moderate beer, liquids or wine con-
sumption are equally associated with a reduced risk of dementia,2, 4 though the Copenhagen 
City Heart Study found the association only for moderate wine consumption.10 
Light-to-moderate alcohol drinking is associated with a reduced risk of cognitive impairment 
and dementia compared to lifetime abstention.1-4, 10, 33, 34 In line with the beneﬁcial effects of 
alcohol on lipid proﬁle, hemostatic factors,6 and atherosclerosis,35 most investigators found 
a reduced risk of vascular dementia in light-to-moderate alcohol consumers.2, 4, 5 Consistent 
with these vascular effects of alcohol and with observations in the Cardiovascular Health 
Study (CHS),36 we found that light-to-moderate alcohol consumers had less cerebral white 
matter lesions -in particular in the periventricular region- and infarcts on MRI. Different patho-
physiological events may lead to either periventricular or subcortical white matter lesions.14 
Especially the periventricular white matter is vulnerable to ischemia and severe periventricular 
white matter lesions are related to carotid atherosclerosis.37 Light-to-moderate alcohol drink-
ing has also been associated with a reduced risk of Alzheimer’s disease in several,1, 3, 4, 10, 38 
but not all studies.39, 40 Besides reducing cerebrovascular pathology which contributes to the 
development of symptoms of Alzheimer’s disease8, 9, 24 alcohol in moderate amounts may also 
increase the release of acetylcholine of the hippocampus,11 has antioxidative effects41 and in-
duce the release of potentially beneﬁcial prostaglandins.12 The traditional Alzheimer pathology, 
i.e. amyloid plaques and neuroﬁbrillary tangles accumulates in the brain with high predilection 
of the medial temporal lobe.42 This may lead to neuronal loss and atrophy in vivo detectable on 
MRI even in persons who have not yet developed clinical symptoms of dementia.17-22 APOE ε4 
carriers are at increased risk to develop Alzheimer neuropathology,43 atrophy of structures in 
the medial temporal lobe44 and clinical Alzheimer’s disease.13 Observations in the Rotterdam 
Study suggested that light-to-moderate alcohol consumption is associated with a reduced risk 
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of Alzheimer’s disease only in APOE ε4 carriers.2 Carmelli et al45 also reported a stronger as-
sociation of light drinking and better cognitive performance in APOE ε4 carriers. In our current 
study, we found that APOE ε4 carriers who were light-to-moderate alcohol drinkers had less 
hippocampal and amygdalar atrophy compared to abstainers. Although not all persons with 
hippocampal or amygdalar atrophy will develop Alzheimer’s disease, they are at increased risk 
to develop clinical symptoms of Alzheimer’s disease18 and, as such, our ﬁnding support the 
hypothesis that there could be a reduced risk of Alzheimer’s disease for light-to-moderate 
alcohol drinkers with the APOE ε4 allele. Alcohol has antioxidative properties41 and this might 
suppress the highly sensitive peroxidation of the apolipoprotein ε4,46 and thereby amyloid 
plaque formation in the medial temporal lobe47, 48 or neurotoxicity of ß-amyloid.49 Surprisingly, 
the CHS found a lower risk of dementia in alcohol users to be more consistent among persons 
without the APOE ε4 allele.4 Possibly the younger population studied in the Rotterdam Study 
compared to the CHS led to these discrepancies because the APOE ε4 allele is a stronger 
risk factor for Alzheimer’s disease at younger ages.13 The EVA study also found a reduced risk 
of cognitive deterioration with alcohol intake in non-ε4 carriers but in that study the APOE ε4 
allele itself was not a risk factor for cognitive decline.50 
To conclude, our ﬁndings suggest that light-to-moderate alcohol intake is associated to brain 
MRI ﬁndings indicative of cerebrovascular disease and -in APOE ε4 carriers- to hippocampal 
and amygdalar atrophy on MRI. Given the possibility of confounding in observational studies 
on alcohol use, and the potentially dangerous effects of alcohol, recommendations to start 
drinking alcohol cannot be given. Our ﬁndings are however in line with observations that light-
to-moderate alcohol consumption is associated with a reduced risk of dementia. 
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Chapter 2.5
Apolipoproteine E genotype and brain atrophy
The ε4 allele of the APOE gene increases the risk for Alzheimer’s disease (AD), 
whereas the ε2 allele may be protective. The authors assessed the impact of 
APOE genotype on hippocampal, amygdalar and global brain atrophy as puta-
tive markers of preclinical AD in a non-demented population. Carriers of ε4 had 
signiﬁcantly more hippocampal and amygdalar atrophy than ε3ε3 subjects, but 
not more global brain atrophy. Carriers of ε2 did not have less brain atrophy than 
ε3ε3 subjects.
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Introduction
The elevated risk of APOE allele ε4 for AD is well established, whereas the APOE allele ε2 
may have a protective effect on AD. Hippocampal and amygdalar atrophy are putative early 
markers of AD. MRI studies investigating the impact of APOE genotype on the degree of 
hippocampal atrophy have yielded contradictory ﬁndings.1-6 Some studies found demented 
persons carrying the ε4 allele to have more severe hippocampal atrophy1, 2 but other studies 
did not.3, 4 Suggestions that primarily the right hippocampus is affected in non-demented and 
demented ε4 carriers need further study.5, 6 Most studies, although not all,7 showed no effect 
of the ε4 allele on the degree of global brain atrophy, which occurs probably later in the course 
of AD.3, 6, 8  To our knowledge, no studies speciﬁcally evaluated the relation of the ε2 allele with 
the degree of hippocampal, amygdalar, and global brain atrophy. The aim of this study was to 
assess whether hippocampal, amygdalar, and global brain atrophy in non-demented elderly 
subjects differed according to APOE genotype. We hypothesized that ε2 carriers would have 
less and ε4 carriers more atrophy than those with the common APOE ε3ε3 genotype.
Methods
Subjects and procedures
In 1995 and 1996, we invited 1,904 elderly aged 60 to 90 years to participate as part of the 
Rotterdam Scan Study.9 We excluded persons who were demented, were blind or had MRI 
contraindications, leaving 1,717 persons eligible. Complete information, including a cerebral 
MRI scan, was obtained in 1,077 individuals, who gave written informed consent (participa-
tion rate 63%). The medical ethics committee of Erasmus University, Rotterdam, the Nether-
lands approved the study. 
MRI examinations were done using a 1.5 Tesla MR unit and included an axial T1 weighted 
scan (repetition time [TR] 485 ms or 700 ms, echo time [TE] 14 ms, slice thickness 5 or 6 
mm, interslice gap 20%). For volumetric measurements of the hippocampus and amygdala, 
a custom-made, inversion recovery - double contrast 3D half-Fourier acquisition single-shot 
turbo spin echo (HASTE) sequence was included (inversion time 440 ms, [TR] 2800 ms, 128 
contiguous sagittal slices of 1.2-mm, matrix 192x256, ﬁeld of view 256x256). Two HASTE 
modules were sequentially acquired after the inversion pulse (effective TE of 29 ms and 440 
ms); the ﬁrst was used for the volume measurements. This 3D sequence was done in a sub-
sample of 563 subjects; 52 developed claustrophobia during the measurement, leaving 511 
subjects. APOE genotyping was performed on coded DNA samples10 without knowledge of 
MRI measurements. APOE genotyping was present for 971 in the total sample and 437 in 
the subsample; the remainder was missing owing to no blood available. The allele frequencies 
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were ε2=0.08, ε3=0.77, and ε4=0.15, which was in Hardy-Weinberg equilibrium (χ2=0.6, df=3: 
P>0.2). Memory function was evaluated by a 15 word verbal word learning task that tests im-
mediate and delayed recall (after 15 minutes). 
MRI measurements
MRI measurements were done blinded to clinical characteristics. Global brain atrophy was 
scored on T1 weighted scans for cortical atrophy based on the size of gyri and sulci at ﬁve 
locations (0 [no cortical atrophy] to 3 [severe cortical atrophy]: total range 0 to 15), and for 
subcortical atrophy by the ventricle-to-brain ratio (average of assessments at three loca-
tions). Intra- and interreader studies showed moderate to good agreement. Hippocampal 
and amygdalar volumes were measured on coronal slices (1.5-mm, no interslice gap) recon-
structed from the HASTE to be perpendicular to the long axis of the hippocampus. The left 
and right hippocampus and amygdala were manually traced with a mouse-driven cursor on a 
SUN work station featuring a Magic View 1000 program using boundaries similar to others.4 
The anterior boundary of the amygdala was deﬁned as the plane including the most anterior 
part of the temporal stem. Volumes were calculated by summing the areas multiplied by slice 
thickness. Intra- and interreader studies showed intraclass correlation coefﬁcients exceeded 
r=0.77. We also measured the midsagittal area by tracing the inner skull in order to have a 
proxy for intracranial volume.
Data analyses
APOE genotypes were grouped in at least one APOE ε2 allele (APOE ε2+), APOE ε3ε3, or 
at least one APOE ε4 allele (APOE ε4+). Subjects with APOE ε2ε4 genotype were excluded 
(n=22 in the total study sample and n=9 in the subsample). The APOE group was entered as 
a categorical dummy variable (with APOE ε3ε3 as reference) into a multiple linear regression 
model (analysis of covariance). This model included age, sex and -in the hippocampal and 
amygdalar analyses- midsagittal area as covariates. We calculated adjusted means in cortical 
and subcortical atrophy and hippocampal and amygdalar volumes across APOE genotypes 
by entering the mean age, sex distribution, and -in the hippocampal and amygdalar analyses- 
mean midsagittal area in the linear regression model. Analyses were done for the left and 
right hippocampal and amygdalar volume separately and for the sum of left and right volumes. 
Finally, we repeated the analyses excluding persons with a memory score (immediate or de-
layed recall) <1.5 SD of the age- and education- adjusted means.
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Results
Characteristics according to APOE genotype are shown in Table 1. The total study sample 
comprised 24 subjects homozygous for the ε4 allele, 10 of whom were in the subsample. 
Carriers of ε4 had more often a low memory score than those with APOE ε3ε3 (P=0.01). 
APOE genotype was not related to global brain atrophy (age- and sex- adjusted means [SEM] 
for cortical atrophy: ε2+ =5.63 [0.21], ε3ε3 =5.46 [0.09], ε4+ =5.57 [0.14], [P=0.65]; for sub-
cortical atrophy ε2+ =0.321 [0.003], ε3ε3 =0.316 [0.001], ε4+ =0.316 [0.002], [P=0.19]).
Carriers of ε4 had signiﬁcantly smaller hippocampi and amygdalae than did subjects with 
APOE ε3ε3, both on the left and right side (Table 2). APOE ε2 carriers did not have larger hip-
pocampal or amygdalar volumes compared to APOE ε3ε3 subjects. In contrast, their average 
volumes approximated those of ε4 carriers (difference in total hippocampal and total amy-
gdalar volume for ε2 versus ε4 carriers 0.09 ml [-0.18 to 0.35] and 0.13 ml [-0.10 to 0.35]). 
Table 1. Characteristics of study sample according to APOE genotype   
APOE genotype*
Characteristic
APOE ε2+
(n=120)
APOE ε3ε3
(n=568)
APOE ε4+
(n=261)
Age, years 72 ± 7 73 ± 7 71 ± 7
Sex, % women 58 51 52 
Mini-Mental State Examination 27.7 ± 2.0 27.5 ± 2.1 27.1 ± 2.5
Memory score < 1.5 SD, %† 7 9 15
Cortical atrophy, range 0-15 5.63 ± 2.71 5.56 ± 2.77 5.35 ± 2.82
Subcortical atrophy, ratio 0.321 ± 0.039 0.317 ± 0.036 0.314 ± 0.032
Hippocampus (ml)‡
Left 3.12 ± 0.45 3.19 ± 0.46 3.12 ± 0.45
Right 3.21 ± 0.39 3.26 ± 0.45 3.19 ± 0.47
Amygdala (ml)‡
Left 2.22 ± 0.30 2.25 ± 0.38 2.17 ± 0.41
Right 2.31 ± 0.36 2.35 ± 0.41 2.28 ± 0.40
Values are unadjusted means ±SD or percentages.
* Subjects with APOE ε2ε4 (n=22) were excluded.
† Percentage of subjects with memory score <1.5 SD below the age and education adjusted means.
‡ Hippocampal and amygdalar volumes were assessed in 428 subjects
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Hippocampal and amygdalar volumes decreased with increasing ε4 dose (difference with 
ε3ε3 subjects, total hippocampal volume: 1 allele –0.17 ml [95% CI –0.35 to 0.02], 2 alleles 
–0.71 ml [95% CI –1.22 to –0.20]; total amygdalar volume: 1 allele –0.17 ml [95% CI –0.33 to 
–0.02], 2 alleles –0.42 ml [95% CI –0.85 to 0.02]). 
Table 2. Difference in hippocampal and amygdalar volume according to APOE genotype
Difference in volume (95% CI) 
as compared to subjects with APOE ε3ε3 (n=259)*
Number
Hippocampus Amygdala
Left Right Left Right
APOE ε2+ 52
–0.08 
(–0.21 to 0.05)
–0.05 
(–0.17 to 0.08)
–0.03 
(–0.14 to 0.07)
–0.03 
(–0.14 to 0.08)
APOE ε4+ 117
–0.11 
(–0.20 to –0.01)
–0.11 
(–0.20 to –0.02)
–0.10 
(–0.18 to –0.02)
–0.09 
(–0.17 to –0.01)
*Values are differences (95% CI) in volume (ml), adjusted for age, sex and midsagittal area
Subjects with memory performance lower than 1.5 SD below the age- and education- adjust-
ed means had smaller hippocampal (adjusted difference –0.25 ml [95% CI –0.50 to –0.01]) but 
not amygdalar volumes (–0.08 ml [95% CI –0.29 to 0.13]). When we excluded these subjects, 
we found a similar effect of ε4 on volumes (Table 3).
Table 3. Difference in hippocampal and amygdalar volume according to APOE genotype, in total sample 
and in sample after exclusion of subjects with low memory performance 
Difference in volume (95% CI) 
as compared to subjects with APOE ε3ε3*
Hippocampus Amygdala
Total
Exclusion low memory 
performance†
Total
Exclusion low memory 
performance†
Number 428 369 428 369
APOE ε2+
–0.13
(–0.37 to 0.12)
–0.20
(–0.45 to 0.05)
–0.06 
(–0.27 to 0.14)
–0.13 
(–0.35 to 0.08)
APOE ε4+
–0.21
(–0.39 to –0.03)
–0.21 
(–0.40 to –0.02)
–0.19 
(–0.34 to –0.04) 
–0.17
(–0.33 to –0.01)
*Values are difference (95% CI) in volume (ml), adjusted for age, sex and midsagittal area.
†Subjects with memory score <1.5 SD below the age and education adjusted means were excluded
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Discussion
We found that non-demented ε4 carriers had more hippocampal and amygdalar atrophy, but 
not more global brain atrophy, than those with the APOE ε3ε3 genotype. Suggestions from 
smaller studies in both nondemented (n=54) and demented (n=42) subjects that the ε4 allele 
especially affected the right hippocampus and amygdala could not be conﬁrmed.5, 6 Contrary 
to expectations, ε2 carriers had more atrophy than those with the ε3ε3 genotype, but the 
difference was not statistically signiﬁcant. Our ﬁnding that APOE genotype is not related 
to global brain atrophy is in keeping with previous studies in non-demented and demented 
elderly.3, 6, 8 However, the rating of global brain atrophy was less sensitive than our volumetric 
measurements and subtle differences in global brain atrophy across genotype may have been 
missed. We considered that the associations that we found in this non-demented population 
may reﬂect preclinical AD in ε4 carriers. Indeed, the ε4 carriers more often had low memory 
performance which was associated with smaller hippocampal volumes. However, excluding 
subjects with memory performance lower than 1.5 SD below the age- and education- adjust-
ed means did not change results. Although we cannot exclude the possibility that ε4 carriers 
have smaller hippocampi and amygdalae throughout life, our data suggest that measurable 
hippocampal and amygdalar atrophy occurs before memory decline can be objectively deter-
mined. 
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Chapter 3.1 
Plasma estrogens, hippocampal atrophy and memory performance
Background: Estrogens may prevent cognitive decline and Alzheimer disease. Animal study 
ﬁndings have shown beneﬁcial effects of estrogen on the brain, particularly on the hippocam-
pus, a structure related to memory performance and early Alzheimer disease.
Objective: To investigate whether higher levels of endogenous estradiol in older women and 
men are associated with larger hippocampal volumes on magnetic resonance imaging and 
better memory performance.
Design and Setting: Cross-sectional analysis within the Rotterdam Scan Study, a population-
based study in the Netherlands of elderly subjects who do not have dementia.
Participants: Two hundred ten women and 202 men, aged 60 to 90 years, with plasma levels 
of total estradiol and, in part, 162 women and 149 men also with levels of bioavailable and 
free estradiol.
Main Outcome Measure: Hippocampal volumes on magnetic resonance imaging and 
memory performance (delayed recall).
Results: Women with higher total estradiol levels had smaller hippocampal volumes and 
poorer memory performance –0.29 ml (95% conﬁdence interval, –0.57 to –0.00) and –0.4 
(95% conﬁdence interval, –1.3 to 0.5) fewer words in delayed recall testing for the highest 
tertile compared with the lowest tertile. Similar inverse associations were found among bio-
available and free-estradiol levels, hippocampal volumes, and memory. In men, no association 
was observed between estradiol levels and hippocampal volume, but a trend was found for 
higher levels of total estradiol to be associated with poorer memory performance.
Conclusion: Our data do not support the hypothesis that higher levels of endogenous es-
tradiol in older women and men are associated with larger hippocampal volumes and better 
memory performance.
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Introduction
After menopause, women have low levels of circulating estrogens. Observational studies 
reported a reduced risk of cognitive decline and Alzheimer disease (AD) in postmenopausal 
women using estrogen replacement therapy.1, 2 In animals, estrogens protect hippocampal 
neurons exposed to amyloid-ß,3 improve synapse formation on dendritic spines in the hip-
pocampus,4 and promote survival of hippocampal neurons, acting in concert with growth 
factors.5 Estrogen receptors are located throughout the brain, but especially in the hippocam-
pus.6 Given the beneﬁcial effects of estrogens on the hippocampus in animals, it has been 
hypothesized that estrogens may prevent hippocampal atrophy, a key feature of AD.7 The hip-
pocampus plays a pivotal role in memory function and is one of the ﬁrst regions affected in 
AD.8 The aim of this study was to investigate whether higher endogenous levels of estradiol 
were associated with larger hippocampal volumes on magnetic resonance imaging (MRI) and 
better memory performance. We examined this hypothesis in a population-based study of 
older women and men who did not have dementia.
Methods
Rotterdam Scan Study
This study is based on all participants in the Rotterdam Scan Study that originated from the 
Rotterdam Study. The Rotterdam Study is a large population-based cohort study in the Ne-
therlands that started in 1990 and investigates the prevalence, incidence, and determinants 
of various chronic diseases among elderly participants.9 From 1995 to 1996, we randomly se-
lected 965 living members (aged, 60-90 years) of this cohort in strata of sex and age (5 years) 
for participation in the Rotterdam Scan Study.10 After exclusion of individuals who had demen-
tia (n=16),11 or had contraindications to undergo MRI (n=117), 832 persons were eligible for 
our study. Among these, 563 participants gave their written informed consent to participate in 
the study (response rate, 68%), which included undergoing a MRI brain scan. The study was 
approved by the medical ethics committee of Erasmus MC, Rotterdam, the Netherlands.
MRI procedures
All subjects underwent T1-, T2-, and proton-density–weighted images in a 1.5-T magnetic 
resonance unit (VISION MR; Siemens, Erlangen, Germany).12 For volumetric measurements 
of the hippocampus, a custom-made, inversion recovery—double contrast, 3-dimensional, 
half-Fourier acquisition single-shot turbo spin-echo (HASTE) sequence was included (inver-
sion time, 440 milliseconds; repetition time, 2800 milliseconds; 128 contiguous sagittal slices 
of 1.2-mm; acquisition matrix, 192×256 pixels; and ﬁeld of view, 256×256 cm). Two HASTE 
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modules were sequentially acquired after the inversion pulse (effective echo times of 29 mil-
liseconds and 440 milliseconds). Each HASTE module combined nonselective radiofrequency 
excitations to provide a short interecho spacing of 3.9 milliseconds. The ﬁ rst HASTE module 
was used for the hippocampal volume measurement.
Hippocampal volumes
We reconstructed a series of coronal brain slices (contiguous 1.5-mm slices) based on the 
HASTE sequence, aligned to be perpendicular to the long axis of the hippocampus. All recon-
structed slices were transferred to a workstation (Magic View 1000; Siemens) for volumetric 
assessment of the left and right hippocampi (Figure 1). 
Figure 1. Coronal slice on which left and right hippocampus (H) are depicted
Referencing to an anatomical atlas,13 we manually traced the boundaries of both hippocampi 
on each slice using a mouse-driven pointer. We proceeded from posterior to anterior, starting 
on the slice where the crux of the fornices was in full proﬁ le. The alveus could often be used 
to delineate the boundary of the hippocampal head from the amygdala. Entering the outlined 
surface areas (expressed in millimeters squared), we multiplied the summed surface areas 
on each side with slice thickness to yield estimates of the left and right hippocampal volume 
(expressed in milliliters). In the current analyses the left and right hippocampal volumes were 
summed.
We also reconstructed a midsagittal slice (thickness 3.0 mm). The midsagittal area, which 
was used as a proxy for intracranial volume, was measured by tracing the inner table of the 
skull. Two raters (T.d.H. and a colleague) who were blinded to any clinical information related 
to the participants, assessed the scans. Studies performed on 14 random scans to evaluate 
intrarater and interrater correlation showed good overall agreement.
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Memory performance
All participants underwent neuropsychological testing.12 The Mini-Mental State Examination 
was administered to assess global cognitive function.14 Memory function was evaluated by 
a 15-word learning test based on the Rey Auditory Verbal Learning Test.15 This test consists 
of 3 learning trials in which 15 words have to be remembered. After 15 minutes, the subject 
is asked to recall as many words as possible (delayed recall). In the present study we used 
the delayed recall score because this score is most strongly associated with hippocampal 
volumes16 and with early AD.17
Blood measurements
Venapuncture was done in nonfasting subjects between 8:30 AM and 4 PM at baseline exam-
ination of the Rotterdam Scan Study (1990-1993). Blood samples were collected in 5-ml tubes 
containing a 0.5-ml sodium citrate solution. All tubes were stored on ice before and after 
blood sampling. Platelet-free plasma was obtained by 2-stage centrifugation (10 minutes at 
1600g at 4ºC and 30 minutes at 7000g at 4ºC). Platelet-free samples were immediately frozen 
in liquid nitrogen and stored at –80ºC. Assays were performed blinded to information on the 
subject. Plasma levels of estradiol and sex hormone–binding globulin were estimated with 
double antibody radioimmunoassays (ultrasensitive method for estradiol; Diagnostic Systems 
Laboratories, Webster, Tex). Because of the small volumes of plasma available, all estradiol 
levels are single sample estimations. Intra-assay coefﬁcients of variation, determined on the 
basis of duplicate results of internal quality control pools with 3 different levels of each ana-
lyte, were below 4% for sex hormone–binding globulin and 18% for estradiol. Because inter-
assay variations were 14% (sex hormone–binding globulin) and 21% (estradiol), results of all 
batches were normalized by multiplying all concentrations within a batch with a factor, which 
equalized results for the internal quality control pools. As measures of the levels of bioavail-
able and free estradiol, nonsex hormone–binding globulin-bound estradiol, and nonprotein-
bound estradiol, respectively, were calculated on the basis of hormone and binding protein 
levels.18, 19 The median interval from blood sampling (1990-1993) to hippocampal volumes and 
memory testing (1995-1996) was 2.9 years (range, 1.6-6.6 years).
Covariates
Several variables may confound an association between estradiol levels and hippocampal 
volume or memory performance, such as age at the time of venapuncture, educational level, 
smoking habits, alcohol intake, body mass index (BMI) (calculated as weight in kilograms 
divided by the height in meters squared), depressive symptoms, apolipoprotein E (APOE) 
genotype, and for women, the variables included type of menopause, age at menopause, and 
use of hormone replacement therapy (HRT) (ie, those who ever used HRT or those who never 
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used HRT) for menopausal reports  (Anatomical Therapeutical Chemical code g03). The level 
of education was dichotomized into primary education and lower vocational training and uni-
versity education. We categorized smoking status into current, former, and never and made 
dummy variables for the analyses. Alcohol intake was recorded in grams per day.20 Depres-
sive symptoms were assessed using the Center for Epidemiologic Studies Depression Scale 
(CES-D)21 at time of assessment of memory performance. Apolipoprotein E genotyping was 
done according to standard methods22 and was coded into non-APOE ε4 carrier and APOE 
ε4 carrier. Type of menopause was classiﬁed into natural or artiﬁcial (surgically or chemically 
induced). Age at natural menopause was deﬁned as the age at which menses had not oc-
curred for at least 1 year. Type and age of menopause were combined in 1 categorical variable 
with 4 groups: (1) artiﬁcial menopause, (2) natural menopause before the age of 48 years, (3) 
natural menopause between ages 48 and 52 years, or (4) natural menopause after the age of 
52 years.
Study sample
To obtain the study samples for the analyses, we excluded 4 women who used HRT at the 
time of blood drawing, leaving 559 subjects (Figure 2). Because estradiol levels were meas-
ured as part of several blood measurements and small amounts of plasma were available, we 
randomly missed total estradiol levels for 147 subjects. Thus, 412 subjects for the analyses 
on total estradiol levels were included. Because of missing data on binding protein levels 
(n=101), we had bioavailable and free-estradiol levels in 311 subjects. These 311 subjects with 
bioavailable and free-estradiol levels were similar to the 248 subjects who were dropped from 
these analyses for age, hippocampal volume, and delayed recall score.
Data analysis
All analyses were performed in women and men separately. We ﬁrst investigated whether 
there was a threshold in the relation between estradiol level and outcome by analysis of 
covariance (ANCOVA). Tertiles of total, bioavailable, and free estradiol were the group vari-
able and we calculated adjusted mean hippocampal volumes and delayed recall scores in 
each tertile. Three consecutive models were used. The ﬁrst adjusted for age and —in the 
hippocampal analyses— midsagittal area to account for intracranial volume.23 After separately 
investigating several covariates, it appeared as if the BMI was the strongest confounder in the 
associations so the second model was adjusted, in addition to age and midsagittal area, for 
BMI. In the third model we additionally entered educational level, smoking, alcohol use, CES-
D score, APOE genotype, and, for women, age at menopause, type of menopause, and use 
of ever taking HRT. Because the ANCOVA did not suggest a speciﬁc threshold in the relation 
between estradiol levels and outcome, we performed a multivariate linear regression analysis 
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to calculate the difference in hippocampal volume and delayed recall score per SD increase 
in estrogen levels. To investigate whether there was an indication of differential associations 
in age strata (<70 years and ≥70 years) or APOE genotype, we included in the multivariate 
linear model an interaction term and performed stratiﬁ ed analyses. Finally, we repeated the 
analyses excluding women with a history of HRT use.
Figure 2. Description of study sample
Results
Of the 210 women and 202 men with total estradiol measurements, 24 women and 16 men 
had no hippocampal volume assessment (because they developed claustrophobia during the 
MRI) and 6 women and 8 men had no reliable delayed recall data (mostly owing to motiva-
tional problems). Characteristics of the study sample are given in Table 1. There were no differ-
ences in the characteristics between subjects with total estradiol levels and subjects without 
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total estradiol levels. Estradiol levels of women were lower than those of men, reﬂecting the 
fact that women were postmenopausal and were not taking HRT at time of venipuncture.
Table 1. Characteristics of study sample 
Characteristic
Women 
(n=210)
Men
(n=202)
Subjects without total 
estradiol levels (n=147)
Age, years 70 ± 8 69 ± 8 71± 8
BMI, kg/m2 26.8 ± 3.9 26.1 ± 2.9 26.3 ± 3.2 
Primary education, % 37 23 34
Current smoking, % 16 24 23
Alcohol, g/day 7.6 ± 11.5 17.4 ± 10.9 13.7 ± 17.0
CES-D score 7.0 ± 6.6 4.6 ± 5.3 5.0 ± 5.7
APOE genotype, % ε4 carrier 27 32 27
MMSE score 27.6 ± 2.3 27.8 ± 2.1 27.7 ± 2.0
Total estradiol
   median (range), pmol/l
13.4 (0.0-65) 45.3 (0.0-157) -
Bioavailable estradiol
   median (range), pmol/l*
8.8 (0.0-49) 34 (0.0-120) -
Free estradiol
   median (range), pmol/l*
0.32 (0.00-1.73) 1.22 (0.00-4.20) -
Midsagittal area, cm2† 143.1 ± 8.8 155.2 ± 9.9 149.3 ± 11.1
Hippocampus, ml† 6.17 ± 0.81 6.59 ± 0.89 6.36 ± 0.88
Delayed recall score‡ 6.2 ± 2.8 5.5 ± 2.4 5.4 ± 2.6
Values are means ± standard deviation or percentages unless otherwise speciﬁed
*Values were present in 162 women and 149 men
†Values were present in 186 women and 186 men
‡Values were present in 204 women and 194 men. Higher scores reﬂect better performance
In women, estradiol levels were negatively correlated with age and positively correlated with 
BMI. In men, estradiol levels were negatively correlated with age and positively correlated 
with alcohol intake and CES-D score (Table 2). Hippocampal volumes and delayed recall 
scores decreased with increasing age (both in women and men, –0.03 ml/y and –0.1 words 
per year).
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Figure 3. Adjusted hippocampal volumes (SE) (A and C) and delayed recall (SE) (B and D) across tertiles of 
total, bioavailable, and free-estradiol levels in women and men, respectively. A and B, Means are adjusted 
for age, educational level, BMI, alcohol, smoking, CES-D, type of menopause, age at menopause, ever 
use of HRT, APOE genotype, and the hippocampal volumes–midsagittal area. Tertile ranges (in picomoles 
per liter) were for total estradiol levels 0.0-7.3, 7.3-19, and 20-65; for bioavailable estradiol levels 0.0-5.2, 
5.2-14, and 14-49; and for free-estradiol levels 0.00-0.19, 0.19-0.50, and 0.50-1.73. Asterisks indicate 
statistically signiﬁcantly (P<0.05) smaller than lowest tertile. C and D, Means are adjusted for age, edu-
cational level, BMI, alcohol, smoking, CES-D, APOE genotype, and the hippocampal volumes–midsagittal 
area. Tertile ranges (in picomoles per liter) were for total estradiol level 0.0-36, 36-52, and 52-157; for 
bioavailable estradiol level 0.0-27, 27-40, and 40-120; and for free-estradiol level 0.00-0.97, 0.97-1.49, and 
1.49-4.20
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Table 2. Correlations between several continuous variables in women (n=210) and in men (n=202)
Total estradiol Age Education BMI
Alcohol 
intake
CES-D
Age 
   (per year)
-0.49*
-0.62*
Education
   (per grade)
-0.08 -1.02*
-0.87 -0.22
BMI 
   (per kg/m2)
0.97* 0.24 -0.05*
1.04 0.04 -0.06
Alcohol intake 
   (per grams/day)
0.01 -0.13* 0.01 -0.03
0.33* -0.04 -0.00 0.02
CES-D 
   (per point)
-0.27 0.20* -0.02 -0.04 0.02
0.77* -0.05 0.02 0.03 0.20
Midsagittal area 
   (per cm2)
0.23 -0.22* 0.02* 0.01 -0.05 -0.10*
0.14 -0.07 0.02 -0.01 -0.11 0.05
Values are unadjusted regression coefﬁcients in women and in men (italic numbers). The variables in the 
left column are the independent variables and the variables in the upper row the dependent variables.
*P<0.05
Women
Estradiol level and hippocampal volume
In women, the age- and midsagittal-adjusted mean hippocampal volumes decreased across 
higher tertiles of total (SE) estradiol levels from 6.24 (0.10) ml to 6.22 (0.10) ml to 6.07 (0.10) 
ml, but there were no signiﬁcant differences between tertiles. When the BMI was included as 
a covariate, the mean (SE) hippocampal volumes were 6.28 (0.10) ml; 6.21 (0.10) ml, and 6.04 
(0.10) ml, respectively, but differences were again not statistically signiﬁcant. Figure 3A shows 
that after additional adjustments for all other covariates the negative association between 
the total estradiol level and hippocampal volume became statistically signiﬁcant (difference 
between the highest and lowest tertile of total estradiol –0.29 ml [95% conﬁdence interval 
(CI), –0.57 to –0.00]). When we analyzed the total estradiol level as a continuous measure, we 
found a nonsigniﬁcant decrease in hippocampal volume per SD increase in total estradiol level 
(Table 3). There was a nonsigniﬁcant inverse relation between the bioavailable estradiol level 
and hippocampal volumes (the age- and midsagittal-adjusted means of hippocampal volume 
across higher bioavailable estradiol tertiles was 6.22 (0.12) ml, 6.17 (0.11) ml, and 6.00 (0.11) 
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ml. When the BMI was included in the model, a signiﬁcant smaller hippocampal volume was 
found in women with bioavailable estradiol levels in the highest tertile of bioavailable estradiol 
compared with the lowest tertile (difference, –0.37 ml [95% CI, –0.71 to –0.03]). Additional 
adjustments did not change this inverse relation (Figure 3A). When we analyzed bioavailable 
estradiol levels as a continuous measure, we found a nonsigniﬁcant decrease of hippocampal 
volume of –0.09 ml (95% CI, –0.25 to 0.06) per SD (10-pmol/L) increase. 
Table 3. Associations between total estradiol levels, hippocampal volumes and memory performance
Women Per increase of 1 SD (14 pmol/l) in total estradiol level 
Adjusted for Hippocampal volume (ml) Delayed recall
Age, midsagittal area* -0.01 (-0.12 to 0.10) -0.1 (-0.4 to 0.3)
Age, midsagittal area*, BMI -0.04 (-0.16 to 0.08) -0.1 (-0.5 to 0.3)
Age, midsagittal area*, BMI, 
education, alcohol intake, 
smoking, CES-D, APOE 
genotype, age and type of 
menopause, ever use of HRT
-0.06 (-0.18 to 0.06) -0.1 (-0.5 to 0.3)
Men Per increase of 1 SD (23 pmol/l) in total estradiol level
Adjusted for Hippocampal volume (ml) Delayed recall
Age, midsagittal area* 0.02 (-0.10 to 0.15) -0.4 (-0.7 to –0.0)
Age, midsagittal area*, BMI -0.01 (-0.05 to 0.03) -0.4 (-0.7 to 0.0)
Age, midsagittal area*, BMI, 
education, alcohol intake, 
smoking, CES-D, APOE 
genotype
0.04 (-0.09 to 0.18) -0.3 (-0.7 to 0.1)
Values are adjusted regression coefﬁcients (95% CI) of the relation between total estradiol level and hip-
pocampal volume/delayed recall.
*Adjusted for only in the hippocampal analyses
The relation between free estradiol levels and hippocampal volumes was similar to that of 
bioavailable estradiol levels (Figure 3A). The inverse associations between estradiol levels and 
hippocampal volumes were primarily seen in the oldest age group (in age<70 years: per SD 
Plasma estrogens and hippocampal atrophy
77
increase in total estradiol level the fully adjusted difference in hippocampal volumes was 0.07 
ml [95% CI, –0.09 to 0.23]; in age ≥70 years: –0.24 ml [95% CI, –0.44 to –0.04]; P of interac-
tion term 0.04). The negative associations between estradiol level and hippocampal volumes 
were more pronounced in APOE ε4 carriers than in non-APOE ε4 carriers, although the inter-
action term was not statistically signiﬁcant (Table 4).
Table 4. Associations between total estradiol levels and hippocampal volumes and memory performance 
in women according to APOE  ε4 strata
Hippocampal volumes
Adjusted for Non-APOE ε4 carrier APOE ε4 carrier P interaction term*
Age, midsagittal area, BMI, 
education, alcohol intake, 
smoking, CES-D, age and type 
of menopause, ever use of 
HRT
0.01  (–0.16 to 0.17) –0.25 (–0.46 to –0.03) 0.07
Delayed recall
Adjusted for Non-APOE ε4 carrier APOE ε4 carrier P interaction term*
Age, BMI, education, alcohol 
intake, smoking, CES-D, age 
and type of menopause, ever 
use of HRT
–0.10 (–0.61 to 0.41) 0.44 (–0.21 to 1.09) 0.29
Values are adjusted regression coefﬁcients (95% CI) of the relation between total estradiol level (per 1 
SD increase) and hippocampal volume/delayed recall
* P-value of interaction term (APOE strata x total estradiol level) in the multivariate linear regression 
analysis
Estradiol level and memory
The age-adjusted delayed recall score decreased nonsigniﬁcantly across total estradiol tertiles 
from 6.5 (0.3) to 6.1 (0.3) to 6.1 (0.3) words. Figure 3B shows that additional adjustments for 
other covariates did not substantially change these results. The fully adjusted difference in 
delayed recall words between the highest and lowest tertile of total estradiol levels was –0.4 
(95% CI, –1.3 to 0.5). When we analyzed the total estradiol level as a continuous measure, 
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we found a nonsigniﬁcant decrease in delayed recall words (Table 3). There was a signiﬁcant 
inverse relation between bioavailable estradiol tertiles and delayed recall (Figure 3B), although 
when we analyzed bioavailable estradiol levels continuously, we found a nonsigniﬁcant de-
crease in delayed recall words of –0.2 (95% CI, –0.7 to 0.2) per SD increase. The results were 
similar for the relation between the free estradiol level and delayed recall score (Figure 3B). 
Again, the inverse associations between the estradiol level and memory were stronger in the 
oldest age groups (data not shown). The associations were not different in APOE ε4 strata 
(Table 4). Exclusion of women who had used HRT in the past (n=17) did not change any of 
the above results.
Men
Estradiol level and hippocampal volume
In men, there was no association between estradiol levels and hippocampal volumes (age and 
midsagittal-adjusted hippocampal volumes in total estradiol tertiles: 6.55 [0.11] ml, 6.68 [0.11] 
ml, and 6.52 [0.11]) ml). Additional adjustments for the other covariates did not change these 
estimates (Figure 3C and Table 3). There was also no association between bioavailable or free-
estradiol levels and hippocampal volume (Figure 3C). There were no differential associations 
in age strata or in APOE ε4 strata (data not shown).
Estradiol level and memory
When we investigated the relation between estradiol levels and memory performance in 
men, a similar pattern as in women emerged. The age-adjusted delayed recall scores de-
creased across increasing total estradiol tertiles from 6.1 (0.3) to 5.4 (0.3) to 5.1 (0.3) words. 
When we analyzed the total estradiol level as continuous measure, we found a decrease in 
delayed recall with increasing levels (Table 3). Additional adjustments for covariates did not 
change this association (Figure 3D and Table 3). The association of delayed recall score with 
bioavailable and free estradiol levels showed a similar pattern as with the total estradiol level 
(Figure 3D). There were no differences in the associations in age strata or in APOE ε4 strata 
(data not shown).
Discussion
In this population-based study in elderly subjects with no dementia, we could not support the 
hypothesis that higher endogenous levels of estradiol are associated with larger hippocampal 
volumes on MRI and better memory performance. Women with higher estradiol levels had 
smaller hippocampal volumes and poorer memory performance than women with lower lev-
els. In men, there was no relation between estradiol level and hippocampal volumes, but 
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memory performance was worse in those with higher levels of total estradiol compared with 
those with lower levels.
The strengths of this study are that it is population based and involves a large number of 
volumetric hippocampal assessments. Our study has several methodological limitations that 
need to be discussed. First, owing to the small amounts of plasma available, we had a large 
number of missing data on bioavailable and free-estradiol levels. Although these missing data 
were random, the smaller sample size will have resulted in less precise estimates of the as-
sociations. Second, blood was drawn several years before MRI and memory performance. It 
is difﬁcult to determine if this inﬂuenced our results. It may have led to biased associations if 
subjects with estradiol levels on one side of the distribution selectively died between blood 
drawing and MRI measurement. This does not seem likely, however, because the interval be-
tween blood drawing and MRI was not long, and the relation between endogenous estradiol 
levels and mortality is not strong.24 Third, HRT use in the Netherlands is infrequent compared 
with, for example, the United States. Our results were based on observations in non-HRT 
users and they may not be generalizable to HRT users.
The most consistent support for the hypothesis that estrogens prevent dementia comes 
from animal studies that showed that estrogens protect against cell loss in the hippocam-
pus, increase neurite outgrowth, and have antioxidative properties.3, 25 In humans, observa-
tional studies on endogenous levels of estrogen in relation to cognitive function have been 
inconclusive. Some reported negative effects of higher endogenous estrogen levels on de-
layed visual reproduction26 and attention tasks27 in women and on the results of the MMSE, 
memory tasks,28 and spatial performance29 in men, while others showed in women posi-
tive effects of higher endogenous estrogen levels on verbal memory30 or cognitive decline.31 
Population-based studies on exogenous estrogens showed that women who used HRT had a 
reduced risk of AD1, 2, 32 but these studies may have been confounded by healthy-user effect. 
Also, other studies did not conﬁrm this observation.33-35 Recent randomized trials with HRT 
in patients with AD showed no36-38 or a beneﬁcial effect of exogenous estrogen on cognitive 
decline.39 Together, the biological plausibility of the estrogen hypothesis in dementia is its 
strongest plea, whereas studies in humans are far from conclusive. Our results are contrary 
to what we expected in that we observed a small negative effect of higher estradiol levels on 
both hippocampal volumes in women and memory performance in women and men. As yet, 
we do not have a biological plausible explanation for these results. When interpreting these 
data, one has to keep in mind that the endogenous levels in our study sample of postmeno-
pausal women are much lower than the levels obtained after supplemental use of exogenous 
estrogens. Therefore, our data do not reject the possibility that exogenous estrogens are 
related to larger hippocampal volumes and better memory performance.
Chapter 3.1
80
Conclusion
This study does not support the hypothesis that higher endogenous estrogen levels in older 
women and men without dementia are associated with larger hippocampal volumes and 
better memory performance.
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Chapter 3.2
Estrogen receptor α polymorphisms, dementia and atrophy of the 
medial temporal lobe
The role of estrogens in Alzheimer’s disease is controversial. We investigated the association 
between well-recognized, and potentially functional, polymorphisms in the estrogen recep-
tor (ER) α gene and risk of Alzheimer’s disease in a large prospective study of 6056 Cauca-
sian elderly aged 55 years and over. Furthermore, we performed a meta-analysis based on 
published results of 5 other studies. In a subset of 468 non-demented elderly we assessed 
volumes of the hippocampus and amygdala, which have a high density of ERα, by means of 
brain magnetic resonance imaging (MRI). During a total of 35405 person-years of follow-up 
(mean per persons 5.8 years), 312 new cases of dementia were detected of whom 230 were 
diagnosed with Alzheimer’s disease. Neither the PvuII nor the XbaI polymorphism or haplo-
types thereof were associated with the risk of all-cause dementia or Alzheimer’s disease, 
which was conﬁrmed by the meta-analysis. In contrast, we found that non-demented women 
who carried the PvuII p allele or haplotype ‘px’ had smaller amygdalar volumes on MRI in 
an allele-dose dependent fashion. Further studies are required to investigate whether this 
smaller amygdalar volume has functional signiﬁcance.
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Introduction
In the last decade of the 20th century numerous cellular, molecular and epidemiological studies 
suggested a protective effect of estrogen on Alzheimer’s disease. Estrogen protects against 
neuronal death,1 improves survival of hippocampal neurones,2 acts as an antioxidant,3 and 
stimulates cerebral blood ﬂow.4 Observational studies reported that postmenopausal women 
who used estrogen replacement therapy have a lower risk of dementia.5, 6 Conversely, a large 
randomised trial on estrogen replacement therapy for preventing Alzheimer’s disease was 
negative.7 This, in turn, is in line with ﬁndings from our group that higher endogenous estradiol 
levels, if anything, are associated with a higher risk of dementia.8
Estrogens exert most of their effects through intracellular activation of estrogen receptors. 
There are two known forms of estrogen receptors: the estrogen receptor α (ERα) and the 
estrogen receptor ß, both expressed in the brain.3, 9 Several studies examined the PvuII and 
XbaI polymorphisms in the gene for ERα in association to Alzheimer’s disease with different 
results.10-16 Except for one prospective study,10 most reports were based on case-control se-
ries with inherent limitations of selection.11-16 The aim of the current study was to investigate 
polymorphisms in the ERα gene and risk of dementia in a large prospective population-based 
cohort study in the Netherlands. We included a meta-analysis of all published data. In a sub-
set of the cohort, MRI of the brain was made to assess volumes of the hippocampus and 
amygdala. The hippocampus and amygdala are structures in the medial temporal lobe that 
express ERα at relatively high levels.9 If ERα polymorphisms are associated with macroscopic 
changes in brain volume, we would expect to ﬁnd it for these two structures. An additional 
rationale for studying these structures is that hippocampal and amygdalar atrophy on MRI are 
seen early in Alzheimer’s disease.17, 18 The putative risk on Alzheimer’s disease associated with 
ERα polymorphisms could be mediated through effects on the hippocampus and amygdala. 
The ε4 allele of the apolipoprotein E (APOE) is a well-known genetic risk factor for Alzheimer’s 
disease,19 and estrogens inﬂuence regulation of APOE synthesis.20 Previous reports suggest-
ed differential effects of the ERα genotype on risk of Alzheimer’s disease within APOE ε4 or 
non-ε4 carriers,12, 14 therefore we performed stratiﬁed analyses according to APOE genotype.
Methods
Study population
This study is based on the Rotterdam Study, a large prospective population-based study in 
7983 elderly aged 55 years or older that aims to assess determinants of diseases in later life.21 
The Medical Ethics Committee of Erasmus Medical Center approved the study protocol and 
participants gave written informed consent. Baseline examinations took place from 1990 to 
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1993. A trained research assistant visited participants at home and obtained information on 
medication use, medical history and determinants of diseases. Participants were invited to 
visit the research center for clinical examinations by the research physicians. Re-examinations 
were performed in 1993 to 1994 and 1997 to 1999. Of the 7983 participants at baseline, 7528 
(94.3%) were screened and examined for prevalent dementia. There were 482 participants 
diagnosed with prevalent dementia.22 Thus, 7046 participants comprised the cohort at risk for 
dementia of whom 6934 were of Caucasian origin.
Dementia diagnosis
Participants were examined for presence of dementia at the research center at follow-up 
visits. A three-step protocol was used as described in detail elsewhere.23 Brieﬂy, all partici-
pants were screened with the Mini-Mental State Examination (MMSE) and the Geriatric Men-
tal State schedule (GMS), organic level. Screen positives (persons scoring below 26 on the 
MMSE or more than 0 on the GMS) underwent cognitive testing with the Cambridge ex-
amination for mental disorders in the elderly, which included an informant interview. Persons 
suspected of dementia were examined by a neurologist and underwent extensive neuropsy-
chological testing. In addition to this in-person screening,24 all participants were continuously 
monitored for development of dementia through linkage of the general practitioners’ medical 
record system to the database of the Rotterdam Study. We also consulted the Regional In-
stitute for Outpatient Mental Health Care (RIAGG) at a regular basis and checked all relevant 
reports. Surveillance of the population through the general practitioner and RIAGG reports 
continued up to December 31, 1999. A diagnosis of dementia and its subtypes were made 
according to international standard criteria by a panel consisting of a neurologist, neuropsy-
chologist and study physician.25, 26 
Subset with MRI examinations
In 1995 to 1996, we made a random selection of 965 living members of the cohort in strata 
of age (5-years strata from 60 to 90) and sex for participation in the Rotterdam Scan Study, 
designed to study age-related brain changes on MRI.27 As part of the eligibility criteria, we ex-
cluded persons who had developed dementia between baseline and time of selection (n=17) 
and persons who had contraindications to undergo MRI (n=116). This left 832 participants 
eligible. Complete MRI data, including a three-dimensional (3D) volumetric MRI sequence 
covering the whole brain, was obtained in 511 persons. 
MRI procedures 
We reformatted coronal brain slices (contiguous 1.5-mm slices) and a middle sagittal slice 
from the 3D MRI sequence. The coronal slices were orientated perpendicular to the long 
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axis of the hippocampus. The procedure of segmenting the hippocampus and amygdala on 
coronal slices has been described.28 The left and the right hippocampus and amygdala were 
manually outlined on each slice with a mouse-driven cursor.29 Absolute volumes (ml) were 
calculated by multiplying the areas on each slice by the slice thickness and left and right side 
were summed. As a proxy for head size, we measured on a reformatted middle sagittal MRI 
slice the intracranial cross-sectional area.29 We corrected for head size differences across 
individuals by dividing the uncorrected volumes by the subject’s calculated head size area 
and subsequently multiplying this ratio by the average head size area (men and women sepa-
rately).18, 30 
ERα polymorphisms
Genomic DNA was isolated from peripheral leucocytes by standard procedures. Genotypes 
were determined using the Taqman allelic discrimination assay. Primer and probe sequences 
were optimized using the single nucleotide polymorphism assay-by-design service of Applied 
Biosystems. For details see http://store.appliedbiosystems.com. Reactions were performed 
on the Taqman Prism 7900HT 384 wells format. The coding for the ERα polymorphisms PvuII 
and XbaI follows that of previous studies on the ERα polymorphisms. Capital “P” and “X” 
stands for absence of a restriction site (indicating respectively nucleotide C and nucleotide 
G) and lower case letter “p” and “x” stands for presence of restriction site (nucleotide T and 
nucleotide A). Persons were classiﬁed as either non-carrier, heterozygous or homozygous for 
the allele. To increase genetic resolution we created also PvuII-XbaI haplotypes as reported 
previously.31 Haplotype alleles were coded as haplotype numbers 1 through 4 in order of de-
creasing frequency in the population (1=px, 2=PX, 3=Px, and 4=pX). We examined the poly-
morphisms PvuII and XbaI separately in relation to outcome to make our results comparable 
with earlier studies on dementia and examined haplotype 1 based on previous work from our 
group showing this to be the risk allele of osteoporosis.31 
Analytical study samples
We missed genotyping of the ERα polymorphism in some persons because no blood was 
drawn or there were problems in the technical processing of the blood samples. Of the 6934 
members of the cohort at risk for dementia, we determined the PvuII and XbaI genotype in 
6056. The 878 persons without genotype were on average 4.8 years older (P<0.001); and 
more frequently women (67% versus 59%; P<0.001) compared to the 6056 participants with 
genotype. Of the 511 participants in the subset with MRI examinations, we determined the 
ERα genotype in 468 participants. The remaining 43 participants were similar in mean age 
(P=0.31) but more frequently women (63% versus 48%, P=0.06) compared to the 468 par-
ticipants with genotype.
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Other measurements
At baseline examinations, we ascertained by interview or physical examination level of educa-
tion (primary versus lower vocational to university education), smoking status (current, former 
or never), body mass index (weight divided by the square of the height), age at menopause 
(either natural or surgically induced)32 and use of estrogen replacement therapy (ever versus 
never). APOE genotype was determined in 5281 participants of the total cohort and in 404 
participants of the subset with MRI examination.33 We classiﬁed participants into those with 
or without the ε4 allele. 
 
Data analysis
Analyses were done separately in men and women. We compared baseline characteristics in 
ERα genotype using one-way analysis of variance or χ2 analysis in the total study cohort. The 
hazard ratios of dementia and Alzheimer’s disease were estimated using a Cox proportional 
hazard model in which time scale is the age of participants. Left truncation of the cohort was 
accounted for by using the “counting process” notation available in S-Plus.34 In the subset 
with MRI examinations, we used analysis of covariance to compute age adjusted means of 
the brain volumes on MRI within genotype. Because preliminary analyses did not suggest 
a dominant or recessive effect of the polymorphisms, we analyzed the association using an 
allele-dose model. The genotype was entered as a linear term in the model to yield P-values of 
the allele-dose trend. Besides age, we additionally included the following confounders in the 
analyses that have previously been associated to dementia: level of education,22 body mass 
index,35 smoking,36 age at menopause,37 and ever use of estrogen replacement therapy.38 
Meta-analysis
We identiﬁed studies on the ERα polymorphisms and Alzheimer’s disease by searching 
Medline (1966 to May 2003) using “Alzheimer’s disease” and “estrogen receptor” as key 
words. The reference list of each paper was checked for additional studies. Seven papers 
were identiﬁed10-16 of which ﬁve investigated Caucasian populations.10, 13-16 These ﬁve papers 
reported on six independent case-control series and one prospective study. Odds ratios (OR) 
of Alzheimer’s disease with 95% conﬁdence interval (CI) were computed for each study. In 
case a paper did not report results in men and women separately we contacted the authors 
to provide these data. From one author we could not retrieve the data and this study was 
excluded.16 The meta-analyses were based on the log odds ratios and their standard errors 
and we used random effects models to compute the combined OR of Alzheimer’s disease 
across ERα genotype.
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Results
Allele frequencies of the ERα polymorphisms were in Hardy-Weinberg equilibrium and similar 
to frequencies found in other Caucasian populations (Table 1).39, 40
Table 1. ERα polymorphisms (PvuII and XbaI) in total study sample and in subset with MRI examina-
tions
Total sample (n=6056) Subset with MRI (n=468)
Men 
(n=2483)
Women 
(n=3573)
Men 
(n=244)
Women 
(n=224)
PvuII*
P 2326 (47) 3312 (46) 235 (48) 199 (44)
p 2640 (53) 3834 (54) 253 (52) 249 (56)
PP 539 (22) 780 (22) 58 (24) 39 (17)
Genotype Pp 1248 (50) 1752 (49) 119 (49) 121 (54)
pp 696 (28) 1041 (29) 67 (27) 64 (29)
Hardy-Weinberg† 0.64 0.40 0.72 0.16
XbaI*
X 1720 (35) 2487 (35) 183 (38) 157 (35)
x 3246 (65) 4759 (65) 305 (62) 291 (65)
XX 290 (12) 445 (13) 37 (15) 23 (10)
Genotype Xx 1140 (46) 1597 (45) 109 (45) 111 (50)
xx 1053 (42) 1531 (43) 98 (40) 90 (40)
Hardy-Weinberg† 0.49 0.37 0.47 0.19
*Numbers (%).
†P-value for test of Hardy-Weinberg equilibrium
Baseline characteristics of the total study sample and of the subset with MRI examinations 
are given in Table 2. Characteristics across genotype were analyzed in the total study sample. 
There were no signiﬁcant differences in age, educational level, smoking, body mass index or 
Allele
Allele
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ever use of hormone replacement therapy across genotype. Women with the pp genotype 
had a 0.5 years later age of menopause compared to women with the PP genotype (P = 0.03), 
which conﬁrms our previous report in a smaller part of the cohort.32
Table 2. Baseline characteristics of the total study sample and of the subset with MRI examinations
Total sample (n=6056) Subset with MRI (n=468)
Characteristic
Men
(n=2483)
Women
(n=3573)
Men
(n=244)
Women
(n=224)
Age, yr 67.9 ± 7.9 69.8 ± 9.2 68.7 ± 7.8 68.7 ± 8.3
Primary education only, % 25 44 22 38
Current smoker, % 29 18 22 19
Body mass index, kg/m2 25.8 ± 3.7 26.8 ± 4.1 26.0 ± 2.7 26.7 ± 3.9
Age at menopause, yr - 48.8 ± 5.0 - 48.7 ± 5.1
Ever use of HRT, % - 10 - 9
APOE, ε4 carriers, % 28 28 31 28
MMSE, mean score 27.8 ± 1.7 27.5 ± 2.0 27.9 ± 1.8 27.7 ± 2.2
Values are means ± SD or percentages
 
The MMSE score at baseline was similar across genotype. After baseline, during 35405 per-
sons-years of follow-up (mean per person 5.8 years), 312 participants developed dementia. 
A diagnosis of probable Alzheimer’s disease was made in 230 participants. We found no as-
sociation between ERα polymorphisms and risk of all-cause dementia or Alzheimer’s disease, 
either in men or women (Table 3). This was corroborated by the meta-analysis (Figure 1). 
Additional adjustments for educational level, smoking, body mass index, age at menopause 
and use of estrogen replacement therapy did not change our ﬁndings. There was also no as-
sociation between the ER α polymorphisms and dementia when we separately looked within 
APOE non-ε4 carriers or ε4 carriers (data not shown). 
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In the subset with MRI examinations (n=468), we found smaller hippocampal and amygdalar 
volumes on MRI in women with the pp or xx genotype compared to women with the PP or 
XX genotype (Table 4). There was an allele dose effect: per allele copy of the “p” allele the 
amygdala was –0.17 ml smaller (95% CI –0.30 to –0.05) and per allele copy of the “x” allele 
–0.17 ml (95% CI –0.30 to –0.04). The explained variance in amygdalar volume by the PvuII 
polymorphism above age was 3% (R square change 0.030, F (1,221)=7.11, P=0.008). There 
were 25 cases of incident dementia in the subset with MRI and excluding them did not 
change the results. There was no association between the ERα polymorphism and brain vol-
umes in men. Additional adjustments for educational level, smoking, body mass index, age at 
menopause and use of estrogen replacement therapy did not change the results. There was 
no difference in the results when we stratiﬁed by APOE genotype. 
Table 4. The PvuII and XbaI ERα polymorphism and brain volumes on MRI in the subset (n=468)
Hippocampal volumes (ml) Amygdalar volumes (ml)
Men
(n=244)
Women
(n=224)
Men
(n=244)
Women
(n=224)
PvuII 
PP 6.56 ± 0.12 6.32 ± 0.13 4.73 ± 0.10 4.50 ± 0.10
Pp 6.52 ± 0.08 6.22 ± 0.07 4.74 ± 0.07 4.45 ± 0.06
pp 6.56 ± 0.11 6.06 ± 0.10 4.82 ± 0.09 4.18 ± 0.08
Trend 0.99 0.10 0.49 0.008
XbaI 
XX 6.38 ± 0.15 6.28 ± 0.16 4.72 ± 0.12 4.51 ± 0.13
Xx 6.57 ± 0.09 6.28 ± 0.08 4.73 ± 0.07 4.47 ± 0.06
xx 6.56 ± 0.09 6.06 ± 0.08 4.81 ± 0.07 4.24 ± 0.07
Trend 0.41 0.08 0.41 0.01
Values are age adjusted mean volumes (standard error) and P values for trend analyses
The haplotype 1 (px) genotype followed exactly the PvuII genotype and therefore the analyses 
on haplotype 1 in association with outcome were similar as we report for the PvuII polymor-
phism.
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Discussion
In this report based on a large population-based study and meta-analysis we show no effect 
of the PvuII and XbaI polymorphisms in the ERα gene on risk of dementia. However, we ob-
served women with the p or x allele or haplotypes thereof to have smaller amygdalar volumes 
on MRI compared to women with the P or X allele. There was no differential effect according 
to APOE genotype.
Potential dangers of genetic association studies are population stratiﬁcation or heterogeneity. 
This particularly holds for case-control studies in persons of mixed racial origin. In our study, 
this has played no role since all subjects were of Dutch Caucasian origin and can be consi-
dered ethnically homogeneous. Furthermore, allele frequencies were similar to those found 
in studies of other Caucasian subjects.40 
The disruption of ERα in ER-null mice causes memory impairment,41 a proinﬂammatory phe-
notype of microglia localized in the hippocampus and amygdala,42 and abolishment of the 
protective effect of estradiol on ischaemic brain injury.43 Furthermore, brains of patients with 
Alzheimer’s disease have less hippocampal neurons stained with ERα indicating a poten-
tial role of dysfunctional ERα in the pathogenesis of Alzheimer’s disease.44 The PvuII-XbaI 
polymorphisms in the ERα gene are attractive polymorphisms to investigate in association to 
Alzheimer’s disease as they have been implicated in estrogen-related diseases such as oste-
oporosis,31 heart disease,45 and breast cancer.46 Also, we recently showed that women carry-
ing the px haplotype were shorter. Given that the PvuII and XbaI polymorphisms are in strong 
linkage disequilibrium31 it is difﬁcult to determine which of the two polymorphic sites is driving 
the associations. Both of them have an intronic localization and functional consequences on 
a biochemical level have still not been established. Interestingly though, Herrington et al.47 re-
cently showed that the T-allele of the PvuII polymorphism –corresponding to the “p” allele in 
our analyses– lacks a binding site for the transcription factor bMyb, which might result in low-
er ERα transcription. Nuclear ERα receptors bind to estrogen response elements in promotor 
regions of target genes which in turn stimulate expression of genes thought to be involved in 
neuroprotection.48 Therefore, neurons expressing low ERα may be posed vulnerable to toxic 
events. Moreover, women with the p allele have a later age of menopause as shown in the 
current sample which extends our previous smaller sample32 and later age of menopause is 
associated with a higher risk of Alzheimer’s disease.37 Our ﬁndings however did not support 
the hypothesis that ERα PvuII-XbaI genotypes are associated to vulnerability to Alzheimer’s 
disease. We did ﬁnd the ERα PvuII-XbaI genotype to be associated to amygdalar volume in 
women. This could be a false positive ﬁnding. However, the population-based design, the size 
of the sample and the allele-dose effect of the relation supports a true association. Further-
more, genotype effects were similar, although weaker, for the hippocampus. This is in striking 
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similarity with the higher density of ERα in the amygdala compared to the hippocampus.9, 49 
Although amygdalar atrophy is found in early Alzheimer’s disease,18 exclusion of people who 
developed Alzheimer’s disease during follow-up did not change the results. This limits the pos-
sibility that early Alzheimer’s disease accounted for the ﬁndings on the amygdala. Does this 
smaller amygdalar volume then have any functional signiﬁcance? The amygdala has several 
functions in emotional behavior and fear conditioning and amygdalar atrophy is reported in 
anxiety disorders.50-53 One may speculate that amygdalar atrophy could be the structural link 
between recently reported associations of polymorphisms in the ERα gene and anxiety.50, 51, 
54 Future studies should include both amygdala volume and psychometric assessments of 
anxiety to test this hypothesis.
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Chapter 3.3
Diabetes mellitus and medial temporal lobe atrophy
Aim/hypothesis: Type 2 diabetes increases the risk not only of vascular dementia but also of 
Alzheimer’s disease. The question remains whether diabetes increases the risk of Alzheimer’s 
disease by diabetic vasculopathy or whether diabetes inﬂuences directly the development of 
Alzheimer neuropathology. In vivo, hippocampal and amygdalar atrophy on brain MRI are good, 
early markers of the degree of Alzheimer neuropathology. We investigated the association 
between diabetes mellitus, insulin resistance and the degree of hippocampal and amygdalar 
atrophy on magnetic resonance imaging (MRI) accounting for vascular pathology.
Methods: Data was obtained in a population-based study of elderly subjects without demen-
tia between 60 to 90 years of age. The presence of diabetes mellitus and, in non-diabetic 
subjects, insulin resistance was assessed for 506 participants in whom hippocampal and 
amygdalar volumes on MRI were measured. We assessed the degree of vascular morbidity 
by rating carotid atherosclerosis, and brain white matter lesions and infarcts on MRI.
Results: Subjects with diabetes mellitus had more hippocampal and amygdalar atrophy on 
MRI compared to subjects without diabetes mellitus. Furthermore, increasing insulin resis-
tance was associated with more amygdalar atrophy on MRI. The associations were not due to 
vascular morbidity being more pronounced in persons with diabetes mellitus.
Conclusions/interpretation: Type 2 diabetes is associated with hippocampal and amygdalar 
atrophy, regardless of vascular pathology. This suggests that type 2 diabetes directly inﬂu-
ences the development of Alzheimer neuropathology.
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Introduction
Type 2 diabetes increases the risk of stroke1 and vascular dementia.2 Recently, patients with 
type 2 diabetes were found to have an increased risk of the most common form of dementia, 
Alzheimer’s disease.3, 4 The pathophysiological mechanism of the relation between diabetes 
mellitus and Alzheimer’s disease is not clear. Diabetic vasculopathy can cause cerebrovascu-
lar brain damage, which is frequently found in patients with Alzheimer’s disease5 However, 
other, more direct effects of diabetes on the development of Alzheimer neuropathology can 
also be involved. Advanced glycation end products increase aggregation of proteins involved 
in Alzheimer’s disease.6 Furthermore, dysfunction of insulin signalling in the brain has been 
implicated in the pathogenesis of Alzheimer’s disease.7 The neuropathology of Alzheimer’s 
disease occurs with greatest severity and in an early stage of the disease in the hippocampus 
and amygdala, brain structures in the medial temporal lobe.8 In vivo assessment of hippocam-
pal volume on magnetic resonance imaging (MRI) of the brain provides a good estimate of the 
degree of Alzheimer neuropathology, even in elderly subjects without clinical symptoms of 
dementia.9 Several studies show that patients with mild Alzheimer’s disease have smaller vol-
umes of the hippocampus10-12 and amygdala13, 14 on MRI compared to healthy control subjects. 
We examined the association between diabetes mellitus, insulin resistance and hippocampal 
and amygdalar atrophy on MRI using these as early MRI markers of Alzheimer’s disease. We 
accounted for atherosclerosis and cerebrovascular disease to examine whether any associa-
tion was caused by concomitant vascular disease.
Methods
Participants
The Rotterdam Study is a large population-based cohort study in the Netherlands that in-
vestigates the prevalence, incidence and determinants of chronic diseases in the elderly.15 
Baseline examinations were done in 1990 to 1993. In 1995 to 1996, we randomly selected 
965 living members (60-90 years of age) of the cohort in strata of sex and age (5 years) to 
participate in the Rotterdam Scan Study, designed to investigate age-related brain abnormali-
ties on MRI.16 After excluding individuals who were demented (n=17)17 or had MRI contrain-
dications (n=116), 832 people were eligible and invited. Among these, 563 participants gave 
their written informed consent and underwent MRI scanning of the brain (participation rate: 
68 %). Participants were in general healthier than non-participants.18 The study protocol was 
approved by the medical ethics committee of the Erasmus Medical Center, Rotterdam, the 
Netherlands.
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Assessment of diabetes mellitus and insulin resistance
Presence of diabetes mellitus was assessed at the baseline of the Rotterdam Study (1990-
1993) and at time of MRI (1995-1996). Participants where considered to have diabetes mellitus 
if they reported use of oral anti-diabetic treatment or of insulin, or if they had a random serum 
glucose concentration greater than or equal to 11.1 mmol/l. In addition, if a post-load glucose 
concentration (2 h after a glucose drink of 75 g in 200 ml water) at baseline was greater than 
or equal to 11.1 mmol/l the participant was also considered to have diabetes mellitus. Glucose 
concentrations were measured by the glucose hexokinase method. Insulin resistance in non-
diabetic subjects at baseline was assessed by the ratio of the post-load insulin concentration 
(Medgenix, Brussels, Belgium) over post-load glucose concentration.
MRI procedures
In 1995 to 1996, standard T1, T2 and proton-density weighted MR sequences of the brain 
were made using a 1.5 Tesla MR unit (VISION MR, Siemens, Erlangen, Germany).19 After 
these sequences were ﬁnished, an additional custom-made three-dimensional MRI sequence 
of the whole brain was acquired (named half-Fourier acquisition single-shot turbo spin echo 
20). This three-dimensional MRI sequence was used for later volumetric assessments of the 
hippocampus and amygdala. A total of 52 participants developed claustrophobia during the 
MRI scanning period, leaving 511 participants with a completed three-dimensional MRI se-
quence.
Hippocampal and amygdalar volumes on MRI
For the 511 participants with a three-dimensional MRI sequence, we reformatted a series of 
coronal brain slices (contiguous 1.5-mm slices) aligned to be perpendicular to the long axis of 
the hippocampus and the middle sagittal slice. The procedure of segmenting the hippocam-
pus and amygdala has been described in detail.20 Brieﬂy, we manually traced the boundaries 
of the hippocampi and amygdalae using a mouse-driven pointer (Figure 1), which yielded 
outlined areas (mm2). We proceeded from posterior to anterior, starting on the slice where 
the crux of the fornices of the hippocampus was in full proﬁle. We multiplied the summed 
areas with slice thickness (1.5-mm) to calculate estimates of the left and right hippocampal 
and amygdalar volume (ml). Total hippocampal and amygdalar volumes were calculated by 
summing the left and right hippocampal volume and the left and right amygdalar volume. As 
a proxy for head size, we measured on the middle sagittal MRI slice the intracranial cross-
sectional area.20, 21 We corrected for head size difference across the subjects as follows.13, 21 
First, each subject’s hippocampal or amygdalar volumes were divided by their measured head 
size area. Next, to obtain head size corrected, normalised volumes the ratios for each subject 
were multiplied by the average head size area (men and women separately).
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Figure 1. Coronal MRI slice on which the hippocampus (H) and amygdala (A) are depicted
Other measurements
We interviewed and gave physical examinations to the participants to obtain information on 
their: educational level (according to UNESCO22), BMI (weight divided by the square of the 
height), pack-years of cigarette smoking, blood pressure and serum total cholesterol.23 Mem-
ory function was evaluated with a 15-word learning test which consisted of three immediate 
learning trials and a delayed recall trial.19 For each participant, we calculated z-scores (individual 
test score minus mean test score divided by the standard deviation). We constructed a com-
pound score for memory performance by averaging the z-score of the three immediate recall 
trials and the delayed recall trial.19 Apolipoprotein E (APOE) genotyping yielded the following 
alleles: ε2, ε3, and ε4.24 We classiﬁed participants into those with and without a ε4 allele be-
cause the ε4 allele is a strong risk factor of Alzheimer’s disease.25 Because the presence of 
the ε2 allele can reduce the risk of Alzheimer’s disease,25 we excluded persons with genotype 
ε2ε4 (n=9) in the analyses considering APOE genotype. To assess carotid atherosclerosis, 
participants underwent ultrasonography of the carotid arteries.26 Presence of atherosclerotic 
plaques was determined at the common carotid artery, the carotid bifurcation, and the internal 
carotid artery at the left and right side and summed (range 0-6). The intima-media thickness 
was measured by longitudinal two-dimensional ultrasound of the anterior and posterior wall of 
both common carotid arteries. We calculated the mean of these four locations. Cerebral white 
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matter lesions were assessed on proton-density weighted axial MR images and were scored 
in the periventricular regions (range 0-9) and the subcortical regions (approximated volume).19 
Brain infarcts were deﬁned as focal hyperintensities on T2 weighted images, and, if present 
in the white matter, with corresponding prominent hypointensity on T1.23
Data analysis
We missed information on the presence of diabetes mellitus in ﬁve participants, leaving a 
total of 506 participants for the analyses. We used multiple linear regression modelling to 
quantify the relation between diabetes, insulin resistance in non-diabetic subjects, and MRI 
volumes. Adjustments were made for age and sex. Additional adjustments included BMI, 
pack-years of cigarette smoking, blood pressure and serum cholesterol as co-variates. To in-
vestigate whether vascular disease was mediating any association between diabetes, insulin 
resistance and MRI volumes, we adjusted for carotid atherosclerosis, white matter lesions 
and brain infarcts on MRI. We repeated all analyses excluding subjects with infarcts on MRI. 
Finally, because the effect of diabetes on the risk of dementia might differ across APOE geno-
types,4 we studied possible effect modiﬁcation by APOE genotype through stratiﬁed analyses 
(non-carrier of the ε4 allele versus carrier of the ε4 allele). Assumptions of the model were 
veriﬁed by residual diagnostics. A P-value of less than 0.05 was considered to be statistically 
signiﬁcant.
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Results
Selected characteristics of the study cohort according to the presence of diabetes mellitus 
are given in Table 1. 
Table 1. Characteristics of participants with and without diabetes mellitus
Characteristic
No 
diabetes 
mellitus
(n=465)
Diabetes 
mellitus
(n=41)
Adjusted difference*
Age, years 73±8 77±8 4 (1; 6)
Women, % 50 34 -17 (-33; -0.6)
Education, primary only % 30 38 7 (-8; 20)
Memory performance, Z-score 0.03±0.92 -0.51±0.80 -0.33 (-0.60; -0.06)
Body mass index, kg/m2 26.2±3.7 26.8±2.9 0.7 (-0.5; 1.8)
Pack-years of cigarette smoking 20±25 24±24 2 (-5; 10)
Diastolic blood pressure, mmHg 77±11 75±13 -1 (-5; 3)
Systolic blood pressure, mmHg 146±20 146±21 -1 (-8; 5)
Total cholesterol, mmol/l 5.8±1.0 5.9±1.3 0.2 (-0.2; 0.5)
Carotid plaques, total number 1.6±1.6 2.6±1.6 0.7 (0.2; 1.3)
Intima-media thickness, mm 0.86±0.14 0.93±0.13 0.04 (-0.01; 0.08)
Periventricular white matter lesions, grade 2.7±2.2 3.6 (2.2) 0.4 (-0.2; 1.1)
Subcortical white matter lesions, ml 1.7±3.4 2.3 (3.6) 0.01 (-1.0; 1.0)
Brain infarcts, % 27 44 11 (-3; 25)
APOE, ε4 carriers, % 27 31 5 (-11; 21)
Postload insulin, pmol/l† 422.0±312.6 - -
Insulin resistance, pmol/mmol† 65.1±40.1 - -
Values are means ± standard deviation or percentages
*Age and sex adjusted difference (95% CI) in characterstic between participants with and without dia-
betes mellitus
†Present for 405 participants without diabetes
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In total, 41 participants (8.1%) had diabetes mellitus. Twenty-six of them were treated with 
anti-diabetic medication at time of MRI. Their median age when they were diagnosed with 
diabetes mellitus was 64 years (range 43-84), suggesting that they all had type 2 diabetes. Of 
note, although all participants were clinically free from dementia, persons with diabetes mel-
litus performed worse on memory tests (Table 1). Persons with diabetes mellitus had more 
atherosclerotic plaques in the carotid arteries (Table 1). They also had more cerebral white 
matter lesions on MRI, but this was not statistically signiﬁcant after accounting for age and 
sex differences. Brain infarcts were 1.7 times (95% CI 0.8 to 3.3) more frequent in subjects 
with diabetes mellitus compared to those without diabetes mellitus, after adjusting for age 
and sex.
Subjects with diabetes mellitus had smaller hippocampal and amygdalar volumes on MRI 
(Figure 2). Diabetes mellitus had a similar effect on the left and the right-sided brain volumes 
separately. Additional adjustments for BMI, pack-years of cigarette smoking, blood pressure 
and cholesterol, did not change the results. 
Figure 2. Hippocampal volumes and amygdalar volumes (+standard error) on brain MRI in participants 
with diabetes (n=41) and without diabetes (n=465). Volumes are adjusted for age and sex and normalised 
to average head size
Although subjects with diabetes mellitus had more vascular disease, accounting for markers 
of vascular disease did not change the association between diabetes and hippocampal or 
amygdalar volumes (Table 2). Exclusion of participants with infarcts (n=142) did not change 
the results either. There was no difference in association between diabetes and MRI volumes 
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according to APOE strata. In non-carriers of the ε4 allele, the age and sex adjusted difference 
in hippocampal volume between persons with and without diabetes mellitus was –0.30 (95% 
CI –0.66 to 0.06). In carriers of the ε4 allele the difference in hippocampal volume was –0.31 
(95% CI –0.84 to 0.21). In non-carriers of the ε4 allele, the age and sex adjusted difference in 
amygdalar volume between persons with and without diabetes mellitus was –0.28 (95% CI 
–0.58 to 0.01). In carriers of the ε4 allele the difference in amygdalar volume was –0.41 (95% 
CI –0.86 to 0.04).
Table 2. Hippocampal and amygdalar volume on MRI in participants with and without diabetes mellitus 
accounting for markers of vascular disease
Volume difference between participants with and without diabetes 
mellitus, ml (95% CI)
Difference adjusted for Hippocampus* P Amygdala* P
Age and sex -0.28 (-0.55 to -0.01) 0.042 -0.33 (-0.55 to -0.11) 0.004
Age, sex, and carotid 
atherosclerosis
-0.27 (-0.55 to 0.00) 0.053 -0.32 (-0.54 to -0.10) 0.005
Age, sex, white matter le-
sions and infarcts on MRI
-0.27 (-0.54 to 0.00) 0.053 -0.33 (-0.56 to -0.11) 0.003
Values are adjusted differences (95% CI and P-value) in MRI volumes (ml) between participants without 
diabetes mellitus (n=465) and participants with diabetes mellitus (n=41)
*Volumes are normalised to average head size
In non-diabetic participants (n=465), post-load insulin concentrations and insulin resistance 
were present for 405 participants. Persons with higher post-load insulin concentrations or 
insulin resistance had smaller amygdalar volumes, but not smaller hippocampal volumes on 
MRI (Table 3). Additional adjusting for BMI, pack-years of cigarette smoking, blood pressure, 
cholesterol, carotid atherosclerosis, white matter lesions and infarcts did not change the as-
sociations, nor did excluding participants with infarcts. The association between insulin re-
sistance and amygdalar volumes on MRI was similar in APOE strata, although statistically 
signiﬁcant only in non-carriers of the ε4 allele [non-carriers: adjusted difference in amygdalar 
volume per standard deviation increase in insulin resistance –0.11 (95% CI –0.19 to –0.04); 
carriers:  –0.02 (95% CI –0.18 to 0.15)]. 
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Table 3. Insulin resistance in participants without diabetes (n=405) in relation to hippocampal and 
amygdalar volumes on MRI
Volume difference per SD increase in insulin concentrations and insulin 
resistance, ml (95% CI)
 Hippocampus* P Amygdala* P
Post-load insulin (per SD)
Adjusted for
Age and sex -0.02 (-0.11 to 0.06) 0.57 -0.08 (-0.14 to -0.01) 0.020
Age, sex and carotid athero-
sclerosis
-0.03 (-0.11 to 0.05) 0.51 -0.08 (-0.14 to -0.01) 0.018
Age, sex, white matter le-
sions and infarcts on MRI
-0.02 (-0.11 to 0.06) 0.56 -0.08 (-0.15 to -0.02) 0.013
Insulin resistance (per SD)
Adjusted for
Age and sex -0.00 (-0.09 to 0.08) 0.93 -0.08 (-0.15 to -0.02) 0.012
Age, sex and carotid athero-
sclerosis
-0.01 (-0.10 to 0.07) 0.75 -0.09 (-0.15 to -0.02) 0.008
Age, sex, white matter le-
sions and infarcts on MRI
-0.00 (-0.08 to 0.08) 0.95 -0.09 (-0.15 to -0.02) 0.008
Values are adjusted differences (95% CI and P-value) in MRI volumes (ml) per standard deviation (SD) 
increase in post-load insulin concentration and insulin resistance
*Volumes are normalised to average head size
Discussion
We observed that people with type 2 diabetes had more hippocampal and amygdalar atrophy 
on MRI than people without diabetes. Moreover, in persons without diabetes mellitus, insulin 
resistance was associated to amygdalar atrophy on MRI. The presence of atherosclerosis or 
cerebrovascular disease did not explain the associations.
The strengths of our study are its population-based design and the large sample with volu-
metric MRI. The prevalence of diabetes mellitus in our study was comparable to another 
Dutch population study,27 leading to a moderate number of people with diabetes mellitus 
studied in the sample. However, the associations were robust and statistically signiﬁcant sug-
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gesting that we had sufﬁcient power. A limitation of our study was the indirect assessment 
of insulin resistance through calculating the ratio of post-load insulin concentrations with 
glucose concentrations. This ratio however in non-diabetic subjects correlates well with the 
degree of insulin resistance assessed with precise clamping techniques.28
Several studies have found an increased risk of Alzheimer’s disease in people with diabetes 
mellitus.3, 4, 17, 29-31 Other studies did not ﬁnd this association or merely an association between 
diabetes mellitus and vascular dementia.32-35 Difﬁculties in diagnosing Alzheimer’s disease 
in life and distinguishing it from vascular dementia could have resulted in different ﬁndings 
across studies. Alzheimer’s disease is generally characterised by slow progression in clinical 
symptoms which is thought to reﬂect gradual development of the speciﬁc Alzheimer pa-
thology over time.8 The pathological hallmarks of Alzheimer’ s disease, neuroﬁbrillary tan-
gles and amyloid plaques, occur in the most early stage of the disease in the hippocampus 
and amygdala8 causing neuronal loss and atrophy that can be visualised on MRI.36 At this 
stage, dysfunction of the hippocampus could cause memory impairment, a well known early 
neuropsychological sign of Alzheimer’s disease.37 In our study, we used hippocampal and 
amygdalar atrophy on MRI in elderly subjects who were clinically free of dementia as mark-
ers of pre-clinical Alzheimer’s disease. Several studies including our own20 show that peo-
ple with hippocampal atrophy on MRI have lower verbal memory performance.38 Moreover, 
besides memory impairment, people with hippocampal atrophy on MRI frequently develop 
other symptoms of Alzheimer’s disease later in life.11, 12 To our knowledge, no study has pro-
spectively examined the speciﬁc role of amygdalar atrophy in Alzheimer’s disease. However, 
patients with very mild Alzheimer’s disease have equal volume losses in the hippocampus 
and amygdala on MRI compared to control subjects.13, 14 suggesting that atrophy of both hip-
pocampal and amygdalar are early MRI markers of incipient Alzheimer’s disease.
Three biological explanations support an association between diabetes mellitus and hip-
pocampal and amygdalar atrophy on MRI. First, diabetes mellitus leads to vasculopathy and 
changes in lipid metabolism, which in turn could be associated to hippocampal and amygdalar 
atrophy. Although we found a clear association between diabetes mellitus and carotid athero-
sclerosis, the relation between diabetes and cerebrovascular disease, as noted by the degree 
of white matter lesions and brain infarcts on MRI, was not very strong. Moreover, when we 
accounted for vascular disease the relation between diabetes mellitus and atrophy on MRI re-
mained the same. This is in line with a recent study in people free of cerebrovascular disease 
that showed impaired glucose tolerance to relate to hippocampal atrophy on MRI.39 Thus, al-
though diabetes mellitus is a vascular risk factor, other non- vascular pathways seem to play a 
role in the ﬁndings. A second biological explanation is that hyperglycaemia in diabetic patients 
is directly associated to hippocampal and amygdalar atrophy. A prospective study found that 
subjects with diabetes mellitus have increased amyloid plaques and neuroﬁbrillary tangles 
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in the hippocampus at autopsy,4 though another post-mortem study did not.40 In diabetic 
subjects, accelerated formation of advanced glycation endproducts can cross-link amyloid 
proteins leading to aggregation into the amyloid plaques.6, 41 In addition, glycation of the mi-
crotubule associated protein-tau could lead to formation of neuroﬁbrillary tangles.42 Pointing 
to a third biological explanation was the ﬁnding that peripheral insulin resistance was associ-
ated to amygdalar atrophy on MRI. Insulin resistance is characterised by high plasma insulin 
concentrations and relatively normal glucose concentrations. Patients with Alzheimer’s dis-
ease have higher plasma insulin concentrations compared with control subjects43, 44 but lower 
cerebrospinal-ﬂuid insulin concentrations.44 This suggests that insulin transport from plasma 
to the brain is diminished in Alzheimer patients.44 Other investigations report that dysfunction 
of insulin signal transduction is involved in Alzheimer’s disease.7, 45 Genetic variability in genes 
encoding for components of the insulin-signalling pathway is associated to Alzheimer’s dis-
ease.46 Insulin regulates metabolism of amyloid proteins, prevents tau phosphorylation7 and 
promotes neuronal survival,47 all actions that in case of dysfunction of the insulin pathway can 
lead to Alzheimer’s disease. Furthermore, the insulin-degrading enzyme is, in addition to its 
role in degrading insulin, important in cleaving amyloid protein in the brain.48 Mice with hypo-
function of this enzyme have increased accumulation of amyloid in the brain and increased 
plasma insulin concentrations,  further supporting a connection between insulin and Alzhei-
mer’s disease.49 It is postulated that patients with Alzheimer’s disease try to compensate for 
impaired insulin signalling by increasing the amount of insulin receptors.50 Interestingly, we 
found a restricted relation between insulin resistance and amygdalar atrophy on MRI. Higher 
plasma insulin concentrations or insulin resistance were not related to hippocampal atrophy 
on MRI, in agreement with others.39 The hippocampus and amygdalar differ according to the 
amount of insulin receptors, the hippocampus having a higher density.51 A speculative expla-
nation for the absence of a relation between insulin concentrations and hippocampal volumes 
is that the high density of insulin receptors in combination with high plasma insulin concentra-
tions compensates for dysfunctions in the insulin-signalling pathway. However, the differential 
effects of insulin on the hippocampus and amygdala have yet to be conﬁrmed.
In summary, in this community sample we found that people with type 2 diabetes have 
smaller hippocampal and amygdalar volumes on MRI, supporting the view that diabetes is a 
risk factor for Alzheimer’s disease. Since atherosclerosis or cerebrovascular disease were not 
explaining the associations, it is likely that direct metabolic effects of diabetes mellitus are 
involved. Our ﬁnding that insulin resistance was associated to amygdalar atrophy on MRI is 
in line with suggestions that dysfunction of insulin signalling is involved in the pathogenesis 
of Alzheimer’s disease. 
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Chapter 4.1
Hippocampal atrophy and memory performance
The hippocampus plays a crucial role in the consolidation of memory. Anatomically, the hip-
pocampal head, body, and tail are connected to separate regions of the entorhinal cortex, 
which conveys processed information from the association cortices to the hippocampus. Lit-
tle is known, however, about the functional segregation along its longitudinal axis. In the 
present study, we investigated whether the hippocampal head, body, or tail is selectively 
involved in verbal memory performance. A total of 511 nondemented participants, aged 60-
90 years, underwent a three-dimensional HASTE brain scan in a 1.5-T MRI unit. Hippocampal 
volumes were measured by manual tracing on coronal slices. Segmentation was performed 
in anterior-posterior direction on the basis of predeﬁned cut-offs allocating 35, 45, and 20% 
of slices to the head, body, and tail, respectively.  Memory performance was assessed by a 
15-word learning test including tasks of immediate and delayed recall. To analyze the associa-
tion between head, body, and tail volumes and memory performance, we used multiple linear 
regression, adjusting for age, sex, education, and midsagittal area as a proxy for intracranial 
volume. Participants with larger hippocampal heads scored signiﬁcantly higher in the memory 
test, most notably in delayed recall [0.41 words per SD increase in left hippocampal head 
(95% CI 0.16, 0.67), 0.33 words per SD increase in right hippocampal head (95% CI 0.06, 
0.59)]. Our data suggest selective involvement of the hippocampal head in verbal memory, 
and add to recent ﬁndings of functional segregation along the longitudinal axis of the hip-
pocampus.
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Introduction
The hippocampus is generally assumed to play a key role in the consolidation of memory, 
i.e. the integration of relevant new information and its transfer from short-term to long-term 
memory.1 A host of magnetic resonance imaging (MRI) studies have found positive asso-
ciations between total hippocampal volume and memory performance.2-5 Anatomically, the 
hippocampus can be divided into three distinct segments: (a) an anterior part, or head, (b) 
an intermediate part, or body, and (c) a posterior part, or tail.6 These subdivisions are recipro-
cally connected to separate regions of the entorhinal cortex.7 In addition, a number of studies 
suggest that the hippocampal head, body, and tail may have different functions. Presentation 
of novel information, for instance, was associated with activity in the left anterior hippocam-
pus during functional MRI (fMRI),8 while a positron emission tomography (PET) study found 
memory impairment in amnesiacs and in Alzheimer patients to be associated with decreased 
glucose metabolism in the hippocampal head.9 A recent small volumetric MRI study demon-
strated that impaired verbal memory in ﬁrst-degree relatives of schizophrenic patients was 
associated with lower volumes in the anterior part of the hippocampus.10 The goal of our study 
was to investigate, in a large sample of nondemented elderly participants, whether MRI vol-
umes of hippocampal head, body, and tail are differentially associated with verbal memory 
performance.
Methods
Participants
The Rotterdam Study is a large population-based cohort study in the Netherlands that started 
in 1990 and investigates the prevalence, incidence and determinants of various chronic dis-
eases among elderly participants.11 From 1995 to 1996, we randomly selected 965 living mem-
bers (aged 60-90 years) of this cohort in strata of sex and age (5 years) for participation in the 
Rotterdam Scan Study.12 After exclusion of individuals who were demented, blind, or had MRI 
contraindications, the number of eligible participants was 832. Subjects with dementia were 
excluded based on a stepwise approach as used in the Rotterdam Study.13 Subjects were 
screened using the Mini-Mental State Examination (MMSE)14 and the Geriatric Mental State 
Schedule (GMS). Those scoring below 26 on the MMSE or more than 0 on the GMS were 
additionally assessed by means of the CAMDEX interview.15 Subjects suspected of dementia 
based on the CAMDEX were examined by a neurologist. Finally, an expert panel reviewing all 
relevant information decided whether an individual was to be considered demented or not, 
based on the criteria of the DSM-IIIR. Among the 832 eligible, 563 participants gave their 
written informed consent to participate in the present study (response rate: 68%), which 
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included undergoing a MRI brain scan. The study 
was approved by the medical ethics committee 
of the Erasmus Medical Center, Rotterdam, the 
Netherlands.
Magnetic resonance imaging acquisition
Brain scans were performed using a 1.5-Tesla 
MRI System (VISION MR, Siemens AG, Erlan-
gen, Germany). The protocol included, in the 
following order, a) a sequence of proton-density 
images b) a sequence of T2-weighted images c) 
a sequence of T1-weighted images.16 Finally, for 
volumetric measurements of the hippocampus, 
a custom-made, inversion recovery - double con-
trast 3D half-Fourier acquisition single-shot turbo 
spin echo (HASTE) sequence was included  (inver-
sion time 440 ms, [TR] 2800 ms, 128 contiguous 
sagittal slices of 1.2-mm, matrix 192x256, ﬁeld 
of view 256x256). Two HASTE modules were 
sequentially acquired after the inversion pulse 
(effective TEs of 29 ms and 440 ms), the ﬁrst of 
that was used for the volume measurements. 
Fifty-two participants developed claustrophobia 
during MRI acquisition. Thus, complete MRI data 
were available from a total of 511 participants.
 
Hippocampal volume measurement
For each participant, we reconstructed a se-
ries of coronal brain slices (contiguous 1.5 mm 
slices) based on the 3D HASTE sequence, 
aligned to be perpendicular to the long axis of 
the hippocampus. All reconstructed slices were 
transferred to a Siemens Magic View 1000 work-
station for volumetric assessment of the left and 
right hippocampus. 
Figure 1. Hippocampal head (H), body (B) and tail (T)  manually outlined on coronal images 
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Referencing to an anatomical atlas,6 we manually traced the boundaries of both hippocampi 
on each slice by means of a mouse-driven pointer (Figure 1). We proceeded from posterior 
to anterior, starting on the slice where the crux of the fornices was in full proﬁle. Segmenta-
tion of the hippocampal head from the overlying amygdala was facilitated by identifying the 
alveus, which demarcated the undulating superior surface of the hippocampal head. The intra-
plane hippocampal boundaries were deﬁned to include the CA1 through CA4 sectors of the 
hippocampus proper, the dentate gyrus, and the subiculum. The number of slices measured 
ranged from 16 to 31 (left hippocampus, median = 25) and from 18 to 31 (right hippocampus, 
median = 25) per individual. Entering the outlined surface areas (in mm2) into a spreadsheet 
program (Microsoft Excel 97), we multiplied the summed surface areas on each side with 
slice thickness to yield estimates of the left and right hippocampal volume (ml). We also re-
constructed a midsagittal slice (thickness 3.0 mm). The midsagittal area, which we used as 
a proxy for intracranial volume, was measured by tracing the inner table of the skull. The 511 
scans were randomly split between two raters who were blinded to any participant-related 
clinical information. Studies performed on 14 random scans to evaluate intra- and interrater 
correlation showed good overall agreement. Intrarater intraclass correlation coefﬁcients were 
r = 0.93 for the left and r = 0.90 for the right hippocampus, whereas interrater intraclass cor-
relation coefﬁcients were r = 0.87 and r = 0.83, respectively. For the midsagittal area, intra- 
and interrater intraclass correlation coefﬁcients were 0.995 and 0.96, respectively. To obtain 
separate volumes for the hippocampal head, body, and tail, we subdivided the hippocampus 
into three segments, such that the anterior 35% of coronal slices (or any rounded integer of 
slices closest to this cut-off) included the head with the hippocampal digitations, while the 
intermediate 45% represented the body of the hippocampus, and the remaining 20% the tail 
(Figure 2). These cut-offs were based on photographs of histological preparations.6 Grouping 
hippocampi by length (i.e. by number of slices), and plotting graphs of mean cross-sectional 
volumes over the anterior-posterior extent of the hippocampus, we conﬁrmed that the 35% 
cut-off was a stable proxy for the boundary between head and body over the whole range of 
hippocampal lengths, as it invariably fell into, or near, the region of steepest slope  correspond-
ing to the anterior bend of the hippocampus. The cut-off between body and tail coincided well 
with the region where cross-sectional hippocampal volumes reached a minimum.
Measurement of memory function
Memory was assessed by means of a 15-word learning test, which is used to evaluate the 
ability to acquire and retain new verbal learning information based on Rey’s auditive recall of 
words.17 To test immediate recall, participants were presented three times with a sequence 
of 15 words and subsequently asked to recall as many of these words as possible. Free de-
layed recall was tested 15 minutes later. Outcome variables were the mean of the number of 
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words recalled over the ﬁrst three trials (as a summary score for immediate recall), and the 
number of words remembered after the 15-minute delay (as a score for free delayed recall). 
Immediate and delayed recall scores were normally distributed. The frequency of the highest 
and lowest scores (i.e., 0 and 15) was less than 3%. Therefore, no ceiling or ﬂoor effects were 
observed. As a measure of global cognitive function we used the MMSE.14
Figure 2. A. Sketch of right hippocampus as seen from above. Hippocampal head, body, and tail (dashed 
lines represent 35% and 20% cut-offs for the boundaries between head and body, and body and tail, 
respectively) are depicted.
B. Mean coronal volumes plotted over the anterior-posterior extent of the hippocampus (graph is based 
on hippocampi with a longitudinal extent of 25 slices.
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Other measurements
Level of education according to UNESCO was obtained.18 The presence of depressive 
symptoms was determined by the Center of Epidemiologic Studies on Depression (CES-D) 
scale.19
 
Data analysis
To assess the association between hippocampal head, body and tail volumes and memory, 
we ﬁrst constructed simple x,y scatter plots. As the scatter plots suggested approximately 
linear associations we decided to use multivariable linear regression for our analyses. We 
included all factors that were signiﬁcantly correlated with hippocampal volumes (age, sex, 
education, midsagittal area) in our model. Thus, our model was represented by the following 
equation: memory performance = B0 + B1 X age + B2 X sex+ B3 X education+ B4 X mid-
sagittal area + B5 X hippocampal head volume (SD) + B6 X hippocampal body volume (SD) + 
B7 X hippocampal tail volume (SD). The regression coefﬁcients of the hippocampal volumes 
(B5-B7) reﬂect the average difference in number of words recalled between individuals for 
a given volume difference of 1 SD. Appropriate checks revealed no indication of nonlinearity.
To conﬁrm regional patterns of association and to check whether the association between 
the volumes of head, body and tail and performance in the 15-word learning test was inde-
pendent of our chosen cut-off points, we performed additional slice-by-slice analyses. For 
this purpose, we transformed the number of slices to a standard of 20 for all hippocampi by 
means of linear interpolation. Thus, slice volumes were calculated for 5% intervals, given a 
relative length of 100% for all hippocampi. Each of the 20 slices was individually assessed for 
its potential association with memory performance, adjusting for age, sex, level of education, 
midsagittal area, and the volume of the remaining 19 slice locations combined.
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Results
Relevant characteristics of all 511 participants are summarized in Table 1. 
Table 1. Characteristics of the study sample (n=511)
Age, years 73 ± 8
Sex, % women 49
Highest education, % 
               Primary 31
               Intermediate/Higher 60
               College/University 9
Depressive symptoms (CES-D), range 0-31 5.6 ± 6.1
15-Word Learning Test
               Immediate Recall, mean over three trials 6.57 ± 1.81
               Delayed Recall 5.78 ± 2.63
MMSE score 27.7 ± 2.1
Midsagittal area, cm2 149.1 ± 11.1
Total hippocampus, ml
               Left 3.15 ± 0.46
               Right 3.22 ± 0.44
Hippocampal head, ml
               Left 1.46 ± 0.22
               Right 1.52 ± 0.24
Hippocampal body, ml
               Left 1.18 ± 0.23
               Right 1.19 ± 0.21
Hippocampal tail, ml
               Left 0.51 ± 0.12
               Right 0.52 ± 0.11
Values are unadjusted means ± standard deviation or percentages
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Volumes of the left and right hippocampus were highly correlated with each other (r = 0.88; 
P < 0.001). Volumes of hippocampal head, body and tail were positively and moderately cor-
related with each other (correlation between head and body r = 0.45 (left) and r = 0.48 (right), 
between head and tail r = 0.30 (left) and r = 0.21 (right), and between body and tail r = 0.57 
(left) and r = 0.63 (right)). The number of immediate words recalled decreased 0.08 per year 
and of delayed recall words 0.11 per year. 
Table 2 shows the association between hippocampal head, body and tail volumes and vari-
ables that may confound the association with memory performance. Age, sex, education 
and midsagittal area were signiﬁcantly associated with subdivisional volumes. Slice-by-slice 
analysis revealed that the association between age and hippocampal volume was strongest 
in the region between 20% and 35%, corresponding to the posterior part of the hippocampal 
head.
Table 2. Association between several variables and hippocampal head, body and tail
Head (ml) Body (ml) Tail (ml)
Left Right Left Right Left Right
Age 
 (per 10 years)
-0.07 
(<0.001)
-0.08
(<0.001)
-0.05
(<0.001)
-0.06
(<0.001)
-0.03
(<0.001)
-0.03
(<0.001)
Sex* 
-0.07
(0.002)
-0.07
(0.001)
-0.00
(0.85)
0.00
(0.90)
0.03
(0.007)
0.03
(0.002)
Education (range 0-7) 
0.01
(0.02)
0.02
(0.008)
0.00
(0.44)
0.00
(0.10)
-0.00
(0.37)
0.00
(0.34)
Depressive symptoms 
 (per 10)†
-0.02
(0.14)
-0.03
(0.14)
0.01
(0.50)
0.00
(0.96)
0.00
(0.99)
-0.00
(0.66)
Midsagittal area 
 (per 10 cm2)
0.06
(<0.001)
0.08
(<0.001)
0.04
(<0.001)
0.04
(<0.001)
0.01
(0.15)
0.01
(0.03)
Values given are regression coefﬁcients (P-values in parentheses)
*Regression coefﬁcient adjusted for midsagittal area. Minus sign denotes that volume is smaller in wo-
men. Positive sign denotes that volume is smaller in men
†Score on the CES-D, range 0-31
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Total hippocampus and memory
Table 3 summarizes the results of our multivariable linear regression analysis which demon-
strated a strong positive and highly signiﬁcant association between total hippocampal vol-
umes and performance in the 15-word learning test, in both immediate recall and delayed 
recall.
Table 3. Association between total hippocampal volume and number of words recalled 
 Immediate recall Delayed recall
Difference per SD (95% CI) P Difference per SD  (95% CI) P
Left hippocampus 0.21 (0.05, 0.36) 0.008 0.41 (0.19, 0.64) <0.001
Right hippocampus 0.22 (0.06, 0.38) 0.006 0.47 (0.23, 0.70) <0.001
Values are adjusted difference in number of words recalled per standard deviation of hippocampal vol-
ume, with 95% conﬁdence intervals (CI), and P-values. Adjusted for age, sex, education, and midsagittal 
area. 
Table 4. Association between volume of hippocampal head (cut-off 35%), body (45%), and tail (20%) and 
number of words recalled 
Immediate recall Delayed recall
Difference per SD (95% CI) P Difference per SD (95% CI) P
Left Hippocampus
Head 0.26 (0.09, 0.44) 0.003 0.41 (0.16, 0.67) 0.002
Body -0.08 (-0.29, 0.14) 0.49 -0.03 (-0.35, 0.28) 0.83
Tail 0.11 (-0.08, 0.31) 0.26 0.19 (-0.09, 0.48) 0.19
Difference per SD (95% CI) P Difference per SD (95% CI) P
Right Hippocampus
Head 0.19 (0.01, 0.37) 0.035 0.33 (0.06, 0.59) 0.015
Body 0.01 (-0.22, 0.20) 0.94 0.06 (-0.25, 0.36) 0.71
Tail 0.12 (-0.07, 0.31) 0.22 0.24 (-0.04, 0.51) 0.10
Values are adjusted estimates of the change in number of words recalled per increase in standard de-
viation of volume, with 95% conﬁdence intervals (CI), and P-values. Adjusted for age, sex, education 
midsagittal area.
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Hippocampal head, body, and tail and memory
Table 4 shows the association between volume of the hippocampal head, body, and tail and 
test performance. Individuals with larger hippocampal heads performed signiﬁcantly better in 
the 15-word learning test, most notably in delayed recall. Estimates for the left hippocampal 
head tended to be slightly higher than estimates for the right hippocampal head. No signiﬁcant 
associations were observed for the hippocampal body or hippocampal tail. The hippocampal 
head was the only region associated to the MMSE score [per SD 0.27 (95% CI 0.05-0.48) for 
the left hippocampal head; per SD 0.23 (95% CI 0.02-0.45) for the right hippocampal head]. 
Hippocampal body and tail were not associated to MMSE score. Slice-by-slice analyses of 
delayed recall performance revealed signiﬁcant associations only for the most anterior part of 
the hippocampus (i.e., the ﬁrst three slices of the left and right hippocampus), the region cor-
responding to the anterior half of the hippocampal head (Figure 3). No signiﬁcant associations 
were observed at any other slice location.
Figure 3. Association between left (top) and right (bottom) regional hippocampal volumes and number of 
words recalled in the delayed recall test (x-axis: location percentiles along the longitudinal axis of the hip-
pocampus, y-axis: difference in the number of words recalled per standard deviation of hippocampal slice 
volume; * signiﬁcant at the P=0.05 level). Adjusted for age, sex, educational level and midsagittal area
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Discussion
We found that a larger volume of the hippocampal head, rather than the hippocampal body 
or tail, was signiﬁcantly associated with better verbal memory performance, in tasks of both 
immediate and delayed recall.
Our large number of participants and the regional approach are obvious strengths of our 
study. Nevertheless, some methodological issues remain to be addressed. First, no precise 
deﬁnitions for the boundaries between hippocampal head, body and tail on MRI exist, and 
hence the cut-offs we chose are somewhat arbitrary. However, our slice-by-slice analysis sug-
gested that the associations did not depend on the choice of cut-offs. Second, the method 
we used to deﬁne the hippocampal subdivisions was implicitly based on the assumption that 
all individual hippocampi, irrespective of their shape or length, share the same proportions 
regarding the longitudinal extent of the hippocampal head, body, and tail (i.e., 35%, 45%, and 
20%, respectively). Although this assumption was mostly met, our subdivisions in volume 
were likely to be affected by some degree of random misclassiﬁcation, leading to a weaken-
ing of the associations we found. 
The observation that larger hippocampal volume is associated with better verbal memory is 
in keeping with numerous MRI studies,2-5 even though surprisingly some studies found an 
inverse association.20, 21 More speciﬁcally, our study showed that hippocampal involvement in 
verbal memory performance may be limited to the head region. Few MRI studies investigated 
subdivisions of the hippocampus in relation to function. A study in taxi drivers showed the 
posterior hippocampus to be associated with spatial memory.22 Another study in psychopaths 
showed the posterior hippocampus to be associated with the degree of psychopathology.23 
A volumetric MRI study assessed the role of longitudinal subdivisions of the hippocampus 
in verbal memory in ﬁrst-degree relatives of schizophrenic patients.10 This study found that 
amygdalar and anterior hippocampal volumes were signiﬁcantly associated with delayed ver-
bal recall, whereas no such association was shown for the posterior hippocampus. Most 
PET studies discussed in a review of medial temporal lobe (MTL) activation in fMRI and PET 
studies of episodic encoding and retrieval reported anterior medial temporal lobe activation, 
while the fMRI studies reviewed found activation mainly in the posterior part of the MTL.24 
A recent fMRI study observed activation of the left anterior hippocampus in participants pre-
sented with novel verbal stimuli, suggesting that the anterior hippocampus plays a crucial role 
in novelty encoding.8 No activation was observed in the posterior hippocampal region. A PET 
study measuring glucose metabolism in amnesic patients and in patients with Alzheimer’s 
disease revealed that both groups had a signiﬁcantly decreased glucose metabolism in the 
hippocampal head in comparison to controls.9 Again, no association was observed for the 
hippocampal tail or body. 
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Memory is acquired through the processing of incoming information by the association cor-
tices which, by way of the parahippocampal and perirhinal cortex, send their output to the 
entorhinal cortex. Cells in the entorhinal cortex supply most of the ﬁbers that enter the hip-
pocampal formation through the perforant pathway, while most efferent connections from 
the hippocampus project back to the entorhinal cortex.25 A recent study has shown that the 
perforant pathway is characterized by a topographical organization along the longitudinal axis 
of the hippocampal formation, such that a medial-to-lateral gradient in the entorhinal cortex 
corresponds to an anterior-posterior gradient in the hippocampal formation.7 This special archi-
tecture may be the underlying substrate for the functional segregation between hippocampal 
head, body, and tail that we and others have found. 
The effect of hippocampal volume on number of words recalled may seem small and not clini-
cally relevant. However, it is important to realize that these are not differences on an individual 
level, but average differences across groups of nondemented persons and adjusted for pos-
sible confounders. The effect size per SD increase in hippocampal volume in words recalled 
approximately equaled the effect of a 4-year age increase. 
One explanation that would ﬁt our data is that people with better memory have larger hip-
pocampal heads. However, we also found a relation between hippocampal head volume and 
the MMSE score, which is a more global cognitive measure. This suggests that individuals 
who do not fulﬁll criteria of dementia but do have slight impairment of verbal memory or 
global cognitive function may have selective atrophy of the hippocampal head. Whether they 
are destined to develop clinically evident dementia is yet unclear. MRI in early Alzheimer’s 
disease showed patients’ hippocampi to be smaller than those of controls, while hippocampal 
head size in Alzheimer patients seems to be inversely related to disease severity.26 Prospec-
tive studies suggested that smaller total hippocampal volume may predict dementia.5, 27, 28 
Possibly, subdividing the hippocampus into head, body or tail or even smaller subdivisions 
may show atrophy in regions speciﬁc for imminent Alzheimer’s disease. Prospective follow-up 
investigations of the individuals participating in our study will enable us to conﬁrm whether 
there is early - and possibly selective - involvement of the hippocampal head region in Alz-
heimer’s disease. If this is the case, hippocampal head volume – in combination with other 
variables – may help to reﬁne prediction of dementia and enhance the identiﬁcation of at-risk 
individuals who might beneﬁt from early intervention. 
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Chapter 4.2
Hippocampal, amygdalar atrophy and inicident dementia
Background: Patients with Alzheimer’s disease have pronounced atrophy of the hippocam-
pus and amygdala on magnetic resonance imaging (MRI). In persons with mild cognitive im-
pairment, hippocampal atrophy predicts conversion to dementia. Whether atrophy is evident 
even before symptom onset is unclear. We studied the longitudinal relation between atrophy 
on MRI and incident dementia in a population-based cohort accounting for neuropsychological 
performance. 
Methods: We obtained volumetric MRI assessments of the hippocampus and amygdala at 
baseline in a cohort of 511 elderly free of dementia (age 60-90 years). Each participant was 
asked about memory problems in daily life and cognitive performance was assessed. The 
cohort was followed for possible development of dementia by in-person screening and moni-
toring of medical records.
Results: During a total of 3043 person-year of follow-up (mean per person 6.0 years), we 
detected 35 incident dementia cases (26 with Alzheimer’s disease). Those who developed 
Alzheimer’s disease had on average 10% smaller volumes of the hippocampus and amygdala 
on MRI. The risk to develop dementia was higher in persons with hippocampal or amygdalar 
atrophy (age, sex and education adjusted relative risk per standard deviation decrease 2.99 
(95% CI 1.96-4.57) for the hippocampus and 2.06 (95% CI 1.46-2.90) for the amygdala. In per-
sons without memory complaints or cognitive impairment at baseline, the relation between 
atrophy on MRI and incident dementia was similar as that in the total population.
Conclusions: Atrophy of the hippocampus and amygdala on MRI predict dementia over a 6-
year follow-up even in cognitively intact elderly.
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Introduction
Alzheimer’s disease is the most common cause of dementia in late life.1 Strategies to prevent 
or delay the disease are under development.2 Once available, it will be important to identify 
people at high risk to develop dementia who may beneﬁt from such therapies. Magnetic 
resonance imaging (MRI) of the brain provides one potential tool for detecting the preclinical 
stages of the disease. Pathologically, Alzheimer’s disease is characterized by dense accumu-
lation of neuroﬁbrillary tangles and amyloid plaques in the medial temporal lobe,3 leading to 
neuronal loss that is visible as atrophy on MRI.4 Several studies have shown in patients with 
Alzheimer’s disease5-7 pronounced reductions in hippocampal and amygdalar volumes on MRI 
compared to healthy elderly. Patients with mild cognitive impairment (MCI), at high risk of de-
veloping Alzheimer’s disease,8 have also smaller hippocampal volumes than healthy elderly.9-15 
It is unclear whether in persons destined to develop dementia, atrophy on MRI is observed 
even before persons would be designated as having MCI. We focused on this question by 
studying the longitudinal relation between volumes of the hippocampus and amygdala on 
MRI and incident dementia in a population dwelling in the community. By taking into account 
memory complaints and neuropsychological performance at baseline we sought to investi-
gate whether atrophy on MRI predicts dementia even in people without cognitive problems. 
We used data from the population-based Rotterdam Scan Study in whom 511 non-demented 
elderly had volumetric MRI assessments of the hippocampus and amygdala and whom we 
followed for an average period of 6 years.  
Methods
Subjects
The Rotterdam Study is a large population-based cohort study in the Netherlands that started 
in 1990 and investigates the prevalence, incidence and determinants of chronic diseases 
among elderly participants.16 From 1995 to 1996, we randomly selected 965 living members 
(aged 60 to 90 years) of this cohort in strata of sex and age (5 years) for participation in the 
Rotterdam Scan Study, a study on age-related brain changes on MRI.17 As part of the eligibility 
criteria we excluded individuals who were demented,18 blind, or had MRI contraindications. 
This left 832 persons eligible for participation. Among these, 563 persons gave their written 
informed consent to participate in the present study (response rate: 68%). Complete MRI 
data, including a three-dimensional (3D) MRI sequence, was obtained in 511 persons.19 The 
study was approved by the medical ethics committee of the Erasmus Medical Center, Rot-
terdam, the Netherlands.
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MRI assessments
At baseline examinations in 1995 to 1996, a three-dimensional (3D) MRI sequence covering 
the whole brain was made using a 1.5 Tesla MRI unit.19 We reformatted coronal slices (1.5-mm 
contiguous slices) from this 3D MRI sequence in such a way that they were perpendicular 
to the long axis of the hippocampus. The left and the right hippocampus and amygdala were 
manually outlined on each slice with a mouse-driven cursor.19 Absolute volumes (ml) were cal-
culated by multiplying the areas on each slice by the slice thickness. We summed the left and 
right side to yield total volumes because the analyses did not suggest laterality of effects. As 
a proxy for head size, we measured on a reformatted middle sagittal MRI slice the intracranial 
cross-sectional area.19 We corrected for head size differences across individuals by dividing 
the uncorrected volumes by the subject’s calculated head size and subsequently multiplying 
this ratio by the average head size area (men and women separately).7, 20 
Ascertainment of incident dementia
All participants were free of dementia at baseline and we followed the cohort for incident de-
mentia.18 Brieﬂy, participants were screened at follow-up visits (1997-1999, 1999-2000, 2002-
2003) with the Mini Mental State Examination (MMSE) and the Geriatric Mental Schedule 
and when screen positive assessed with the Cambridge Examination for Mental Disorders 
of the Elderly interview.21 Participants suspected of dementia were examined by a neurolo-
gist and underwent extensive neuropsychological testing. The MRI at baseline was not used 
in the diagnosis of dementia. In addition to these examinations in-person, we continuously 
monitored the medical records of all participants at the general practitioners’ ofﬁces and the 
Regional Institute for Ambulatory Mental Health Care to obtain information on diagnosed 
dementia until January 1, 2003. A diagnosis of dementia and AD was made by a panel of a 
neurologist, neuropsychologist and research physician that used standard criteria.22, 23 The on-
set of dementia was deﬁned as the date on which clinical symptoms allowed the diagnosis of 
dementia. Duration of follow-up for each participant was calculated from baseline examination 
until death, diagnosis of dementia or the end of follow-up whichever came ﬁrst.
Other measurements
As memory impairment is the ﬁrst detectable neuropsychological sign of incipient Alzhei-
mer’s disease,24 we questioned persons on memory complaints (by a single question), and 
assessed memory performance (by a 15-word verbal learning task).25 For each participant, we 
calculated z scores based on the results of the memory test (z score =individual test score 
minus mean test score divided by the standard deviation). We constructed a compound score 
for memory performance by averaging the z scores of the total of the three immediate recall 
trials and the delayed recall trial of the 15-word verbal learning task.25 In accordance with cur-
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rent criteria, we deﬁned MCI as having a memory score <1.5 standard deviation (SD) of age 
and education speciﬁc means and memory complaints.26 To further reduce the possibility that 
the associations were only present in persons with low memory performance at baseline we 
also deﬁned a group with a score of <1 SD below age and education speciﬁc means. Additio-
nally we administered tests that assess psychomotor speed25 and used a cut-off of <1 SD be-
low age- and education adjusted means to indicate low performance of psychomotor tasks. 
We measured other characteristics on brain MRI that have previously been associated to 
dementia.18 White matter lesions were considered present if visible as hyperintense on pro-
ton-density and T2 weighted axial images, without prominent hypointensity on T1 weighted 
scans. Periventricular white matter lesions were scored semi-quantitatively from 0-9.25 We 
deﬁned infarcts as focal hyperintensities on T2 weighted images. Infarcts in the white matter 
also had to have corresponding hypointensities on T1 weighted images in order to distinguish 
them from white matter lesions. Subcortical brain atrophy was calculated by averaging the 
ventricle-to-brain ratio on T1 weighted images at the frontal horns, the occipital horns and the 
caudate nucleus.
Data analysis
With Cox proportional hazards models we calculated the adjusted relative risk of dementia 
per SD decrease in volumes on MRI. We made also age- and sex speciﬁc tertiles of volumes, 
which we denote as severe, moderate and no atrophy. Adjusted volume differences at base-
line between those developing Alzheimer’s disease and those remaining free of dementia 
were computed from these Cox models. We plotted this difference against the time after 
MRI that the diagnosis of Alzheimer’s disease was made in three equally sized groups of time 
after MRI. In the basic model we adjusted for age, sex and level of education. Additional ad-
justments included periventricular white matter lesions, brain infarcts and subcortical atrophy 
on MRI.18 Analyses were repeated after excluding persons with memory complaints, with a 
MMSE<26, with a low performance on psychomotor tasks (<1 SD below age and education 
adjusted means), with a low performance on memory tasks (<1 or <1.5 SD below age and 
education adjusted means) or MCI at baseline. 
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Results
Table 1 gives the baseline characteristics of the study sample. Sixteen persons fulﬁlled criteria 
of MCI at baseline (3%), a prevalence in line with other studies.27 
Table 1. Baseline characteristics of the study sample
Characteristic n=511
Age, y 73.4 ± 8.0
Sex, % women 49
Primary education, % 31
MMSE, score 27.7 ± 2.1
Memory complaints, % 31
Speed performance
<1 SD*, % 15
Memory performance
<1 SD*, % 17
<1.5 SD*, % 6
MCI†, % 3
Hippocampal volume, ml 6.38 ± 0.88
Amygdala volume, ml 4.57 ± 0.72
Values are mean (± SD) or percentages
*Deﬁned as scoring less than 1 or 1.5 SD below the age and education 
adjusted means
†Presence of memory complaints and memory performance <1.5 SD 
below the age and education adjusted means in memory tests26
During a total of 3043 person-years of follow-up (mean per person 6.0 years), there were 35 
persons who developed dementia of whom 26 received a clinical diagnosis of Alzheimer’s 
disease. Persons with severe atrophy of the hippocampus or amygdala had the highest risk 
to develop dementia, independent of other brain MRI measures (table 2 and 3). In people 
with no hippocampal atrophy, the incidence rate of dementia was 4.8 per 1000 person-years, 
whereas in people with severe hippocampal atrophy the incidence rate was 21.6 per 1000 
person-years. For the amygdala we found in people with no atrophy an incidence rate of 2.9 
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per 1000 person-years and in people with severe atrophy 19.4 per 1000 person-years.
Table 2. Baseline hippocampal atrophy on MRI and risk of dementia 
 Relative risk (RR)
Adjusted for age, sex and 
education
Adjusted for age, sex, educa-
tion and other MRI measures*
Atrophy severity† Dementia RR 95% CI RR 95% CI
No atrophy (n=169) 5 1.00 Ref 1.00 Ref
Moderate atrophy (n=173) 9 1.81 0.61-5.39 1.87 0.63-5.60
Severe atrophy (n=169) 21 4.53 1.70-12.1 3.89 1.45-10.46
P trend 0.001 0.004
Values are adjusted relative risks (RR) of dementia with 95% conﬁdence interval (CI) compared to no 
atrophy and P-value of trend analysis
*The MRI measures adjusted for were severity of periventricular white matter lesions, brain infarcts, and 
severity of subcortical atrophy
†Based on age- and sex speciﬁc tertiles
Table 3. Baseline amygdalar atrophy on MRI and risk of dementia 
 Relative risk (RR)
Adjusted for age, sex and 
education
Adjusted for age, sex, educa-
tion and other MRI measures*
Atrophy severity† Dementia RR 95% CI RR 95% CI
No atrophy (n=170) 3 1.00 Ref 1.00 Ref
Moderate atrophy (n=171) 13 4.42 1.26-15.54 4.17 1.18-14.72
Severe atrophy (n=170) 19 7.33 2.15-24.96 6.01 1.74-20.77
P trend 0.001 0.003
Values are adjusted relative risks (RR) of dementia with 95% conﬁdence interval (CI) compared to no 
atrophy and P-value of trend analysis
*The MRI measures adjusted for were severity of periventricular white matter lesions, brain infarcts, and 
severity of subcortical atrophy
†Based on age- and sex speciﬁc tertiles
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In the whole population, we found per SD decrease in hippocampal volume an age, sex and 
education adjusted relative risk of 2.99 (95%CI 1.96-4.57) and in amygdalar volume 2.06 (95% 
CI 1.46-2.90). This effect was similar after exclusion of persons with memory complaints, a 
low MMSE, low performance on psychomotor speed, low memory performance or MCI at 
baseline (Figure 1). 
Figure 1. Relative risk of dementia with smaller hippocampal and amygdalar volumes on MRI (per SD 
decrease with 95% conﬁdence interval). Analyses were done in the whole population and in persons 
without memory complaints, without a MMSE<26, without a low performance on psychomotor tasks (<1 
SD below age and education adjusted means) without a low memory performance (<1 or 1.5 SD below 
age and education adjusted means) and without MCI at baseline. Adjustments were made for age, sex 
and education
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Figure 2 shows that incident Alzheimer cases had signiﬁcantly smaller hippocampal and 
amygdalar volumes at baseline than persons without incident dementia. Age, sex and educa-
tion adjusted volumes were on average –10.7 % (95% CI –19.3 to –2.1) smaller for the hip-
pocampus and –10.3 % (95% CI –19.9 to –0.8) smaller for the amygdala. Atrophy was also 
evident at baseline in people who received a diagnosis of Alzheimer’s disease more than 5 
years after the MRI but this was less pronounced.
Figure 2. Volume difference at baseline MRI in hippocampus (left panel) and amygdala (right panel) of per-
sons who developed AD (n=26) at different time points after baseline compared to the volume of people 
who were free of dementia and alive. We made tertiles according to time after baseline the diagnosis was 
made and plotted the differences (with standard error) at the median time point in these tertiles. Adjust-
ments were made for age, sex and education. *P<0.05
Discussion
In this large cohort study in elderly people dwelling in the community, we found atrophy of 
the hippocampus and amygdala on MRI to predict dementia and Alzheimer’s disease over a 
6-year follow-up even in persons without memory complaints or low cognitive performance 
at baseline.
Despite our large cohort only few people developed clinical symptoms of dementia, as ex-
pected based on incident rates in the general population.28 Vascular dementia could therefore 
not be analyzed as a separate entity. Clinical studies however suggest that patients with vas-
cular dementia have a degree of hippocampal atrophy that lies between healthy elderly and 
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Alzheimer patients.29 Another issue is that we only assessed the hippocampus and amygdala 
while recently some investigators propose that atrophy of the entorhinal cortex on MRI has 
a greater ability to predict Alzheimer’s disease than the hippocampus.30 However, difﬁculties 
in outlining the boundaries of the entorhinal cortex due to anatomic ambiguity make this as-
sessment not easily applicable.14 
As the neuropathology of Alzheimer’s disease is found ﬁrst, and remains most severe, in 
the hippocampal region, attention of imaging studies in Alzheimer’s disease has been drawn 
to the hippocampus. Moreover, the in-vivo use of MRI of the hippocampus in Alzheimer’s 
disease has been histologically correlated to neuronal loss and Alzheimer pathology.4, 31, 32 
After early MRI studies showing atrophy of the hippocampus in patients with dementia of 
moderate severity,5, 6 later studies found atrophy also in patients with milder dementia.9, 15, 20 
Atrophy on MRI is also observed before the diagnosis of dementia is made in high-risk popula-
tions such as MCI patients9-15 or persons at risk of autosomal dominant familial AD.33, 34 Within 
MCI patients, hippocampal atrophy severity predicts conversion to dementia independent of 
neuropsychological performance.26, 30, 35 We found that hippocampal and amygdalar atrophy 
on MRI predict dementia over a long follow-up period even when people have no memory 
complaints or cognitive impairment. This suggests that atrophy of structures in the medial 
temporal lobe is detectable several years before symptom onset. Although pathological stu-
dies suggested that the amygdala is affected slightly later in the Alzheimer process than the 
hippocampus,3 we found amygdalar atrophy to a similar extent as hippocampal atrophy in 
persons who develop dementia. Cross-sectional studies in mild AD patients also showed hip-
pocampal and amygdalar atrophy to an equal degree.12, 20 Concerning the extent of atrophy, 
we found on average 10% smaller volumes in those destined to develop dementia. In persons 
with mild to moderate AD, volume reductions are between 25% and 40%36 suggesting that 
atrophy accelerates in incipient AD.13 In a study in 5 middle-aged persons who developed 
familial AD within 3 years, a 16% volume difference in medial temporal lobe structures with 
healthy controls was observed.34 In our elderly sample, the medial temporal lobe could be 
less affected by Alzheimer pathology as comorbid cerebrovascular disease may have contri-
buted to the cognitive decline pushing people earlier over the threshold of dementia.18, 37-39 
Our results were not changed when we took into account concurrent vascular brain changes 
on MRI suggesting that vascular brain pathology and atrophy on MRI reﬂect different underly-
ing processes that both independently predict dementia in late life. 
The emergence of potentially disease-modifying therapies for Alzheimer’s disease urges the 
need to identify high-risk persons who may beneﬁt from such therapies. Treatment or preven-
tion might have the largest effect early in the disease process, in a stage where brain damage 
is not extensive and there are no or only few symptoms. A small hippocampus or amygdala 
on MRI in people without memory complaints or cognitive impairment may be indicative of 
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such a high-risk group early in the disease. However, we must bear in mind that the majority 
of people with atrophy do not develop dementia. Future studies are challenged to investigate 
whether other regions on MRI or other modalities can distinguish those with a small brain 
volume who are in the process of developing dementia and those who are not.  
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Chapter 4.3
Brain atrophy and incident depression
Cross-sectional studies have suggested links between late-life depression and hippocampal, 
amygdalar and frontal atrophy on MRI. It is unclear whether atrophy in these structures could 
precede onset of depression. We followed a population-based sample of 459, non-demented, 
non-depressed elderly a baseline, over a three-year period during which 24 developed a de-
pression. At baseline, MRI of the brain was made on which volumes of the hippocampus and 
amygdala and a score of frontal atrophy were assessed.  Frontal atrophy, but not hippocampal 
or amygdalar atrophy, was associated with an increased risk of depression (per point increase 
odds ratio 2.0, (95% CI 1.1-3.8)).
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Introduction
Several cross-sectional clinical studies found hippocampal, possibly amygdalar, and frontal 
lobe atrophy on magnetic resonance imaging (MRI) in patients with depression (reviewed by 
Sheline1). It has been suggested that atrophy in these regions is a consequence of elevated, 
and neurotoxic, glucocorticoid levels accompanying the depression. However, atrophy could 
also be a cause of depression, as these structures have a role in mood regulation.1 To inves-
tigate the latter hypothesis, we prospectively examined hippocampal, amygdalar and frontal 
brain atrophy on MRI in relation to risk of depression in the elderly. 
Methods
Subjects
This study is based on the Rotterdam Scan Study, a population-based cohort study designed 
to investigate brain abnormalities on MRI.2 The study protocol was approved by the Medical 
Ethics Committee of Erasmus Medical Center and participants gave written informed con-
sent. The cohort consists of 1,077 non-demented elderly persons age 60 to 90 years (mean 
age 73, 49% women) who were examined at baseline in 1995-1996 and underwent brain MRI 
in a 1.5 T scanner (VISION MR). During sample selection, we carefully excluded demented pa-
tients using a stepwise protocol.3 Axial T1 MRI sequences were made in all 1,077 participants. 
In 511 persons, we additionally obtained a three-dimensional (3D) MR sequence covering the 
whole brain. These 511 persons did not differ in several demographics from the original cohort 
of 1,077 persons.2 
Incident depression
At baseline MRI, we excluded 43 participants with depressive symptoms based on the use 
of antidepressant medications or based on a score ≥16 on the Centre for Epidemiologic Stu-
dies Depression scale (CES-D), a cut-off widely used and highly sensitive for depression.4 
This left 468 participants at risk of incident depression. Incident depression was detected 
in two ways. First, we invited all living members of the cohort for follow-up examinations 
in 1999-2000. From the total 432 living members, 334 (77%) agreed to participate and they 
were screened with the CES-D. Persons who refused (n=98) were on average 3.9 years older 
(T-test, P<0.001) but were similar with respect to sex distribution, CES-D score at baseline, 
and MRI assessments compared to participants. Persons with a CES-D score ≥16 at follow-up 
examinations were visited at home by a psychiatrist. The psychiatrist evaluated these partici-
pants with the Present State Examination, a semi-structured psychiatric interview,5 and made 
a diagnosis of major depression, minor depression, or dysthymia according to DSM-IV criteria. 
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As depression can occur between baseline and follow-up examinations and in persons who 
refused follow-up examinations, a second way to detect incident depression was through 
checking of medical records by two raters of all 468 participants at the general practitioners’ 
ofﬁces for reports on treated depression until March 1st 2000. Five persons with no informa-
tion from medical records and four persons with anxiety or other psychiatric disorders were 
excluded, leaving 459 participants for the analyses.
MRI acquisition and measurements
The MRI acquisition parameters are reported elsewhere.2 Coronal MRI slices (contiguous 
1.5-mm slices) were reformatted from the 3D MR sequence. The procedure of segmenting 
the hippocampus and amygdala has been described.2 Brieﬂy, we manually outlined on coronal 
slices the hippocampi and amygdalae on both sides with a mouse-driven cursor. Volumes were 
calculated by summing the areas multiplied by slice thickness. As a proxy for head size, we 
measured on the middle sagittal slice the intracranial area by tracing the inner skull. Volumes 
were divided by the intracranial area and the resulting ratio was standardized towards average 
head size (men and women separately). As one volumetric assessment was time-consu-
ming (1-hour), the 459 scans were equally divided between two raters. Intra- and interrater 
studies based on 14 subjects done by both raters showed intraclass correlation coefﬁcients 
to exceed r=0.77. We rated frontal cortical atrophy semi-quantitatively on axial T1 MRI slices. 
Two raters scored independently all the scans and gave a score of 0 (no atrophy) to 3 (severe 
atrophy) based on the average widening of the sulci of the frontal lobe and in comparison to 
reference scans. The central sulcus was the delimiter between the frontal and parietal lobe. 
In case of disagreement of more than 1 point between the raters a consensus reading was 
held, otherwise the mean score was calculated. Weighted kappa values of intra- and interrater 
agreement were 0.57 and 0.71 based on 200 scans. Other regions were similarly assessed 
for severity of atrophy (insular region, parietal lobe, occipital lobe and temporal lobe). 
Data analysis
First, we used multiple linear regression modeling to compare hippocampal and amygdalar 
volumes and frontal atrophy score between persons with and without incident depression. 
Because the associations were similar for left or right-sided hippocampal or amygdalar vol-
umes, we summed the left and right side to yield total volumes. Second, we calculated odds 
ratios (95% conﬁdence interval CI) of incident depression by baseline MRI variables with 
logistic regression using the non-depressed as reference group. Adjustments were made for 
age and sex and additionally for baseline CES-D. Additionally, we excluded persons with a his-
tory of a depression before baseline (based on medical records), and persons who developed 
dementia in follow-up.3
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Results
Hippocampal and amygdalar volumes on baseline MRI were similar in participants who deve-
loped a depression during follow-up (n=24 of whom 8 diagnosed by medical records) compared 
to those who did not (n=435) (Table 1). The corresponding odds ratios of incident depression 
were 0.9 (95% CI 0.6-1.4,P=0.6) per standard deviation (SD) decrease in hippocampal volume 
and 1.3 (95% CI 0.8-2.0,P=0.2) per SD decrease in amygdalar volume. In contrast, there 
was signiﬁcantly more frontal atrophy in persons who developed depression during follow-up 
compared to persons who did not (Table 1); corresponding odds ratio per point increase 2.0 
(95% CI 1.1-3.8,P=0.031). Adjusting for baseline CES-D did not change these results. Other 
regions for which we assessed cortical atrophy were not associated with depression. Persons 
with a history of depression at baseline (n=14) had not more frontal atrophy (adjusted differ-
ence compared to people with no history 0.10, 95% CI –0.23;0.42,P=0.57). Excluding them, 
of whom 4 developed a depression during follow-up, or persons with incident dementia (n=15 
of whom 2 developed a depression) did not substantially change the association with frontal 
atrophy (odds ratio for frontal atrophy 2.2 (95% CI 1.1-4.4,P=0.030) and 1.8 (95% CI 0.9-3.5, 
P=0.088), respectively).
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Discussion
In this community-sample in the elderly, we observed no relation between hippocampal or 
amygdalar volumes on MRI and the risk of depression. Conversely, frontal brain atrophy was 
associated with an increased risk of depression.
A limitation of our study was the small number of incident depression cases, which explains 
the wide conﬁdence intervals around the estimates. Furthermore, we recognize that currently 
more sophisticated, volumetric, assessments of the frontal lobe and speciﬁc regions in the 
frontal lobe are available6, 7 than at baseline in 1995. However, the fact that we found an asso-
ciation between our crude frontal atrophy assessment and incident depression suggests that 
we had enough power to detect associations between MRI variables and incident depression, 
strengthening the negative ﬁnding for the hippocampus and amygdala.
A reduced hippocampal or amygdalar volume on MRI in patients with late life depression has 
been observed though results are mixed.1 Two explanations for this association have been 
proposed. First, a smaller hippocampal volume may be a consequence of depression due to 
associated hypercortisolemia. Elevated cortisol levels are neurotoxic to the hippocampus,8 
but possibly this effect plays a role especially in early onset depression. A second explana-
tion may be that volume reduction in the hippocampus and amygdala precedes onset of 
depression, given that these structures are involved in mood regulation.1 In this report, we 
showed that neither hippocampal nor amygdalar atrophy on MRI increased the risk to develop 
depression. This observation strongly challenges the idea that atrophy of the hippocampus 
or amygdala precedes depression in later life. Consistent with this idea is a recent study that 
showed no hippocampal atrophy on MRI in persons with a ﬁrst episode of depression, sug-
gesting that reductions in hippocampal volume do not precede illness onset.9 Furthermore, 
persons with a longer disease duration have smaller hippocampal volume suggesting that vol-
umes decrease after disease onset.9, 10 Longitudinal clinical studies should focus on whether 
hippocampal and amygdalar volume decrease in patients with depression, possibly due to 
lasting hypercortisolemia. 
Most clinical studies in patients with late life major or minor depression found reductions in 
the frontal lobes on MRI.1 Functional imaging studies have also implicated hypometabolism of 
the frontal lobes in depression.11 The prefrontal cortex has high concentrations of glucocorti-
coid receptors potentially rendering it vulnerable to hypercortisolemic damage.1 This suggests 
that damage to the frontal lobe is a result of depression. However, we observed that frontal 
atrophy on MRI is detectable before disease onset, and non-depressed persons with a history 
of depression had no increased frontal atrophy. This suggests that frontal atrophy indicates an 
increased vulnerability to develop depression in late life.
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This thesis presents studies on causes and correlates of brain atrophy on MRI in non-de-
mented elderly. Studying causes of atrophy on MRI has potential advantages for unraveling 
the etiology of Alzheimer’s disease compared to traditional studies associating risk factors 
to clinical Alzheimer’s disease. First, as we focus on the preclinical period, we study factors 
that could initiate brain changes involved in the early pathogenesis of Alzheimer’s disease. 
Second, the degree of brain atrophy on MRI is a continuous outcome in contrast to clinical 
Alzheimer’s disease, and we have increased power to detect associations. Third, our study 
examined cognitively intact people and may therefore suffer less from selective attrition com-
pared to studies based on patients with Alzheimer’s disease. 
Before we started to investigate potential causes of brain atrophy on MRI there was some indi-
cation that atrophy on MRI, in particular of the hippocampus and amygdala, could be observed 
in the preclinical period of Alzheimer’s disease. However, we wanted to validate and quantify 
in our study sample the association between atrophy on MRI and future clinical symptoms of 
Alzheimer’s disease. We further examined whether atrophy also predicted depression. In this 
chapter, I will ﬁrst discuss a few methodological considerations. Then, I will discuss the main 
ﬁndings, the implications of our ﬁndings, and suggestions for future research.
Methodological considerations
The speciﬁc limitations of each study have been discussed in the previous chapters. In this 
part I will discuss two general issues, which pertain to all studies performed.
Study design
The studies described in this thesis were done as part of the Rotterdam Scan Study.1 This is 
a population-based prospective study among 1,077 non-demented elderly between 60-90 
years of age that started in 1995-1996. In all 1,077 persons, we had assessments of global 
brain atrophy on MRI. In 511 persons, we additionally had volumetric assessments of the hip-
pocampus and amygdala. A speciﬁc feature of this design is that we invited people randomly 
from the general population. This is in contrast to clinical studies which use a selection of 
people who have memory problems and have taken the step to visit a physician. In etiological 
research we are interested in what triggers the ﬁrst pathological signs, as the pathology starts 
before symptom onset. For this purpose, population studies are more suitable than clinical 
studies. Inherent to our approach is the fact that only a few people develop dementia, as 
expected in a low risk population. To investigate whether atrophy on MRI predicts dementia, 
we therefore needed a long follow-up duration and a large cohort in order to detect enough 
incident cases of dementia.
In 1995-1996, we assessed potential risk factors in persons at the same time that we made 
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the brain MRI on which we assessed atrophy. This cross-sectional design is a limitation that 
needs further discussion. In cross-sectional analyses, one cannot invariably draw the conclu-
sion that the risk factor under study really is a cause of brain atrophy. Because we have no 
information on whether the risk factor preceded brain atrophy or vice versa, brain atrophy may 
have also resulted in physiological changes. When genetic determinants are concerned, this 
is not an issue as atrophy will not induce point mutations in DNA. However, in the analyses 
on alcohol intake and plasma homocysteine levels, which depend on folate and vitamin B12 
intake, persons with brain atrophy and self-noticed cognitive decline could have changed food 
intake behavior. This in turn may induce associations between alcohol intake or homocysteine 
levels and brain atrophy. Although we tried to account for several confounding parameters, 
residual confounding is still possible. To resolve or limit the possibility that atrophy induced 
the change in a physiological marker, follow-up studies are needed where the baseline risk 
factor is associated with change in atrophy over time. These analyses are on the other hand 
limited by the fact that atrophy has developed over years due to lifetime cumulative exposure 
of determinants whereas the relation between determinant and change in atrophy over time 
may be less outspoken.
Brain atrophy as preclinical marker of Alzheimer’s disease
Our studies were based on the major assumption that atrophy on MRI is a preclinical bio-
marker of Alzheimer’s disease. To what extent does this assumption hold? Several studies 
have shown that patients with Alzheimer’s disease have severe hippocampal, amygdalar and 
global brain atrophy on MRI compared to healthy elderly.2 Preclinically, there are studies in 
at-risk patients such as those with genetic mutations3 or with mild cognitive impairment4 that 
show brain atrophy on MRI before a diagnosis of Alzheimer’s disease can be made. Our own 
data (chapter 4.2) also indicated that even when there are no cognitive symptoms of incipi-
ent Alzheimer’s disease, hippocampal and amygdalar atrophy on MRI predict a diagnosis of 
Alzheimer’s disease several years later. These observations all favor the idea that atrophy on 
MRI can indeed be considered a relatively early preclinical marker of Alzheimer’s disease. 
However, not every person with atrophy on MRI will later express clinical symptoms of Alz-
heimer’s disease. Some will die before they have the chance to develop clinical symptoms 
of Alzheimer’s disease. In others, a small brain volume on MRI may have been present since 
adulthood instead of being indicative of an underlying Alzheimer process. Finally, in several 
other diseases besides Alzheimer’s disease, atrophy can occur such as in temporal lobe epi-
lepsy (hippocampal/amygdalar atrophy)5 or anxiety (amygdalar atrophy).6 Therefore, when we 
identify a risk factor for brain atrophy on MRI, we have to be careful to interpret this as being 
a risk factor for the development of clinical Alzheimer’s disease without further evidence. In 
chapter 3.2, we found that estrogen receptor α polymorphisms were associated with hippo-
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campal and amygdalar atrophy on MRI yet not with dementia. Risk factors of atrophy should 
always be seen in light of evidence concerning these risk factors in Alzheimer’s disease. 
Studies on risk factors for atrophy should not replace research of risk factors for clinical Alz-
heimer’s disease but rather complement it in order to increase the understanding of what 
could elicit the preclinical brain changes.
Main ﬁndings
I will ﬁrst discuss the main ﬁndings on putative causes of brain atrophy on MRI (chapter 2 and 
3). Then, I discuss the clinical correlates of brain atrophy on MRI (chapter 4). 
Causes of brain atrophy
Despite intensive research, the etiology of Alzheimer’s disease remains largely unclear. Two 
aspects of the disease complicate etiological research. First, once symptoms of Alzheimer’s 
disease are clearly evident, a long prodromal phase has been passed in which the brain pa-
thology has accumulated. Physiological factors present at time of diagnosis of Alzheimer’s 
disease, may not be the ones that effectuated the brain damage in the preclinical period. Sec-
ond, late-onset Alzheimer’s disease is pathologically a heterogeneous disease.7 The brain of 
a person who died with clinical symptoms of Alzheimer’s disease is often destructed by vari-
ous pathologies: besides neuroﬁbrillary tangles and amyloid plaques in gray matter, lacunar 
infarcts and ischemia in the white matter are also frequently visible.8 Among individuals with 
clinical symptoms of Alzheimer’s disease, the extent to which each pathology contributed to 
symptoms may differ, as well as the key mechanisms underlying these brain changes. We 
took the approach of investigating risk factors of brain atrophy on MRI in vivo, which is evident 
in the preclinical phase, and reﬂects a relatively distinct pathology. By doing so, we hoped to 
further increase insight into which risk factors contribute to the development of Alzheimer’s 
disease. The risk factors we studied were not arbitrarily chosen but selected because of their 
putative role in Alzheimer’s disease. 
Vascular risk factors 
A great deal of research over the last decade has added to the idea that vascular factors 
contribute to the development of clinical Alzheimer’s disease in late life.9 Vascular factors 
can cause cerebrovascular damage, which enhances cognitive decline in a brain with exist-
ing Alzheimer pathology.10 However, cerebral ischemia can also upregulate amyloid-ß in the 
hippocampi of rats11 supporting a more direct link with Alzheimer’s disease. We investigated 
several vascular risk factors in relation to brain atrophy on MRI. 
A high blood pressure level is a well-recognized cardio- and cerebrovascular risk factor. The 
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relation between blood pressure and Alzheimer’s disease is less clear.12 Both mid-life high,13, 
14 and late-life low15 blood pressure levels have been associated with the risk of clinical Alzhei-
mer’s disease. In line with these earlier observations, we found that both a high and a low or 
decreasing blood pressure level were associated with medial temporal lobe and global brain 
atrophy (chapter 2.1 and 2.2). Cerebrovascular damage as quantiﬁed by the extent of white 
matter lesions on MRI coexisted with severe hippocampal and amygdalar atrophy. One possi-
bility is that cerebrovascular disease and brain atrophy have common shared risk factors such 
as high blood pressure levels. However, adjusting for blood pressure levels did not change 
this correlation. Possibly, microangiopathy of arterioles supplying the medial temporal lobe, 
visible as white matter lesions on MRI, may reduce cerebral blood ﬂow leading to ischemia in 
the hippocampus and amygdala.16 The association between low blood pressure and atrophy 
on MRI as well as that between low blood pressure and Alzheimer’s disease is difﬁcult to 
interpret. Several regions of the brain, including the hippocampus and amygdala, are involved 
in blood pressure regulation and brain atrophy due to an Alzheimer process could have re-
duced blood pressure levels.17, 18 Alternatively, a low blood pressure level in persons with a bad 
cerebral autoregulation could also cause cerebral ischemia, and thereby actually lead to the 
development of Alzheimer pathology.19 
A high plasma homocysteine level has recently been suggested as a risk factor for Alzheimer’s 
disease.20 In the Rotterdam Scan Study, we previously found that a high homocysteine level 
may cause cerebrovascular damage such as silent brain infarcts and white matter lesions,21 
pointing towards one potential explanation for the association between homocysteine levels 
and clinical Alzheimer’s disease. In chapter 2.3 we report that a high homocysteine level also 
has effects on both hippocampal and global brain atrophy, on MRI, which were not reduced 
when accounting for cerebrovascular disease. This is in line with in vitro studies showing toxic 
effects of homocysteine on cortical and hippocampal neurons.22, 23
A light-to-moderate alcohol intake may reduce cerebrovascular disease24 and vascular demen-
tia.25 Concerning the risk of Alzheimer’s disease, the effect of alcohol intake is less certain and 
a putative reduced risk may be conﬁned to apolipoprotein (APOE) ε4 carriers who consume 
alcohol in light-to-moderate amounts.25 Since we have assessments on MRI of both cerebro-
vascular disease (white matter lesions and infarcts) and ﬁndings more speciﬁc of Alzheimer 
pathology (hippocampal and amygdalar atrophy) in the Rotterdam Scan Study, we decided 
to study this issue further. Our data in chapter 2.4 showed, as expected, a reduced effect of 
alcohol on cerebrovascular disease in general. There was only a beneﬁcial effect of light-to-
moderate alcohol intake on hippocampal and amygdalar atrophy in APOE ε4 carriers further 
strengthening the idea that alcohol has an effect on the risk of Alzheimer’s disease only in 
APOE ε4 carriers.
One of the strongest risk factor for Alzheimer’s disease is carrying an APOE ε4 allele.26 The 
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neurobiologic mechanism through which the ε4 allele confers an increased risk of Alzheimer’s 
disease is not well understood. Some studies suggest that persons with the ε4 allele have 
increased cerebrovascular pathology27 but the bulk of evidence suggests that APOE ε4 leads 
to clinical disease mainly via the speciﬁc Alzheimer pathology.28 In vitro studies suggest that 
the ε4 protein isoform enhances aggregation of amyloid-ß and formation of neuroﬁbrillary 
tangles. APOE ε4 carriers have higher numbers of neuroﬁbrillary tangles and amyloid plaques 
in the hippocampus compared to non-ε4 carriers.29 Our ﬁnding that atrophy in the medial 
temporal lobe was more pronounced in ε4 carriers compared to persons with the APOE ε3ε3 
genotype gave further support to our assumption that atrophy on MRI reﬂects Alzheimer 
pathology (chapter 2.5). 
Taken together, we found several classical or more recently identiﬁed vascular risk factors 
to be associated to brain atrophy on MRI. This supports the idea that vascular factors could 
speciﬁcally trigger Alzheimer pathology in the preclinical phase. 
Endocrine risk factors
Besides vascular risk factors, other risk factors have been suggested to be involved in the 
development of Alzheimer’s disease. 
A substantial body of evidence in animal studies suggest that estrogens have antioxidative 
properties30 and beneﬁcial effects on hippocampal neurons.31 Therefore in theory, a high 
estrogen level in the brain could reduce the risk of Alzheimer’s disease. On the other hand, 
observational data in humans are far from conclusive on the role of estrogens in Alzheimer’s 
disease. Before menopause, women have high endogenous estrogen levels and it could 
therefore be hypothesized that women with a long reproductive period, and hence a high 
lifetime cumulative exposure to estrogen, would have a lower risk of Alzheimer’s disease. 
However, in the Rotterdam Study it was found that their risk to develop Alzheimer’s disease 
was higher compared to those with shorter reproductive periods.32 After menopause, 
endogenous estrogen levels drop and in older women with a relatively high endogenous 
estradiol level the risk to develop dementia was highest.33 In line with this ﬁnding, we showed 
in chapter 3.1 that higher endogenous levels of estrogens are not associated with a larger 
volume of the hippocampus on MRI or better memory performance. Endogenous levels after 
menopause are, however, far below levels obtained after estrogen replacement therapy and 
it could be that “supranatural” estrogen levels protect against Alzheimer’s disease. Recent 
trials on estrogen replacement therapy in preventing or slowing of Alzheimer’s disease do 
not support this idea.34, 35 In fact, elderly women who receive a combination of estrogen and 
progestin have a two times increased risk to develop Alzheimer’s disease compared to women 
on placebo.34 A similar kind of discrepancy between ﬁndings of basic sciences (estrogen is 
protective)36 and randomized trials (estrogen is harmful)37 has been observed in cardiovascular 
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research. In this ﬁeld it has been suggested that genetic variations in the gene encoding 
for estrogen receptor α render some women more susceptible to the beneﬁcial or harmful 
effects of estrogen.38 Effects of estrogen replacement therapy on lipid proﬁle are different 
across genotype39 and polymorphisms in the estrogen receptor α are associated with risk of 
cardiovascular disease.40 We found that polymorphisms in the estrogen receptor α gene are 
not associated with the risk of Alzheimer’s disease (chapter 3.2). This makes it less plausible, 
though not impossible, that estrogen replacement therapy will have a beneﬁcial effect on risk 
of dementia in women with a certain variation in the estrogen receptor α gene.
Other endocrine factors that we examined were diabetes mellitus and insulin resistance (chap-
ter 3.3). Although these factors could also be categorized as vascular risk factors, evidence in 
Alzheimer research suggests that it is not the vascular risk component of diabetes mellitus 
and insulin resistance that causes the increased risk of Alzheimer’s disease. Instead, a high 
glucose level or altered insulin signaling could have direct effects on the development of amy-
loid plaques and neuroﬁbrillary tangles in the brain.41, 42 In line with this idea, we showed that 
persons with diabetes mellitus have increased atrophy of the hippocampus and amygdala on 
MRI. Of interest, the relation between diabetes mellitus and cerebrovascular disease was not 
strong and did not account for the associations with atrophy. The mechanisms that underlie 
the associations between diabetes mellitus and atrophy could be manifold. First, advanced 
glycation endproducts, of which persons with diabetes have increased levels, could trigger 
the aggregation of amyloid proteins into amyloid plaques.41 Second, glycation of the microtu-
bule associated protein-tau could lead to formation of neuroﬁbrillary tangles.43 With respect to 
insulin, evidence from several lines of research has supported links with Alzheimer’s disease. 
Insulin receptors are densely distributed in the brain44 and once activated lead to a cascade of 
events that promote neuronal survival and prevent tau phosphorylation.42 Dysfunction of this 
pathway may therefore lead to Alzheimer’s disease and genetic variations in the genes en-
coding for proteins in this insulin pathway have been associated to Alzheimer’s disease.42, 44, 45 
Plasma insulin levels may secondarily increase to compensate for this loss of receptor func-
tion. Furthermore, the insulin-degrading enzyme (IDE) is present in the brain and, in addition 
to insulin, also degrades amyloid proteins, thereby preventing plaque formation. Mice with 
hypofunction of this enzyme have more amyloid plaques and high insulin plasma levels46 and 
variations in the gene encoding IDE have been found in patients with Alzheimer’s disease.47 In 
our study, interestingly, we found a speciﬁc effect of insulin resistance on amygdalar atrophy 
on MRI but not on hippocampal atrophy.
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Speciﬁcity of measures of brain atrophy on MRI
We investigated putative causes of several different measures of brain atrophy on MRI (hip-
pocampal, amygdalar, cortical and subcortical brain atrophy). Sometimes we found that a risk 
factor was speciﬁcally associated with one brain atrophy measure while not with the other 
atrophy measures. The APOE ε4 allele for example was associated with hippocampal and 
amygdalar atrophy yet not with global brain atrophy. One possible source for different as-
sociations may be that global brain atrophy was less precisely measured (semi-quantitative) 
than the hippocampus and amygdala (volumetric). However, a more likely explanation is that 
anatomically different structures are under study or that the MRI measures have different 
pathological substrates. 
Though frequently observed in Alzheimer patients,48 there is no ﬁrmly deﬁned pathological 
basis of global brain atrophy on MRI, which can be divided in cortical (sulcal widening) and 
subcortical (ventricular enlargement) atrophy. Although the name “cortical” atrophy would 
imply neuronal loss, there is only little neuronal loss with aging.49 Sulcal widening may be the 
result of reduction of myelinated nerve ﬁbers underneath the cortex in the white matter.49 
The nerve ﬁbers that are lost presumably originate from the projecting pyramidal cells in the 
cortex. However, if there is little loss of cortical neurons, then the projecting myelinated ax-
ons must degenerate without the loss of the parental cell body. Subcortical atrophy indicates 
ventricular enlargement at the expense of white matter around the ventricles (hydrocephalus 
ex vacuo). Volumetric MRI studies have shown that brain white matter volume decreases 
with age50 most likely due to loss of myelin with relative preservation of axons. Given that we 
do not have a pathological validation of global brain atrophy on MRI, it remains uncertain on 
which places (cortex or white matter) risk factors act. High blood pressure or homocysteine 
levels could for example induce neuroﬁbrillary tangles and shrinkage of neurons in the cor-
tex. However, effects such as ischemia in the white matter regions and loss of white matter 
volume could also be involved in the associations with global brain atrophy on MRI. Detailed 
segmentation of the brain in gray matter, white matter and cerebrospinal ﬂuid volume and 
separately investigating the correlations with vascular factors could resolve this problem.
Compared to global brain atrophy on MRI, there is a stronger histological validation for hip-
pocampal and amygdalar atrophy on MRI. Volumes of these structures on MRI are strongly 
positively correlated with neuronal count,51, 52 and negatively with the extent of the speciﬁc 
Alzheimer pathology, i.e. neuroﬁbrillary tangles and amyloid plaques.53 The risk factors that we 
found for hippocampal and amygdalar atrophy act therefore speciﬁcally on neurons of these 
brain structures or on the development of Alzheimer pathology for which these structures are 
highly susceptible. From the risk factors we studied blood pressure levels, homocysteine, 
alcohol intake, APOE gene, estrogen receptor α polymorphism and diabetes mellitus were 
more or less similarly associated with hippocampal and amygdalar atrophy on MRI. A notable 
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difference was insulin resistance, which was strongly associated with amygdalar atrophy but 
absolutely not with hippocampal atrophy on MRI (chapter 3.3). A recent study also found no 
association between insulin resistance and hippocampal volumes on MRI54 but that study 
did not assess the amygdala. The biochemical properties of the Alzheimer pathology are, 
to my knowledge, similar in both structures and develop approximately at the same time in 
the process of Alzheimer’s disease.55 This suggests that differences between neurons of the 
hippocampus and amygdala result in differential effects of insulin resistance. The density of 
insulin receptors on hippocampal and amygdalar neurons are slightly different with the hip-
pocampus having a higher density.56 Possibly, the hippocampus is less sensitive for effects of 
insulin resistance than the amygdala due to its higher receptor density.
Clinical correlates of brain atrophy
The work we described on risk factors of brain atrophy on MRI started based on the belief 
that brain atrophy on MRI can be observed early in the process of Alzheimer’s disease. To 
investigate the functional signiﬁcance of brain atrophy on MRI in the preclinical period, we 
addressed the relation between brain atrophy and memory performance since memory im-
pairment is the ﬁrst preclinical neuropsychological sign of Alzheimer’s disease.57 Additionally, 
we quantiﬁed the association between brain atrophy on MRI and risk of dementia and risk of 
depression.
In chapter 4.1 we report that hippocampal atrophy on MRI of non-demented elderly correlates 
with worse memory performance. Persons with smaller volumes of the hippocampus on 
MRI, particularly of the head portion, performed worse on a verbal memory task. Since 1957, 
the medial temporal lobe has been identiﬁed to play an important role in memory function. 
Selective memory impairment was described after bilateral surgical removal of the medial 
temporal lobe in patient H.M.58 However, the medial temporal lobe is a large region that in-
cludes the hippocampus, the amygdala and adjacent cortical areas. The precise contribution 
of each of these structures in memory function is just starting to be disentangled. More-
over, even within a structure, there may exist functional segregation. Response to novelty 
is, for example, mapped on the head portion of the hippocampus59 whereas spatial memory 
is probably located in the posterior hippocampus.60 The early observable verbal memory de-
cline in incipient Alzheimer’s disease is by most researchers attributed to the accumulation 
of Alzheimer pathology in the hippocampus.61 Damage to the hippocampus in this stage may 
go hand-in-hand with complaints of worse memory function and low memory performance. 
However, whether a person complains or not will also depend on personality traits or social 
factors. In chapter 4.2 we show that hippocampal atrophy on MRI predicts dementia even 
when a person did not report memory complaints or had a lower than average memory 
performance. This suggests that although the Alzheimer process already accumulates in the 
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hippocampus and can be detectable as atrophy on MRI, persons do not necessarily com-
plain of bad memory or perform worse on memory tests. We found that amygdalar atrophy 
on MRI also predicts dementia. It is unclear whether in the preclinical phase of Alzheimer’s 
disease amygdalar atrophy has functional correlates. Experiments in monkeys demonstrated 
that amygdalar damage does not impair memory.62 In line, we found no pronounced amy-
gdala atrophy in persons with worse verbal memory (chapter 2.5). The amygdala consists of 
several nuclei which all could have separate functions but, in general, the amygdala functions 
in emotional information processing and fear conditioning.63 In Japanese Alzheimer patients, 
worse memory of a traumatic event arising emotion (earthquake) was stronger correlated to 
amygdalar atrophy than to hippocampal atrophy on MRI.64 Other studies showed increased 
anxiety in Alzheimer patients, which could possibly be contributed to damage of the amygdala 
by the Alzheimer process.65 
Clinical studies have shown atrophy of the hippocampus, the frontal lobe and sometimes 
amygdala in patients with depression compared to healthy controls.66 Most consistently, this 
is observed in patients with a long duration of depression. The observation could be caused 
by hypercortisolemia which is neurotoxic and is present in patients with major depression. 
However, as the hippocampus, amygdala and frontal lobe, as part of the limbic system, are 
involved in emotion regulation it may also be that the presence of atrophy poses people at 
risk of mood disorders or a depression. We studied this latter hypothesis by investigating the 
longitudinal relation between atrophy and depression in persons who were non-depressed at 
baseline. While both hippocampal and amygdalar atrophy were not associated with incident 
depression, frontal atrophy was. These data make it unlikely that atrophy of the hippocampus 
and amygdala precedes a depression in late-life. In line, a recent clinical study showed no hip-
pocampal atrophy in persons who entered the hospital with a ﬁrst episode of depression but 
hippocampal atrophy was prominent in persons with multiple episodes of depression.67 The 
frontal lobe, in particular the orbitofrontal cortex (gyrus rectus), has a connection to the limbic 
system and reductions in the gray matter of this area are observed in persons with depres-
sion.68 What actually leads to this gray matter loss is unknown. Most researchers currently 
adhere to the “vascular depression hypothesis” of late life depression, stating that brain in-
farcts and white matter damage destruct brain pathways important for normal mood regula-
tion. Hyperintensities in the basal ganglia coexist with a smaller orbitofrontal cortex volume 
suggesting a common, possibly vascular pathway of both pathologies.68 
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Implications
Our ﬁndings were based on persons dwelling in the community who as a group are healthier 
than patients seen in clinical practice. However, I do think that our ﬁndings could have clinical 
implications. We showed that atrophy on MRI of the hippocampus and amygdala is a strong 
predictor of dementia independent of neuropsychological performance. In line, clinical studies 
in patients with mild cognitive impairment previously showed that atrophy of the hippocam-
pus on MRI could predict progression to dementia.4 In case of ﬁnding a high degree of atro-
phy on MRI as of yet there is no therapeutical intervention available. However, these patients 
and caregivers can be advised and frequently followed. On the other hand, when ﬁnding no 
atrophy, patients may be reassured that their risk of progressing to dementia is low.4 Assess-
ing MRI volumes by manual outlining of structures will be too labor intensive to implement 
in a normal diagnostic work-up. Visually rating of atrophy may be a good alternative69 or auto-
mated segmentation methods70 can be used. 
We identiﬁed several risk factors for brain atrophy including vascular risk factors. Currently, it 
is not common knowledge that brain atrophy on MRI could have vascular determinants. Most 
frequently, brain atrophy on MRI is regarded as being normal with ageing and only when 
extensive be reported as indicative of neurodegeneration. Our ﬁndings suggest that persons 
with brain atrophy on MRI should at least be screened for potentially treatable risk factors 
such as high blood pressure level, diabetes mellitus and possibly high plasma homocysteine 
levels. It remains however to be demonstrated in clinical trials that treatment of these risk 
factors reduces the incidence of cognitive decline or dementia. 
Suggestions for future research
The research described in this thesis was done in the framework of etiological research on 
Alzheimer’s disease. The approach we took to investigate putative causes of a preclinical 
biomarker of Alzheimer’s disease, in our case brain atrophy on MRI, has not been frequently 
pursued before. I think that this approach deserves further exploration. The following ques-
tions come to mind: which study sample to use? What biomarkers to use? What to do when 
we have identiﬁed a high-risk group?
Particular population-based samples could yield valuable information on the earliest preclini-
cal changes. Clinical study samples are based on people with cognitive impairment and, as 
such, are further along the process of dementia than persons dwelling in the community. 
Because twenty-ﬁve percent of persons at age of 40 already have some neuroﬁbrillary tan-
gles in the brain,71 it is important to include persons in this young age range. A drawback of 
including middle-aged persons is that the incidence of dementia in this age group is very low. 
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Therefore, in a longitudinal setting, repeated measures of neuropsychological tests should be 
administered to detect subtle cognitive decline. 
The biomarkers tested in the preclinical period can be manifold. Peripheral markers such as 
plasma amyloid-ß levels72 or inﬂammatory markers73 should be examined. Brain imaging could 
identify speciﬁc brain markers. We only addressed hippocampal, amygdalar and generalized 
brain atrophy on MRI whereas brain structures such as the entorhinal cortex may be affected 
by Alzheimer pathology even earlier.55 Before jumping into assessing this structure by manual 
outlining, it will be more time-efﬁcient to use automated protocols to label the entire brain.74 
In this way, we might also ﬁnd other brain regions that previously have been unnoticed in 
the early development of Alzheimer’s disease. For this purpose, high-resolution 3D MRI se-
quences should be administered on which, besides gray matter, also white matter lesions 
and brain infarcts can be quantiﬁed. Currently, it is beyond the resolution of MRI to visualize 
amyloid plaques or tangles and we merely see the consequences of these pathologies in 
terms of macroscopic volumes loss. Promising results have been made in postmortem tis-
sue with high ﬁeld strength MRI and binding molecules to detect amyloid plaques.75 Another 
interesting imaging tool is functional MRI (fMRI) which visualizes functional changes in the 
brain. In ‘at-risk’ persons, differences in regional blood ﬂow to brain regions during cognitive 
testing have been reported.76 However, the development of paradigms used for fMRI is dif-
ﬁcult and results will depend on how sensitive these paradigms are for speciﬁc changes in 
the preclinical phase. 
To the extent that preclinical biomarkers predict Alzheimer’s disease, they can be used as spe-
ciﬁc outcome measures in etiologic research. We found several environmental and genetic 
factors to be associated with brain atrophy on MRI. An interesting lead to further explore 
is the role of insulin metabolism in the etiology of Alzheimer’s disease. In our study, insulin 
resistance was speciﬁcally associated with amygdalar atrophy on MRI but not with hippocam-
pal atrophy or cerebrovascular disease. This suggests that Alzheimer patients with insulin re-
sistance77 might be a certain subgroup of patients with particularly severe amygdalar atrophy 
with less pronounced hippocampal atrophy or cerebrovascular disease. Genetic factors likely 
play a large role in the development of Alzheimer’s disease. In interpreting genetic associa-
tions with brain volumes at late life, it must be kept in mind that identiﬁed genetic variations 
are present since conception. Some genetic factors may be involved in the development of 
the brain yet not in the etiology of Alzheimer’s disease. The genetic variation in the estrogen 
receptor α polymorphism in association with amygdalar volumes on MRI may be examined in 
young populations, as this variation was not associated with Alzheimer’s disease. 
If we can reliably identify the preclinical period by a combination of biomarkers and neu-
ropsychological tests, disease-modifying drugs, currently under development, could be tried 
in these people. Biomarkers could help in tracing the effects of treatment. Recently, a ran-
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domized trial showed less pronounced hippocampal volume reduction on MRI over time in 
dementia patients using donepezil.78 Before disease-modifying drugs are fully developed, clin-
ical trials may study the effect of interventions in vascular risk proﬁle in certain risk groups. 
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Alzheimer’s disease is a common disorder in the elderly that is clinically characterized by an in-
sidious onset of memory decline followed by progressive decline in other cognitive domains. 
The cause of the disease is still largely unknown. From pathological studies it has become 
clear that damage to the brain occurs long before the onset of symptoms. Therefore, the em-
phasis of the studies described in this thesis was on brain changes during this preclinical pe-
riod as visualized with magnetic resonance imaging (MRI) of the brain. The studies performed 
are part of the Rotterdam Scan Study, a population-based study among almost 1100 elderly 
who had no symptoms of dementia at time of MRI. On the MRI scans, we visualized the 
extent of brain atrophy, both generalized brain atrophy and of the hippocampus and amygdala, 
structures highly affected by Alzheimer pathology early in the disease. By establishing deter-
minants of brain atrophy, we hoped to provide some clues on the pathogenesis of Alzheimer’s 
disease. Addtionally, we studied whether brain atrophy on MRI is clinically characterized by a 
decline in memory function, and whether it indicates an increased risk of developing clinically 
evident Alzheimer’s disease and depression. 
Chapter 2.1 and 2.2 illustrate the relationship between blood pressure and brain atrophy 
on MRI, both generalized atrophy and regional atrophy of the hippocampus and amygdala. 
Either a high or low diastolic blood pressure level was associated with increased brain atro-
phy. The biological mechanisms for these associations are still unknown, we provide some 
possible explanations. Chapter 2.3 focuses on plasma homocysteine levels, as high levels 
of this amino acid have been associated with clinical Alzheimer’s disease. Elderly with high 
plasma homocysteine levels were found to have more hippocampal and global brain atrophy 
on MRI. Chapter 2.4 addresses the association between alcohol intake and both cerebro-
vascular disease and hippocampal and amygdalar atrophy on MRI. Light-to-moderate alcohol 
consumers have a lower risk of dementia compared to abstainers, particularly of vascular 
dementia. In accordance, we found a lower prevalence of cerebrovascular disease on MRI in 
light-to-moderate alcohol consumers compared to abstainers. Overall there was no effect of 
the degree of alcohol intake on hippocampal and amygdalar atrophy on MRI. However, within 
apolipoprotein E (APOE) ε4 carriers, light-to-moderate alcohol consumers had less atrophy 
compared to abstainers. This ﬁnding is in agreement with recent reports that APOE ε4 carri-
ers who consume light-to-moderate amounts of alcohol have a reduced risk of Alzheimer’s 
disease compared to ε4 carriers who abstain. In chapter 2.5, we studied the effect of the 
APOE genotype on degree of brain atrophy on MRI. Individuals with the ε4 allele, which is the 
risk allele in Alzheimer’s disease, had more hippocampal and amygdalar atrophy but not more 
global brain atrophy compared to persons with the common ε3ε3 genotype. 
In chapter 3.1, a study on plasma estradiol levels and hippocampal atrophy on MRI and mem-
ory performance is described. Based on animal studies showing beneﬁcial effects of estrogen 
on hippocampal neurons, we formed the hypothesis that higher estradiol levels would be 
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associated with less hippocampal atrophy and better memory performance. This hypothesis 
was however not conﬁrmed. The effect of polymorphisms in the estrogen receptor α gene 
on atrophy and risk of dementia is investigated in chapter 3.2. While the polymorphism was 
not associated with the risk of dementia, we found that women with certain genetic varia-
tions had smaller amygdalar volume on MRI. Chapter 3.3 reports on the association between 
diabetes mellitus, insulin resistance and atrophy of the hippocampus and amygdala on MRI. 
Persons with diabetes mellitus had more atrophy on MRI compared to persons without dia-
betes mellitus. Furthermore, in non-diabetic persons, insulin resistance was associated with 
amygdalar atrophy on MRI.
Chapter 4.1 provides evidence that persons with more hippocampal atrophy on MRI perform 
worse on memory performance tasks. In particular, smaller hippocampal head volume was 
associated with decreased performance on a verbal learning task. In chapter 4.2 we validated 
in our sample the assumption that atrophy on MRI could be observed in the preclinical period 
of Alzheimer’s disease. Atrophy on MRI of either the hippocampus or amygdala predicted the 
development of clinical dementia within six years, even when persons were cognitively intact 
at time of MRI. In contrast, in chapter 4.3 we show that hippocampal and amygdalar atrophy 
do not predict depression. However, frontal atrophy was associated with an increased risk of 
depression.
Finally, in chapter 5, methodological issues, the main ﬁndings and their implications, and sug-
gestions for further research are discussed. 
Samenvatting

Samenvatting
175
De ziekte van Alzheimer is een veelvoorkomende ziekte in ouderen. Patiënten met de ziekte 
van Alzheimer merken een sluipende achteruitgang in geheugenfunctie waarna verslechtering 
van andere cognitieve functies volgt. De oorzaak van de ziekte is nog grotendeels onbekend. 
Uit pathologische studies is gebleken dat schade aan de hersenen reeds lang voor het begin 
van symptomen aanwezig is. We legden daarom in dit proefschrift de nadruk op veranderingen 
in de hersenen tijdens deze preklinische periode, zichtbaar gemaakt met behulp van “mag-
netic resonance imaging” (MRI) van de hersenen. De studies in dit proefschrift maken deel uit 
van de Rotterdam Scan Study, een studie onder bijna 1100 ouderen die ten tijde van de MRI 
geen klinische symptomen van dementie hadden. Op de MRI kwantiﬁceerden we zowel ge-
generaliseerde hersenatroﬁe, als atroﬁe van de hippocampus en amygdala, hersenstructuren 
die vroeg in het beloop van de ziekte van Alzheimer zijn aangedaan. Door het vinden van risi-
cofactoren voor hersenatroﬁe, hoopten wij meer inzicht te krijgen in de ontstaanswijze van de 
ziekte van Alzheimer. Daarnaast bestudeerden we de vraag of hersenatroﬁe op MRI klinisch 
gekenmerkt wordt door geheugenachteruitgang, en of het een verhoogd risico op het krijgen 
van klinische symptomen van de ziekte van Alzheimer of een depressie aangeeft. 
Hoofdstuk 2.1 en 2.2 illustreren het verband tussen bloeddruk en hersenatroﬁe, zowel ge-
generaliseerde atroﬁe als speciﬁeke atroﬁe van de hippocampus en amygdala. Een hoge- en 
een lage diastolische bloeddruk stonden beide in verband met meer hersenatroﬁe. De pre-
cieze mechanismen van deze associaties zijn nog onbekend, we geven enkele mogelijke ver-
klaringen. Hoofdstuk 2.3 bestudeert het plasma homocysteine gehalte aangezien een hoge 
concentratie van dit aminozuur mogelijk een verhoogd risico van de ziekte van Alzheimer 
geeft. Ouderen met hogere plasma homocysteine concentraties hebben meer hippocampus 
en gegeneraliseerde hersenatroﬁe op MRI. Hoofdstuk 2.4 kijkt naar de associatie tussen 
alcohol consumptie en zowel cerebrovasculaire schade als hippocampus en amygdala atroﬁe. 
Ouderen die licht tot matig alcohol consumeren hebben een lager risico van dementie in 
vergelijking met geheel onthouders, in het bijzonder van vasculaire dementie. In dit kader 
vonden wij eveneens minder cerebrovasculaire schade op MRI in mensen die licht tot matig 
alcohol consumeren. Er was geen verband tussen alcohol consumptie en ernst van hippo-
campus of amygdala atroﬁe op MRI. Echter, in mensen die het ε4 allel van het apolipopro-
tein E (APOE) gen hebben, is lichte tot matige alcohol consumptie geassocieerd met minder 
atroﬁe. In hoofdstuk 2.5 bestuderen we het effect van het APOE genotype op de mate van 
hersenatroﬁe op MRI. Ouderen met het ε4 allel, het risico allel in de ziekte van Alzheimer, 
hebben meer hippocampus en amygdala atroﬁe, maar niet meer gegeneraliseerde atroﬁe, in 
vergelijking met ouderen met het ε3ε3 genotype. 
In hoofdstuk 3.1 beschrijven we een studie naar het verband tussen plasma oestrogenen 
concentratie, hippocampus atroﬁe en geheugen functie. Dierexperimenteel onderzoek heeft 
veelal positieve effecten van oestrogenen op neuronen in de hippocampus laten zien, dus 
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we formuleerden de hypothese dat ouderen met hogere plasma oestrogenen concentraties 
minder hippocampus atroﬁe zouden hebben, en beter zouden presteren op geheugen taken. 
Deze hypothese konden we echter niet bevestigen. Het effect van een genetische variatie in 
het gen van de oestrogeenreceptor α op atroﬁe en risico van dementie werd onderzocht in 
hoofdstuk 3.2. Alhoewel deze genetische variant niet met het risico van dementie in verband 
staat, hebben vrouwen met een bepaalde genetische variatie kleinere amygdala volumes. 
Hoofdstuk 3.3 laat het verband zien tussen diabetes mellitus, insuline resistentie en hip-
pocampus atroﬁe op MRI. Ouderen met diabetes mellitus hebben meer atroﬁe op MRI in 
vergelijking met ouderen zonder diabetes mellitus. In personen zonder diabetes mellitus, is 
insuline resistentie een risico factor voor amygdala atroﬁe.
Hoofdstuk 4.1 laat zien dat ouderen met meer hippocampus atroﬁe op MRI slechter pres-
teren op geheugen taken. Speciﬁek atroﬁe van het “head” gedeelte van de hippocampus 
staat in verband met verminderde prestaties op een verbale geheugen taak. In hoofdstuk 4.2 
bestudeerden wij onze assumptie dat atroﬁe op MRI tijdens de preklinische periode van de 
ziekte van Alzheimer aanwezig is. Atroﬁe van de hippocampus of amygdala op MRI voorspelt 
de ontwikkeling van dementie zes jaar later, zelfs wanneer ouderen ten tijde van de MRI cog-
nitief goed functioneren. In hoofdstuk 4.3 tonen wij aan dat hippocampus of amygdala atroﬁe 
geen voorspeller is van een depressie. Echter, de aanwezigheid van frontale atroﬁe op MRI 
geeft een verhoogd risico van depressie aan.
In hoofdstuk 5 worden enkele methodologische aspecten, de belangrijkste bevindingen en 
hun implicaties, en suggesties voor verder onderzoek besproken.  
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goede sfeer op de afdeling maakten. Een aantal wil ik hierbij noemen. Natuurlijk de mede-
neuroten: Sandra, Annemieke, Monika, Marianne, Henning, Mirjam, Frank-Jan, Lonneke, 
Marjolein, Marieke en Michiel waarmee ik de liefde voor de hersenen kon delen. Het loopje 
naar de genetische epidemiologie op de 22e verdieping leidde altijd tot leuke discussies met 
Gerwin Roks onder het genot van een kop kofﬁe. Gerwin, ik geef je nu toch gelijk; het is 
amyloid en niet tau! De genepi opvolgers Anna, Kristel, Marie-Josee en Ingrid hebben me 
ingewijd in de vele thee smaken. Ingrid bedankt dat ik tijdens mijn co-schap in Breda een 
logeerplekje had. Met Hok, Simone en Stephanie heb ik naast vele borrels ook nog de laatste 
promotieperikelen meegemaakt.
Jeroen, hoewel ik geen Apple kocht, was je gelukkig toch bereid vele uren te steken in de lay-
out van mijn boekje. Gwenda, bedankt voor de prachtige tekening op de cover. 
Pap en mam, dank voor jullie onvoorwaardelijke steun ondanks dat jullie je wel eens afvroegen 
wanneer ik nou gewoon arts werd. Mijn broers Rik, Wouter en Koen geweldig dat jullie totaal 
iets anders dan geneeskunde doen, helaas kunnen jullie niet alle drie naast me staan tijdens 
de verdediging.
Lieve Martine, de afgelopen jaren waren niet altijd even makkelijk maar jij stond altijd voor me 
klaar wanneer het nodig was. Bedankt voor alles buiten dit proefschrift.  
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